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Medical ultrasound, which is routinely used in diagnostic and therapeutic 
applications, continues to expand into new medical treatments and interventions. 
However, owing to the cost, size and inefficiency of ultrasound systems currently 
available, many potential applications of ultrasound in medicine and biology are 
hindered. We have developed a platform engineering design solution to ultrasound 
transducers and electronics based on ultralow impedance design principles that 
effectively reduce the size and voltage requirements of ultrasound systems, while 
simultaneously improving their efficiencies thereby enabling portable medical 
ultrasound devices covering the spectrum of therapeutic applications. 
We have developed new measurement tools to better understand and 
characterize ultrasound transducers using impulse response, Fourier analysis and 
acoustic delay line modeling. Using these techniques we can calculate electrical to 
acoustic conversion efficiencies and piezoelectric material parameters on a bench top 
with minimal electronic instruments. 
We have engineered ultrasound assisted cannulas’ to improve needle based 
injection therapy. Using ultrasound in combination with diffusion and convection of 
tracers we are able to increase the distribution volume and penetration of various 
molecules in a broad spectrum of tissues ex vivo and in vivo. Specifically, we focused 
on improving pharmaceutical distribution in neurological tissue using a technique of 
direct drug injection to the brain parenchyma called “Convection Enhanced Delivery”.    
 We have generated a portable high intensity focused ultrasound system that we 
tested ex vivo and in vivo for non-invasive ablation tissues. The technology was 
specifically adapted for clinical hands as a tool to non-invasively treat venous 
varicosities and malformations. 
This dissertation presents new ideas and engineering principles of ultrasound 
instrumentation, design, analysis and use in neurological drug delivery and 
rehabilitation medicine. Furthermore, it discusses future applications of the presented 
technology and the adjunct projects that evolved from this research.   
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BIOGRAPHICAL SKETCH
1
 
 
 For Dr. George Lewis, perpetual challenges are the beauty of biomedical 
engineering; they continue to be the benchmark for learning and his drive to succeed 
as an independent investigator. The question to answer, the puzzle to assemble, or 
finding the reason, cure or preventative measure, drives him.  Solutions are not black 
and white, but through complex and thoughtful analysis, curiosity and creativity, the 
answers can be found.   
 George’s extensive research and hands-on experiences have given him critical 
tools to tackle the challenges. Experience drives the development of new solutions; his 
doctoral training with skilled scientists and novel technologies have given him the 
opportunity to study ultrasound-assisted drug transport, improve upon clinical 
approaches for brain cancer treatment and ultimately generate new tools to inspire 
biomedical research. 
 George began studying mechanical engineering at the University of Miami, but 
soon switched to a biomedical engineering concentration, which combined aspects of 
both physics and biological sciences.  Initially, this combination made him think about 
heart transplants, prostheses and diagnostic devices. He now understands that 
biomedical engineering comprises a broad, mesmerizing, spectrum of issues. At the 
University of Miami, under the mentorship of Dr. Brian Coomes, Professor of 
Differential Equations, George performed research in hemodynamics and the Lattice 
Boltzman Method of modeling blood flow. The research was initiated in his 
sophomore year by his desire to model in vivo phenomena, where he connected faculty 
from the Math and Biomedical Engineering Departments to tackle a fluidics 
                                                 
1 The biographical sketch of George K. Lewis Jr.’s Ph.D. dissertation “Medical Ultrasound for Brain 
Drug Delivery and Rehabilitation Medicine” was adapted and edited by Mr. Blaine Friedlander, Cornell 
University, Ithaca, NY. 
 iv 
physiological issue. George designed and executed a lattice-based computer model 
that produced characteristic flow patterns, and he was able to contort the model for 
normal and abstract channel shapes to aid in hemodynamic understanding. The 
modeling of vascular flow characteristics, smooth, turbulent and vortex, have found 
direct correlations to heart disease and aneurisms, and this macroscopic approach was 
one of the first steps in his studies to understand a small picture of complex systems. 
Although this research was purely computational, it greatly improved his ability to 
study current literature in the scientific field and it helped combine his knowledge of 
math, fluids dynamics, software coding and other engineering disciplines to construct 
a solution to the conceived problem. 
 In the summer of 2004, George participated in the National Institutes of Health 
sponsored Bio-Optics Institute at the Massachusetts Institute of Technology and 
Massachusetts General Hospital. He assisted in the research of Fluorescence 
Molecular Tomography (FMT), specifically in size quantification and accuracy of 
imaging cancerous cysts in vivo. A culturally diverse laboratory with broad 
educational backgrounds, he worked with the group in developing phantoms to 
calibrate the system. FMT is a new technology where specific cancer targeting dye is 
injected into the subject. This dye emits non-harmful radiation when excited. The 
radiation is then collected, made into an image and the size/location of the tumor may 
be determined. His work in the lab consisted of developing a method to create hollow 
spheres of 1-3mm diameter, which were then filled with the specific dyes. The 
phantom tumors where then imaged in vitro and implanted for in vivo studies. This 
was done to correlate the intensity of known concentrations of dye with that of actual 
tumors in situ. The approach George helped to develop was used in future studies to 
look at new formulations of specific cancer dyes. 
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 In the summer of 2005, George was a student advisor and mentor to the 2005 
group of Bio-Optic Scholars, and was granted a NIH/NSF research internship in the 
Photon Migration Imaging Laboratory at the Martinos Center for Biomedical Imaging 
at Massachusetts General Hospital. His research internship was also sponsored 
through the Harvard University-MIT Health Sciences & Technology Program. Under 
Dr. David Boas, George conducted interdisciplinary research in several areas, 
including near-infrared spectroscopy and optical breast imaging to image breast cancer 
tumors based on functional information such as vascularization and oxygen 
consumption. George developed a breast spectroscopy system, and conducted 
preliminary clinical trials classifying healthy vs. cancerous (highly vascular, blood 
filled) tissues. This experience brought George closer to clinical engineering, while 
also teaching him new skills such as building fibers, aligning optical lenses and tuning 
high power lasers. He also developed a recipe to create mechanical and optical 
equivalent breast tissue phantoms. The phantoms where then used in the hospital to 
calibrate the optical breast imaging device before patient optical-mammography.  
 In his senior year 2005-06 at The University of Miami, George conducted 
research and developed a novel ultrasound device to measure the thickness and 
properties of tissues in vitro. Under his thesis committee and senior design advisors 
Dr. Weiyong Gu, Dr. Jorge Bohorquez and Dr. Ramarathnam Narashimhan, he 
developed state-of-the-art instrumentation and protocol for analysis of the data sets, 
this was followed by hardwiring circuit components, soldering and housing design, 
and initial testing and system calibration as well as various methods of digital signal 
processing. The 10MHz device was able to measure the thickness of tissues with 
micron resolution through the bottom of the Petri dish. The project and thesis were 
submitted, and approved by the department of Biomedical Engineering and Honors 
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program, for graduation from the University of Miami with summa cum laude honors. 
George was first in his class. 
 George attended Cornell University from 2006-10 where he completed his 
M.S. and Ph.D. in the Department of Biomedical Engineering with minors in 
Mechanical Engineering and Neurobiology. In his time at Cornell, he has mentored 22 
graduate (Ph.D. and M.Eng) and undergraduate students, and introduced them to 
ultrasound in medical applications. Some 5 students worked on fetal heart rate 
monitoring, 7 on ultrasound brain drug delivery, 8 on ultrasound based functional 
hydrogels, and 2 on other medical ultrasound related research. 
 In George’s research at Cornell University covered a wide range of biomedical 
research with a primary focus on acoustic topics and applications for medicine. His 
thesis “Medical Ultrasound for Brain Drug Delivery and Rehabilitation Medicine” has 
three main sections: 1. Development of ultrasound generation technology and 
ultrasound impedance spectroscopy measurements and 2. Ultrasound-assisted 
convection enhanced delivery of drugs to the brain. Beyond his primary thesis topics 
were six additional projects/collaborations: 1. Dr. Jason Spector of Weill Cornell 
Medical Center using handheld noninvasive ultrasound for cauterization of varicose 
veins; 2. Dr. Armen Sarvazyan of Artann Labs using developed technology in Time-
Reversal Acoustic applications for brain drug delivery; 3. Dr. Steven Gelber of 
OB/GYN Associates in developing new wide-beam fetal monitoring transducers; 4. 
Dr. Michael Schuler of Cornell University developing ultrasound-assisted brain cancer 
treatments, 5. Dr. Lyndon Hernandez and Dr. Yosi Kost from GI Associates and 
Massachusetts Institute of Technology, respectively in developing ultrasound 
mediated colonoscopy; and 6. AngioDyanmics Inc. developing tools for deep vein 
thrombosis treatment.  
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 As featured on the NSF and NIH websites, George conducted research in 
developing ultra-efficient, pocket-sized ultrasound generation technology throughout 
his Ph.D. The motivation for the research came from a NIBIB T35 training experience 
at Weill Cornell Medical College in summer 2007 where he worked with practicing 
doctors across the New York City medical campus. The T35 training inspired him 
with innovative ideas of ultrasound-improved treatment options, but he also knew of 
the current limitations in the size, cost and lack of portability of ultrasound 
technology. George effectively worked around this barrier by developing the first 
high-power, battery powered, high intensity focused ultrasound system (HIFU), and 
by developing an efficient new approach to generating low- and high-power 
ultrasound energies for a range of therapeutic applications. He characterized the 
technology in a range of theoretical and experimental applications by using 
computational modeling of the electronics and developing numerous instruments that 
work on the technology platform for academic, medical and industrial collaborators. 
 George transformed his doctoral advisor’s lab to include a state-of-the-art 
acoustics laboratory. There he developed new ultrasound characterization techniques 
for transducer calibrations and acoustic power measurements. First, he developed a 
novel electrical impedance spectroscopy technique, using an impulse response and 
Fourier analysis to map the electrical impedance of ultrasound transducers. He refined 
the technique to be applicable for various transducer designs as well as for non-
acoustic applications in the life sciences, such as measuring the impedance properties 
of cell suspensions and tissue constructs. Second, he created an algorithm based off of 
transmission line modeling to accurately predict electrical-acoustic conversion 
efficiencies for ultrasound therapy.    
George also parametrically explored the potential use of acoustics to overcome 
neurological drug delivery challenges by enhancing the administration and distribution 
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of drug within the brain during convection-enhanced delivery (CED). In CED drugs 
are directly infused into the brain to target specific locations; however the control and 
penetration of infusate is still limited by a variety of reasons as discussed in the 
dissertation. Using a 3D ex vivo model he showed that the transport of various sized 
molecules under controlled diffusion and convective processes may be dramatically 
increased by using therapeutic 1-2 MHz ultrasound over a range of powers. The use of 
ultrasound resulted in a 100-500% enhancement over diffusion alone and convective 
transport in tissue samples. As hypothesized, penetration was inversely related to the 
size of the molecule. Additionally, George transitioned this research into in vivo 
studies and found that ultrasound therapy below tissue damage thresholds improved 
molecular transport in the brain, which is now in the process of clinical translation to 
the medical campus.  
 George’s unique adventures into engineering, physics, biology, electronics, 
anatomy, mathematics and computers, make him into a distinctive researcher. He does 
not shy away from tough medical problems, but drives toward disentangling answers, 
armed with the self-assurance of his education. Surely others have similar talent, but 
George has found a way to blend the flavors of science and the physical world into 
medical solutions for a better tomorrow.  
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Figure 1.1  The action shot of the "ultrasonic fountain" shows the interaction of 
High Intensity Focused Ultrasound (HIFU) waves with water. The ultrasound 
transducer is typical of medical physical therapy ultrasound devices; operating at 1.5 
MHz and with a diameter of 2.54 cm. The difference in this picture is that the 
transducer is powered 20x greater than typical, and the energy from the transducer is 
focused to a 1mm3 volume creating a HIFU spot near the surface of the water. Since 
ultrasound is a mechanical wave, the HIFU spot sees large pressure changes as the 
sound travels via compression and rarefaction in the propagation fluid, which results 
in cavitation and micro-bubble formation in the water. The transfer of ultrasound 
energy/momentum into the fluid causes the water to stream and/or move in the 
direction of the ultrasound field. Combining the cavitation and acoustic streaming, the 
water molecules are shot into the air (some of which are vaporized by the HIFU) 
creating a beautiful acoustic fountain. 
 
Figure 1.2  Dr. Monaghan and Dr. Ferrer from the Vein and Laser Centers of 
Central NY, debuting the Cornell engineering ultrasound technology  
 
Figure 2.1  Schematic and CAD of the 12ns 5 volt pulsing circuit used in the 
impedance measurement study.    
 
Figure 2.2  Circuit representing a simple model of a piezoelectric and PSpice 
model 
 
Figure 2.3 Oscilloscope screen capture of a 4kHz Oscillator. The green, purple 
and yellow curves correspond to the outputs of pin 10, pin 9 and pin 8 of the NAND 
gates, respectively Left: 100µs per division. Right: 10ns per division. 
 
Figure 2.4   Impedance phase (on left) and magnitude (on right) plots for five 
methods and three different piezoelectric materials. 
 
Figure 2.4a-b: 5 MHz 0.5 inch diameter composite piezoelectric impedance plots 
agree well overall. The phase shift of the network analyzer around resonance begins at 
a lower frequency compared to other methods. 
 
Figure 2.44c-d: 4 MHz 0.75 inch diameter piezoelectric impedance plots agree except 
for the lower frequency phase shift of the network analyzer around resonance 
compared with the other methods. The network analyzer shows a higher parallel 
resonant magnitude compared with the other methods. 
 
Figure 2.4e-f: 2 MHz 0.59 inch diameter piezoelectric impedance plots agree well. 
The phase and magnitude measurements of the network analyzer and impulse method 
have low amplitude spectral ripples through EIS plots.  
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Figure 3.1 Circuit schematic of the low output impedance ultrasound driver. A pin 
driver is appropriately timed with a TTL 5 volt signal from a 1.54 MHz crystal 
oscillator that switches the drain of the low output impedance MOSFET from +/- 50 V 
maximum. 
 
Figure 3.2 Driving circuit used in portable ultrasound system. The working unit of 
Figure 1 may be applied in parallel stages to reduce the power/heat dissipation in each 
MOSFET to allow for high current driving to the transducer. 
 
Figure 3.3 Wire layout for portable ultrasound system. 
 
Figure 3.4 Portable therapeutic ultrasound system with 1.54 MHz ultrasonic 
probe.  The unit is 4 x 6 x 2 in and weighs 5.5 lbs. 
 
Figure 3.5 Left: Measured impedance and results from a Mason Model of 
transmission lines.  Right: Calculated acoustic conversion efficiency from the Mason 
Model. 
 
Figure 3.6 (a) Measured 1.54MHz output waveform from the device with slight 
ringing at the corners. The driving signal is mostly clean with no oscillations in the 
waveform and fast rise times between the push-pull cycles. (b) The power spectrum of 
the 1.54 MHz waveform. The drive signals energy concentration is in the early 
megahertz frequencies. (c) Measured while the timing signal came from a function 
generator, the higher frequency of 7.5MHz lead to attenuated drive voltage and 
asymmetry of the waveform with oscillations on both the positive and negative sides. 
 
Figure 3.7 1.54 MHz ultrasound transducer levitating and cavitating water at full 
system power. 
 
Figure 4.1 Schematic of the ultrasound driver. A TTL timed pin driver is used as a 
branching cascade to switch 14 low output impedance MOSFETs.  
 
Figure 4.2 PCB layout for the ultralow output impedance ultrasound driver (2 x 3 
in). Components are shown in white with corresponding values in black text. Extra 
copper visible on the output of components M1-M14 is used for thermal dissipation 
and balancing. 
 
Figure 4.3 Mason model to study the effect of ultralow output impedance 
ultrasound driver in maximum power driving frequency. Amplifier output resistance 
Rs is varied in this model from 0.03-200 Ω, and the piezoelectric material is modeled 
as PZT-4 1.5 MHz and 8.0 MHz transducers. The piezoelectric material and water 
path are considered two port lossy transmission lines. The transformer converts 
electrical energy into pressure for the transducer conversion.  
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Figure 4.4 Predictions of the model shown in Figure 3.  (4a) through (4d) show the 
maximum output power as a function of frequency for values of the amplifier source 
impedance Rs in the range 0.03 to 200 Ω . (4a) 1.5 MHz 10.3 Ω transducer. (4b) 1.5 
MHz 1.2 Ω transducer. (4c) 8 MHz 10.6 Ω transducer. (4d) 8 MHz 0.37 Ω transducer  
 
Figure 4.5 (A and B) Measured 1.54MHz output waveform from the ultrasound 
driver with slight ringing at the corners without and with the ultrasound transducer 
attached, respectively. (C) The power spectrum of the 1.54 MHz waveform. The drive 
signals energy concentration is in the early megahertz frequencies. (D) Measured 8.0 
MHz signal shows attenuated drive voltage and asymmetry of the waveform with 
oscillations on both the positive and negative sides. 
 
Figure 4.6 (A and B) Measured 1.54MHz output waveform from the ultrasound 
driver with slight ringing at the corners without and with the ultrasound transducer 
attached, respectively. (C and D) Output waveform from the ultrasound driver with 12 
Ω impedance matching power resistor attached directly to driver in series to the 12 Ω 
ultrasound transducer without and with the transducer attached, respectively. (E and F) 
Output waveform measured with 50 Ω power resistor in series without and with 
transducer, respectively. 
 
Figure 4.7 Complete high-power ultralow-output impedance ultrasound driver 
powering a 1.54 MHz ultrasound transducer. (A) Ultrasound driver operating at 28 Vpp 
with a clean waveform and high acoustic energy output causing the water to vaporize. 
(B) Close-up of the transducer in the water bath levitating and cavitating the water 
molecules into the air. Cavitation bubbles are visible in the water stream off the front 
face of the transducer. 
 
Figure 5.1  The experimental setup for the phantom study is shown. The sonicated 
phantom is immersed in 0.5 wt% diluted dye and pulse sonicated (15 seconds on and 
off) while simultaneously the transducer is oscillated up and down at 0.25Hz 10mm 
amplitude. The beginning position of the transducer was 40mm above the agar/dye 
interface, so that the US focus was placed on the surface. The control setup was the 
same without US.   
 
Figure 5.2  Top left and right are histology images taken from phantoms with and 
without applied US TP 1 and 4. Visible is the increase in dye penetration and intensity 
of the sonicated phantom. Bottom left and right are the corresponding RGB color 
intensity maps that correspond with the above images. 
 
Figure 5.3  Plot of the theoretical fit to the experimental data for TP 1 and 4. Top 
left we see good agreement with control (No US) and constant source diffusion Eq. 
(5.1), note that US experimental data does not fit Eq. (5.1) well. Bottom left we find 
that Eq. (5.2) fits experimental data with US well but does not fit control. Top right 
graph shows that simple diffusion does not fit control or US phantom well for TP4. 
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Bottom right graph shows that Eq. (5.2). fits both control and US phantom well. 
Overall Figure shows a noticeable increase in dye penetration when US is applied. 
 
Figure 6.1  The experimental setup for the sample study is shown to the left. The 
sonicated phantom is covered  in 0.25 wt% diluted Evans blue dye and sonicated at 
100% duty  while simultaneously the transducer is oscillated up and down at 0.25Hz 
10mm amplitude. The beginning position of the transducer was 40mm above the 
sample/dye interface. 
 
Figure 6.2  The above Figure shows the sectional images and the results of 
enhanced EBD delivery into a tissue mimicking phantom, equine horse brain and 
avian muscle tissues with the application of Therapeutic Ultrasound for two minutes in 
red, compared with the control in blue. The Figure shows concentration curves of the 
EBD uptake into the samples and that local delivery of EBD in conjunction with the 
application of Therapeutic Ultrasound may significantly enhanced the amount of EBD 
delivery into tissue.  Application of US enhanced EBD density of 61.5% (phantom), 
93.2% (brain) and 52.8% (muscle) compared to the control. 
 
Figure 6.3 Dimensionless BCNU concentration profiles in tissue following its 
release from a wafer in monkey brain 
 
Figure 6.4  EBD concentration profiles after 2 min in equine brain tissue without 
ultrasound (red) and with 1W/cm
2
 ultrasound (blue) for 2 min. Ultrasound increases 
the apparent diffusion coefficient by about 40x. 
 
Figure 7.1  Experimental setup for ultrasound-enhanced convection. A 1.58MHz 
transducer sonicated the sample for 1-30 min. The pressure gradient across the sample 
was primarily provided by a vacuum pump, which induced convective flow through 
the sample. 
 
Figure  7.2  EBD profile of avian muscle tissue after sonication at 1.3 W (top) and 
5.25 W (bottom) for 4 min. US combined with CED provided greatest EBD uptake 
enhancement of 240% (left) and 390% (right) as compared with diffusion alone. 
 
Figure 7.3 EBD profile of equine brain tissue (top) and brain-mimicking phantom 
(bottom) after 5.25 W sonication for 2 and 1 min, respectively. US combined with 
CED provided greatest EBD uptake enhancement of 560% (left) and 880% (right) 
compared with diffusion alone. 
 
Figure 7.4 Compilation of sectional profile images to produce EBD profile curves 
in Figures 1 and 2 
 
Figure 7.5 Dimensionless concentration profiles of EBD (left) and AcEBD (right) 
for brain-mimicking phantom after 5.25 W sonication for 1-30 min. US combined 
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with CED provided greatest EBD and AcEBD uptake enhancement of 277% (left) and 
327% (right) compared with diffusion alone. 
 
Figure 8.1 Construction of the transducer cannula assembly. I. Machine the PZT-4 
into a disk with center hole. II. Connect a brass tube to front face of ceramic using 
solder. III. Place the ceramic in a watertight PVC/aluminum housing with sterotaxic 
guide arm, and connect ground and hot leads to the transducer through the guide arm. 
V-VI. Attach the guide-cannula and infusion cannula to the transducer and secure to 
the popper height with epoxy. VII. Actual finished device. 
 
Figure 8.2 Animal experimental setup for using TCA in rat brain. The rat is 
secured with ear bars in a stereotaxic frame and a small craniotomy is performed on 
the left hemisphere. The TCA is guided 5.5 mm deep into the caudate of the rat brain. 
 
Figure 8.3 Electrical impedance of TCA. Resonance occurs at 1.18 MHz with 380 
Ω impedance. The phase angle (not shown) is approximately 0 degrees at resonance. 
Parallel resonance occurs at 3.1MHz. 
 
Figure 8.4 Brain sections from the four subgroups of group 2 studied after 30 
minutes of Evans blue infusions at 0.5 μL per minute with a 30 gauge cannula. A. 
Convection enhanced delivery (CED) and B. Convection enhanced delivery with 
microbubbles (CED+MB) provide similar infusion profiles for the rodents in each 
group. C. Ultrasound-assisted convection enhanced delivery (UCED) delivers EBD 
further into the brain and more diffusely spread across the caudate. D. Ultrasound-
assisted convection enhanced delivery with microbubbles (UCED+MB) shows further 
EBD penetration over CED and CED+MB, but is more localized in the rodent caudate 
versus UCED which spreads EBD out of the caudate region. Backflow of EBD along 
the needle track into the white matter track of the corpus callosum is reduced with 
UCED and UCED+MB as compared to controls.  
 
Figure 8.5 3D Infusion reconstruction of the four subgroups of group 2 brain 
sections from Figure 4. The cannula is in the plane of the Figure and the transducer 
cannula assembly (TCA) is positioned at the top of each Figure. A. Convection 
enhanced delivery (CED). B. Convection enhanced delivery with microbubbles 
(CED+MB). C. Ultrasound-assisted CED (UCED). D. Ultrasound-assisted CED with 
microbubbles (UCED+MB). 
 
Figure 8.6 Analysis of total EBD volume distribution in the rodent brain with 
subgroup standard error bars. UCED and UCED+MB increases EBD volume 
distribution by 2.24x and 1.37x in the left hemisphere and 2.44x and 1.70x in the left 
caudate, respectively, as compared with CED and CED+MB receiving 0.25µL per min 
infusions. For 0.5µL per min infusions of group 2,UCED and UCED+MB increases 
EBD volume distribution by 2.96x and 1.16x in the left hemisphere and 3.25x and 
1.54x in the left caudate, respectively.  The left hemisphere and left caudate subgroups 
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of groups 1 and 2 are statistically significant with independent means p<0.05* and 
p<0.001*.    
 
Figure 8.7.  Group 1 0.25 µL per min infusion analysis of EBD distribution profile 
in the rodent caudate as a function of the AP distance in the region ±4 mm from the 
infusion site. The black line represents the average area of EBD at the given position. 
The shaded region represents the standard deviation of EBD area (n=5) 
 
Figure 8.8.  Group 2 0.5 µL per min infusion Analysis of EBD distribution profile 
in the rodent caudate as a function of the AP distance in the region ±4 mm from the 
infusion site. The black line represents the average area of EBD at the given position. 
The shaded region represents the standard deviation of EBD area (n=5) 
 
Figure 8.9.  The area of EBD in rodent caudate for each slice plotted as a function 
of the square of the AP for group 1 and group 2. Each solid colored line is the average 
area for each treatment at the given position. A dotted line segment with a slope 
magnitude of π is drawn for reference. Data that fall on a line with slope of π or −π 
indicate regions where the infusion of EBD is locally isotropic. Deviations from the 
slope indicate an anisotropic volume distribution. 
 
Figure 8.10 Hematoxylin and eosin stain of rodent brains (10 um coronal slices) in 
the cannula insertion path. CED, CED+MB, UCED and UCED+MB show similar 
histological results in both the cortex and caudate of the rodent brains. Mild 
parenchymal disruption, edema and hemorrhage around the needle track and injection 
site are equivalent for the group. 
 
Figure 9.1  Hematoxylin and eosin stain of rodent brains (10 um coronal slices) in 
the cannula insertion path. Acoustic intensities of 0.062, 0.087, 0.112 and 0.155 
W/cm2 show similar histological results in both the cortex and caudate of the rodent 
brains. Mild parenchymal disruption, edema and hemorrhage around the needle track 
and injection site are equivalent for the group. 
 
Figure 9.2  UCED Infusion Profiles. The rat brain in (A) shows a relatively 
uniform distribution, while the brain in (B) shows clear banding of the infused dye 
approximately 0.6mm apart. 
 
Figure 10.1 Ultralow output impedance ultrasound power generation technology. A 
10-channel high power ultrasound driver is shown on the lab bench. 
 
Figure 10.2 Ultrasound-assisted CED cannula for improved drug delivery in brain 
cancer therapy. 
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Figure 10.3 Delivery and setup of TRA-CED system at Cornell University 
Biomedical Engineering Laboratories. A) Surgical setup of rodent positioned in 
stereotax device and TRA-CED system arranged for preliminary in vivo testing. B) 
Close up of surgical prep, smart ultrasound needle cannula and ultrasound therapy 
transducer resonator. C) First successful TRA-CED focusing in the rodent brain in 
vivo. D) Artann researcher standing next to TRA-CED system in animal surgery suite. 
 
Figure 10.4  Hand held HIFU and its use to non-invasively cauterize and occlude 
veins in vivo. A) Shows the electronic heart of the system and ultrasound transducer 
probes, B and C) Show results from in vivo ablation of rodent inferior vena cava. 
 
Figure 10.5 Dr. Peter Henderson, M.D. performing surgical cauterization using 
portable ultrasound device. 
 
Figure 10.6 Wide-beam ultrasound transducer developed in comparison to 
traditional commercially available transducer for FHM. 
 
Figure 10.7 Schematic of improved detection of fetal heart rate by broadening the 
acoustic beam.  
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Table 2.1  Tabulated model data for piezoelectric materials studied R, L, C and 
CO. Also including the resonant and parallel resonant frequencies and impedance 
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with diffusion alone. The corresponding temperature changes in the samples during 
US application is also shown.  
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CHAPTER 1 
 
ULTRASOUND: HISTORY, PHYSIC AND MEDICINE 
 
1.1 The History of Ultrasound 
The field of acoustics is older than a millennium and continues to evolve at 
Mores law pace. Sound, vibration and the principles of acoustics were first 
documented by Pythagoras, a Greek philosopher, mathematician and scientists, in the 
early 6
th
 century. Acoustic frequency and vibration, musical pitch and tone were later 
studied by Galileo and his father in the mid-1600s. Galileo’s and others scattered 
studies across Europe were later combined by Lord Raleigh into the “Theory of 
Sound” in 1877. The “Theory of Sound” connected the mathematics and physics 
behind acoustics with empirical results. The field of ultrasonics, or the branch of 
acoustics that deals with mechanical oscillatory waves at frequencies above the human 
audible range (greater than 20 kHz), was developed during World War I as the first 
“passive/active sonar” technology capable of detecting enemy vessels using acoustic 
propeller and hull noise signatures [1, 2].  The first hydrophone for passively detecting 
submarines was developed by Wood and Gerrard from England. Langevin from 
France began using piezoelectric materials and vibrating devices for active ultrasonic 
detecting means of military ocean vehicles. The effort of the two groups opened a new 
door to measuring and generating mechanical ultrasonic vibrations for measurement 
applications.  
Since early war time to current day, ultrasonics is used for sonar and other 
measurement capabilities. In the more recent decades, ultrasonics has continued to be 
studied and developed extensively for a vast array of military, medical, and industrial 
applications some of which are discussed in this dissertation. Ultrasound which is a 
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mechanical wave can only exist in matter composed of molecules, since the wave is 
transmitted from one molecule to another by expansion and rarefaction between 
molecules in direct contact. Due to the mechanical vibratory transmission of 
ultrasound , the attenuation of the wave  is highly dependent on the elastic property of 
the medium [3]. These properties of ultrasound allow the acoustic wave to travel 
efficiently through mediums that are relatively dense such as water, tissue and metal 
because the wavelength of sound is large compared to the spatial position of the 
molecules. Conversely, ultrasound does not travel well in gasses and air because 
molecules are too spread out to effectively vibrate and transmit the ultrasonic waves. 
 
1.2 The Physics Behind Ultrasound 
The wave equation describes the propagation of ultrasound waves in isotropic 
homogeneous media and in the simplest 1D form it may be derived from hooke’s law. 
In 3D space the wave equation becomes much more complex particularly when taking 
into account the non-linearity of amplitude and frequency dependence on the 
propagation of ultrasound waves in certain regimes. The physics behind ultrasound 
depends on a number of parameters. Here, we review the fundamental equations that 
describe the ultrasound wave and the elegant physics behind ultrasound. In most of the 
equations presented the terms within them may be considered constants for most 
engineering applications; however the non-linearity of the terms should be noted in 
certain regimes. The ultrasound frequency f is measured in Hertz (Hz).  The speed of 
ultrasound c through a media is a function of elasticity K (N/m
2
) and density ρ 
(Kg/m
3
): 
 

K
c 
        (1.1) 
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The wavelength λ (m) of ultrasound is calculated as:  
 
 f
c

     (1.2) 
The amplitude A of the ultrasound wave is measured in units of length in 
meters (m) or pressure in Pascale (Pa). Length measurements describe the maximum 
distance between the molecules in the rest state in relation to the 
expansion/compression state, while pressure measurements describe the 
maximum/minimum local pressure within the ultrasound wave. 
The velocity of ultrasound in media is temperature dependent and readily 
available for a wide range of materials in ultrasound texts. It is important to note 
however, that ultrasound travels faster in well-ordered solid structures such as 
ceramics, metals and bone, and much slower in non-rigged objects such as water, 
muscle and fat. As a general rule of thumb, ultrasound in soft tissues for medical 
applications has a velocity of approximately cMed=1540 m/s [4]. Furthermore, the 
speed of sound in some cases is frequency and amplitude dependent. 
In the linear and elastic range of a medium, the displacement of particles 
within the ultrasound field is sinusoidal, and the wave amplitude does not affect wave 
propagation. When two or more waves interfere in this regime their amplitudes add to 
one another and their frequencies ride on top of each other.  In special cases of 
interference, stationary nodes are formed with no spatial or amplitude displacement. In 
this case, the ultrasound wave interaction is termed “standing wave”. Standing waves 
can produce interesting affects in medical ultrasound applications as will be discussed 
in Chapter 9. Once the interference of two or more waves concludes, the individual 
waves maintain their initial properties of frequency and amplitude. Should the sum of 
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the two waves produce pressures and temperature rises above the linear and elastic 
range of the medium, non-linear effects need to be taken into account.  
 
1.2.1 Ultrasound Energy, Dissipation and Attenuation 
The frictional forces between molecules in the transmission path absorb the 
energy of the ultrasound waves and convert it into heat. This heat can directly affect 
the speed of propagation in the medium, as well as the quicker dissipation of the 
ultrasound wave’s energy.   Mechanical motion of the wave propagation media 
discussed later can also dissipated energy. The ultrasound intensity of the wave source 
Io is thereby exponentially reduced according to the following equation as it 
propagates into a medium distance x with absorbance coefficient α:   
 
x
ox eII
2
     (1.3) 
where Ix (W/cm
2
) is the intensity of the wave at distance x from the initial source. The 
absorption coefficient is a function of frequency and as frequency increases the 
absorbance coefficient increases. The pressure amplitude P is identically related to 
intensity as a function of distance and the absorption coefficient: 
x
ox ePP
2      (1.4) 
The total ultrasound power produced by the wave is measured in Watts (w) and 
calculated by multiplying the intensity I over the surface area it is applied to. The 
ultrasound power describes the sum of acoustic energy per unit time.  
 
AIPower       (1.5) 
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 The ultrasound energy density (E) is a measure of energy per unit volume and 
calculated by: 
 
c
I
E        (1.6) 
and measured in units of joules per square centimeter (J/cm
2
). 
An ultrasound wave traveling through a medium is dispersed and absorbed 
over a period of time due to matter inconsistency, heterogeneities and friction. This 
combined effect is called attenuation that is measured in (dB) and is estimated along 
the propagation distance x according to: 
 
fxnattenuatio  '     (1.7) 
where α’ is the attenuation coefficient. Values of α’ vary multiple fold depending on 
the media. For water α’ is approximately 0.0022 while for bone α’ is approximately 
20. For various types of soft tissues and fluids  α’ is approximately  1.0 for muscle and 
kidney, 0.94 for liver, 0.85 for brain, 0.63 for fat and  0.18 for blood, all in units of 
dB/(MHz x cm) [5-8].  The attenuation coefficient for skin varies greatly depending 
on the moisture level of the skin – approximate α’ range is 0.7 to 10. 
 
1.2.2 Ultrasound Reflection and Refraction 
Reflection and refraction of a sound wave occurs when it propagates across an 
interface of two different materials of differing acoustic impedance Z calculated by:  
 
cZ        (1.8) 
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where ρ is the density of the material, c is the ultrasound speed and Z is in units of 
Nepers·seconds per cubic meter (N·s/cm
3
) or Megaralys. At the boundary of wave 
propagation and differing acoustic impedances, two or more acoustic waves are 
produced: one continuing to propagate in the forward direction into the next medium 
and the other being reflected back into the initial medium. The forward propagating 
wave changes its transmission angle according to Snell’s Law, while the reflected 
wave’s angle is the same as the incident angle.  The reflected fraction of energy R, is 
proportional to impedance mismatch between the first and second mediums Z1 and Z2, 
and calculated by:  
 
2
21
21









ZZ
ZZ
R
.    (1.9) 
The acoustic impedance of air is 0.0004 Megarayls while it is 1.70 and 7.80 Megarayls 
for muscle and bone, respectively [7]. Such large impedance mismatches between 
bone and soft tissue provide very good ultrasound contrast in medical imaging.  
Understanding reflection and refraction along with the exponential attenuation 
of ultrasound waves in soft tissue is the basic foundation of ultrasound diagnostic 
techniques used in medicine today. It also plays an important role in measuring the 
effective treatment area of ultrasound. 
 
1.2.3 Ultrasound Forces and Physical Mechanisms 
Ultrasound waves apply a force on objects that they are reflected or absorbed 
by.  When a wave of radiating power W and speed c is completely absorbed by the 
medium, the irradiating force F is measured in Newton’s (N) according to: 
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c
W
F 
.     (1.10) 
The radiation force on an object is increased by a factor of two, when completely 
reflected by the object according to: 
 
c
W
F 2
     (1.11) 
The acoustic force can cause the motion of particles in fluid, which is called acoustic 
streaming. The velocity of acoustic streaming v (m/s), is dependent on the viscosity µ 
and absorption coefficient α, and calculated according to: 
 
c
W
v





2
     (1.12) 
Both the acoustic force and streaming velocity play an important role in many of the 
medical applications of therapeutic ultrasound. Understanding these basic physical 
mechanisms and the interactions of ultrasound in medical therapeutic applications in 
vivo still remain unclear and a topic of continued research as well as this dissertation. 
 
1.2.4 Ultrasound Cavitation and Mechanisms 
The formation of microbubbles (gas-filled cavities) or the oscillation of 
microbubbles in an acoustic field is termed “cavitation”   [9-11].  Cavitation activity 
usually involves intrinsic stable bubbles that were already present in the liquid media 
or were created by the propagation of the acoustic wave itself.  In the latter case, the 
negative pressure of the acoustic wave must be below the vapor pressure of the fluid in 
order for a cavitation bubble to form [12]. Once formed within the fluid or when found 
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intrinsically in the fluid, these microbubbles in the acoustic field oscillate and cause 
local fluid motion, swirling, streaming, and mixing [13]. Microbubbles may also be 
actively added into the media from external sources, since they are readily available 
commercially and used as contrast agents in diagnostic ultrasound today. 
There are two well documented types of acoustic cavitation: stable cavitation 
and inertial cavitation and their interactions with tissues and structures are immensely 
different as will be discussed later. 
Stable cavitation is the continuous oscillation of microbubbles in the acoustic 
field with a streaming motion in the path of wave propagation.  In stable cavitation the 
microbubble radius will oscillate with the acoustic pressure field during the 
compression and rarefaction cycle.  
Inertial cavitation is also called “transient cavitation” since it ends with a 
microbubble implosion.  Transient cavitation is the highly active oscillation of 
microbubbles in high amplitude acoustic fields that causes the microbubbles radius to 
resonate, and reach both very large and small lengths to a point where it rapidly 
expands beyond a fatal resonance point and then implodes [14].  
The resonant radius for implosion of an air filed microbubble in water Rr (mm) 
is related to the frequency of sound f (kHz) and can be estimated by: 
 
f
Rr
29.3

 [14].    (1.13)  
The energy released during transient cavitation can produce very high 
pressures generating significant forces on surrounding media. The collapse of 
microbubbles also generates very high but short-lived temperature rises. These 
extreme pressures and temperatures in a temporally compressed window make inertial 
cavitation activity an adiabatic process [12,15]. The properties of the microbubble 
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including the gas inside, its radius, shell properties and fluid surround it determine its 
resonant frequency, resonant radius and inertial cavitation forces generated [14, 16]. 
Low frequency applications of ultrasound result in large oscillating bubbles that are 
used in ultrasonic cleaning and transdermal drug delivery. Higher frequency 
ultrasound may oscillate much smaller microbubbles that may prove useful in 
enhancing the movement of pharmaceuticals through tissues as discussed in Chapters 
5-9.  
When a microbubble collapses near a surface a high-velocity “micro jet” of 
liquid reaching several hundred meters per second, is propelled toward the surface, 
thereby depositing enormous energy densities at the site of impact [17-19]. The 
implosion produces a shock wave with the creation of additional microbubbles, which 
can cause additional cavitation activity in the medium making a cavitation cloud [20]. 
The Mechanical Index (MI) is an indicator of the onset of transient cavitation 
in media exposed to ultrasound [21]. MI is calculated according to: 
 
MI = (Pneg/f
0.5
)     (1.13) 
 
where Pneg is the peak negative pressure, and f is the frequency. When the MI 
is greater than 0.7 the probability of transient cavitation is high [22]. An acoustic peak 
negative pressure of 0.2 MPa will cause inertial cavitation in blood at 1 MHz, but 
much higher pressures are required for inertial cavitation in tissues. The addition of 
commercially available microbubbles may be used to induce stable and inertial 
cavitation in the media at much lower acoustic pressures. In this case, the MI is not 
well defined and is dependent on the microbubble properties. 
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 The Thermal Index (TI) is a measure of acoustic power W required to raise the 
temperature of tissue by 1 degree centigrade (Wdeg) according to: 
 
TI = (W/Wdeg)     (1.13) 
 
For therapeutic applications TI’s are generally maintained below 6 according to FDA 
guidelines. 
 
1.3 Ultrasound in Medical Applications 
The use of ultrasound in medicine has evolved over the last 70 years in 
physiotherapy, simple diagnostics, medical 3D imaging, and drug delivery and novel 
combination diagnostic-therapeutic applications [23, 24]. Ultrasound has its longest 
history of use in physical therapy for musculoskeletal disorders. In recent years the 
medical application of ultrasound has expanded into new applications some of which 
are discussed in this dissertation. Therapeutic ultrasound is being used, by itself or in 
combination with drugs, in various clinical applications such as back and knee pain, 
healing, venous diseases, cancer, cardiovascular diseases, infections, osteoporosis, 
thrombosis, glaucoma, nerve damage, aging skin, wounds, muscle spasms, and bone 
fractures. Many FDA approved ultrasound based devices are available already around 
the world, and countless others are in various preclinical and clinical approval 
processes. As of today, European and Asian countries have been more progressive in 
the regulatory approval, acceptance and use of both traditional and the newer 
applications of therapeutic ultrasound in medical applications. Furthermore, for the 
last 70 years no adverse bio effects do to ultrasound exposure for short or long 
treatment durations have been reported beyond thermal and mechanical effects at 
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relatively high acoustic exposures. The expert consensuses of investigators who use or 
are involved in ultrasound research believe that ultrasound is safe. 
 The interaction of acoustic waves microscopically and macroscopically, and 
the multiplicity of their effects on cells, membranes and tissues provides a range of 
beneficial interactions that can be utilized in therapeutic medicine.  As presented 
earlier, a medium exposed to ultrasound experiences pressure oscillations and the 
possibility for cavitation activity.  The absorbance of ultrasound and the pressure 
oscillations in the tissue both thermally and mechanically affect it. Ultrasound has 
been shown to cause vasodilation and increase tissue plasticity. Additionally, the 
interaction of ultrasound with tissues increases the permeability of it, and may be used 
for a variety of drug delivery and therapeutic effects through it that will be discussed. 
Though the temperature rise of tissue do to the absorption of the ultrasound 
wave is important, perhaps the second most significant effect of ultrasound in medical 
applications is cavitation. Both stable and inertial cavitation have significant 
mechanical, thermal and macro/micro level effects on cells and tissues including  fluid 
mixing and shear forces on tissue matrixes [25, 26], and disruptive shock waves that 
can  induce chemical changes “sonochemistry” [27].  The ultrasonic waves create a 
dynamic moving environment in the treatment zone that may be utilized in a variety of 
medical applications. 
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Figure 1.1 The action shot of the "ultrasonic fountain" shows the interaction of High 
Intensity Focused Ultrasound (HIFU) waves with water. The ultrasound transducer is 
typical of medical physical therapy ultrasound devices; operating at 1.5 MHz and with 
a diameter of 2.54 cm. The difference in this picture is that the transducer is powered 
20x greater than typical, and the energy from the transducer is focused to a 1mm
3
 
volume creating a HIFU spot near the surface of the water. Since ultrasound is a 
mechanical wave, the HIFU spot sees large pressure changes as the sound travels via 
compression and rarefaction in the propagation fluid, which results in cavitation and 
micro-bubble formation in the water. The transfer of ultrasound energy/momentum 
into the fluid causes the water to stream and/or move in the direction of the ultrasound 
field. Combining the cavitation and acoustic streaming, the water molecules are shot 
into the air (some of which are vaproized by the HIFU) creating a beautiful acoustic 
fountain. 
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In sonochemistry, high power ultrasound and cavitation interactions are 
capable of generating highly reactive species that can induce chemical transformations 
in the surrounding medium. Effects of ultrasound can also appear at the cellular and 
tissue-level that will be discussed further in Chapter 8-9. Overall, the effects of 
ultrasound on tissue are governed by several parameters, primarily the frequency, 
amplitude and pulse frequency of the ultrasound [28-31]. In the following chapters we 
discuss the development of ultrasound systems and their application in neurological 
based drug delivery and rehabilitation medicine. 
 
 
Figure 1.2 Dr. Monaghan and Dr. Ferrer from the Vein and Laser Centers of Central 
NY, debuting the Cornell engineering ultrasound technology. 
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CHAPTER 2 
 
COST EFFECTIVE BROAD-BAND ELECTRICAL IMPEDANCE 
SPECTROSCOPY MEASUREMENT CIRCUIT AND SIGNAL ANALYSIS FOR 
PIEZO-MATERIALS AND ULTRASOUND TRANSDUCERS
2 
  
 
2.1 Abstract 
 
This chapter explains the circuitry, and signal processing to perform electrical 
impedance spectroscopy on piezoelectric materials and ultrasound transducers. Here, 
we measure and compare the impedance spectrum of 2-5MHz piezoelectrics, but the 
methodology applies for 700kHz-20MHz ultrasonic devices as well. Using a 12ns 
wide 5 volt pulsing circuit as an impulse, we determine the electrical impedance 
curves experimentally using Ohms law and Fast Fourier Transform (FFT), and 
compare results with mathematical models. The method allows for rapid impedance 
measurement for a range of frequencies using a narrow input pulse, digital 
oscilloscope and FFT techniques. The technique compares well to current 
methodologies such as network and impedance analyzers, while providing additional 
versatility in the electrical impedance measurement. The technique is theoretically 
simple, easy to implement and completed with ordinary laboratory instrumentation for 
minimal cost.  
 
 
                                                 
2This work has been published as Lewis, G.K., Jr., Lewis, G.K., Sr., Olbricht, W.L. (2008). Cost-
effective broad-band electrical impedance spectroscopy measurement circuit and signal analysis for 
piezo-materials and ultrasound transducers. Meas. Sci. Technol. 19 105102 
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2.2 Background 
Electrical Impedance Spectroscopy (EIS) of piezoelectric devices and 
materials, henceforth referred to as PED’s, derives from the measurement of the 
current into and the voltage across the PED as a function of the applied sinusoidal 
voltage frequency. According to Ohm’s Law the impedance can be calculated by 
complex division of the voltage and current. The impedance of the PED can be 
calculated by applying a sinusoidal voltage to the PED in series with a resistor, and 
measuring the voltage across the resistor and across the PED. Performing this 
measurement by sweeping the frequencies of the applied signal provides the 
impedance phase and magnitude. The power - voltage multiplied by current - 
delivered to the PED can also be determined from the voltage and current 
measurements. The impedance plot, and, more importantly the current and voltage 
measurements as a function of frequency, provides useful information to builders and 
users of the piezoelectric device.    
EIS provides many piezoelectric properties that are necessary in developing 
ultrasound transducers for imaging, ablation, level-measurement and other ultrasonic 
applications [1, 2]. The electrical impedance of piezo-material over a range of 
frequencies is important in understanding the behavior of the piezoelectric around 
resonance and parallel resonance. It is also useful to compare different piezoelectric 
materials such as films, composites and single crystals for their possible uses and 
electro–acoustic behavior [3].    
By analyzing the electrical impedance curve as a function of frequency, one 
can determine properties of the piezo-material such as impedance Z, admittance Y, 
maximum impedance frequency fp, maximum admittance frequency fs,  mechanical Q 
Qm, and the components of the RLC circuit that mimics the material [4-7]. Therefore, a 
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quick and affordable way to measure the impedance of a piezo-material and ultrasonic 
devices can be of significant benefit. 
Numerous methods have been introduced to measure electrical impedances for 
transducer sensitivity calibrations [7], maximization of acoustic energy 
conversion/transfer [8, 9] and to determine other properties of piezoelectric ceramics 
[1,2]. A good review of standard methods used at different frequencies and in a variety 
of devices is “Agilent Technologies Impedance Measurement Handbook” [10] at the 
Agilent Technologies website. In practice, EIS of piezoelectrics is easily done using 
network analyzers and impedance meters. However, these devices generally cost ten to 
forty thousand dollars, which is prohibitive for many potential users. In this 
manuscript we demonstrate a practical and affordable pulsing circuit along with the 
methodology to easily perform EIS for assumed lossless PED’s [6, 11] using a well 
established signal processing approach. 
The approach in this paper uses an impulse response to determine the transfer 
function of a simple circuit or system. An applied pulse to a PED in series with a 
known impedance source in time results in a measurable response.  When the 
measured response is converted into the frequency domain, Ohm’s Law can be used to 
determine the impedance of the PED as a function of frequency.  
 
2.3 Methods 
2.3.1 Pulsing Circuit 
The pulsing circuit shown in Figure 2.1 constructed from two common high 
speed integrated circuits (IC) (Mouser Corporation) mounted on a prototyping board. 
The first IC was a Hex Inverter (DM74AS04 Fairchild Semiconductor) wired to form 
a simple 4 kHz square wave oscillator (pins 1-4 and 12-13). The output from the 
oscillator pin 4 was then sent through even multiples of gates as shown in the Figure 
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to obtain two equivalent wave forms. The two outputs from the Hex Inverter (pins 10 
and 8) were sent to the second IC, a high speed Quad NAND Gate (DM74AS00 
Fairchild Semiconductor). The NAND Gate’s intrinsic 4ns propagation delay was used 
to slow the output (pin 8 Hex Inverter) by approximately 12ns. The delayed signal was 
then logically combined with the non-delayed signal (pins 9 and 10 NAND Gate). The 
output at pin 8 of the NAND Gate was a 10ns wide 5 volt pulse. Bypass capacitors 
(pins 14 both IC’s) and a pull-up resistor (pin 8 NAND Gate) were used to sharpen the 
pulse and remove ringing as shown in Figure 2.1. 
 
 
Figure 2.1. Schematic and CAD of the 12ns 5 volt pulsing circuit used in the 
impedance measurement study.    
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2.3.2  Experimental Measurements and Analysis 
The pulsing circuit in Figure 2.1 was connected in series to a known 
impedance source Zp, a simple 49 ohm resistor with 1% tolerance, and the unknown 
PED electrical impedance Zm, as shown in Figure 2.1. The transient voltage responses 
Vp and Vm were measured across Zp with x10 scope probes triggered off of pin 10 of 
the NAND Gate. The measured PED’s were connected to the pulsing circuit and 
known impedance source using a two-point copper prong holder (bottom of Figure 
2.1). To measure Zm, the digital wave forms of Vp and Vm were collected using a 
Tektronics Model# TDS2002B oscilloscope at a sample rate (SR) of 4ns per point. 
The measurements of Vp and Vm were collected using the screen capture setting on the 
oscilloscope out to 20µs in time.      
For each piezoelectric measured, Vp and Vm were padded with zeros to make 
the signal 3x10
6
 points long in time, and the Fast Fourier Transform (FFT) was taken 
in MatLab® (Math Works Corporation, Natick, MA). The FFT of transient voltage 
measurements Vp and Vm provided the frequency domain content of the signals FVp 
and FVm, respectively. The electrical impedance of the unknown PED as a function of 
frequency FZm was determined according to  
 
mp
pm
m
FVFV
ZFV
FZ



  
 (2.1) 
The resulting complex impedance vector FZm was plotted for its magnitude 
and phase (y-axis), in conjunction with its frequency vector (x-axis). The per-point 
frequency step for the x-axis f was given by  
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f


1
   
 (2.2) 
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where SR is the sample rate and F is the number of points for which the FFT was 
taken. 
 
2.3.3 Impedance Measurement Using Network Analyzer 
The impedance phase and magnitude plots were collected with an HP 4194 
impedance analyzer and saved into a digital text file for comparison with results from 
section 2.3.2. The PED’s were placed in a two-point holder with leads that connected 
the PED’s to the system. The holder was identical to the impulse measurements holder 
of section 2.3.1, Figure 2.1.  
 
2.3.4  Impedance Data Fitting 
The impedance phase and magnitude plots from the data were fit to the simple 
model for a piezoelectric using IEEE Standards 1988. The basic model consists of an 
RLC circuit in parallel with another capacitor as shown in Figure 2.2. The impedance 
and admittance functions for a piezoelectric model can also be represented more 
precisely by a transmission line equivalent circuit [12, 13]. 
 
Figure 2.2. Circuit representing a simple model of a piezoelectric and PSpice model  
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For the circuit shown in Figure 2.2, the relationships among parameters may be 
determined using Ohm’s law and circuit theory. The series resonant frequency for the 
circuit ωs is given  
 
 

s

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L C
    (2.3) 
And the conductance at resonance G(ωs)  provides the resistance value R for the model 
according to 
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Manipulating the real and imaginary components of the admittance yields  
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Where )( sB  is the maximum value of the susceptance, eC is the parallel equivalent 
capacitance of the model and ωp is the parallel resonant frequency. 
Four parameters R, L, C and Co for the model were estimated using equations 
2.4-2.7 and the measured impedance data from the impulse method Fzm and the 
network analyzer system.  Then a least squares approach was used to fit the model 
parameters more accurately. 
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2.3.5  PSpice Model of Impulse Impedance Measurement Method and AC Sweep
 Experimental impedance data Fzm from section 2.3.3 and the model fitting of 
section 2.3.4 provided the R, L, C and Co parameter values for the simple circuit in 
Figure 2.2. The corresponding values were then used in a PSpice model (Candence 
Corporation, San Jose, California) to simulate the impulse method of section 2.3.2, 
and to perform a standard AC sweep analysis of the circuit. The PSpice model 
simulated the piezoelectric equivalent circuit shown in Figure 2.2. 
For the impulse model the source was defined as a 4 volt 12ns wide pulse with 
4ns rise and fall times. Transient analysis was used to simulate the circuit in 0.1ns time 
steps to 20µs. Vp and Vm were measured in the program and imported into MatLab® 
for analysis. 
The circuit in Figure 2.2 was used in the PSpice AC Sweep analysis. The 
source was a 4 volt sinusoid that was swept from DC-10MHz in 1kHz increments. The 
current through Zp and voltage Vm were measured in the program, and the impedance 
magnitude and phase were compared with the experimentally measured data.  
 
2.4 Results 
2.4.1 Pulsing Circuit Analysis and Performance 
 Figure 2.3 shows oscilloscope measurements from the pulsing circuit. The 
green and purple square waves shown in the left side of the Figure were logically 
combined at pins 10 and 9 of the NAND gate to produce the test signal in yellow at 
the bottom of the Figure. The signals are shown in more detail on the right side of the 
Figure where each division corresponds to 10ns.  
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Figure 2.3. Oscilloscope screen capture of a 4kHz Oscillator. The green, purple and 
yellow curves correspond to the outputs of pin 10, pin 9 and pin 8 of the NAND gates, 
respectively Left: 100µs per division. Right: 10ns per division. 
 
The high speed NAND Gate produce a stable 12ns wide 4 volt pulse when 
both green and purple logic signals were “on” as shown in Figure 3.3 on the right. The 
yellow pulse was the measured output from pin 8 of the NAND Gate. The yellow 
pulse signal had 5ns rise time and 7ns fall time with minimal ringing around the edges 
of the signal. 
 
2.4.2 Experimental Analysis of Impedance Measurement Approaches 
The following flat disk PED’s were tested: a 0.5 inch diameter 5MHz 
piezoelectric EBL #2 composite,  a 0.75 inch diameter 4MHz piezoelectric EBL #1, 
and a 0.59 inch diameter 2MHz piezoelectric EBL #2 (EBL Products, Hartford, CT). 
The electrical impedance was measured five times using the impulse approach with a 
49 Ohm 1% resistor as Zp and five times using the network analyzer. Figure 4.4 is a 
composite of data from the impulse method, the network analyzer and PSpice models. 
We found good agreement between experimentally measured data for the impulse 
method (blue line) and network analyzer (blue asterisk) for the three samples. There 
were no significant variations among measurements using the two techniques. The 
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impedance calculated from the data and the impedance from the two PSpice models 
gave similar results for each sample as shown in Figure 2.4. The component values of 
the piezoelectric equivalent circuit were determined from the PSpice model of the 
experimental impedance data and compiled in table 2.1. Results for each PED are 
discussed separately. 
5MHz Piezoelectric Composite PZT Disk (Figure 2.4a-b).  Figure 2.4a shows 
the impedance phase measurement obtained from the impulse method, from 
calculations based on equations 2.3-2.7, from the PSpice model of the impulse 
measurement, from the PSpice model of an AC sweep and from the network analyzer. 
The phase shift before resonance occurs at 4.5MHz for the various methods, except for 
the network analyzer where it occurs at 4MHz. Figure 2.4b shows that the impedance 
magnitudes determined for the five methods were similar. 
4MHz Piezoelectric PZT Disk (Figure 2.4c-d).  Figure 2.4c shows the phase 
shift before resonance is similar for the different methods (4MHz), except that it 
occurs at a lower frequency (3.7MHz) for the network analyzer. Figure 2.4d shows the 
impedance magnitudes determined were similar for all five methods, except that the 
magnitude of the impedance at parallel resonance was greater for the network analyzer 
(250 Ohm) compared to the other methods (180 Ohm). 
2MHz Piezoelectric PZT Disk (Figure 2.4e-f). The phase and impedance plots 
(2.4e and 2.4f) were similar quantitatively to those obtained for the two other 
materials, but the data showed small amplitude variations at low frequencies, and 
through resonance and parallel resonance. The phase shift and resonant frequency 
were identical for the impulse method and network analyzer (1.98 MHz). This was 
true for the parallel resonant frequency of 2.2 MHz as well. 
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Figure 2.4.  Impedance phase (on left) and magnitude (on right) plots for five methods 
and three different piezoelectric materials. 
Figure 2.4a-b: 5 MHz 0.5 inch diameter composite piezoelectric impedance plots 
agree well overall. 
The phase shift of the network analyzer around resonance begins at a lower frequency 
compared to other methods. 
Figure 2.44c-d: 4 MHz 0.75 inch diameter piezoelectric impedance plots agree except 
for the lower frequency phase shift of the network analyzer around resonance 
compared with the other methods. The network analyzer shows a higher parallel 
resonant magnitude compared with the other methods. 
Figure 2.4e-f: 2 MHz 0.59 inch diameter piezoelectric impedance plots agree well. 
The phase and magnitude measurements of the network analyzer and impulse method 
have low amplitude spectral ripples through EIS plots. 
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Table 2.1. Tabulated model data for piezoelectric materials studied R, L, C and CO. 
Also including the resonant and parallel resonant frequencies and impedance 
magnitudes measured using the impulse and network analyzer methods. The table 
shows good agreement between the two approaches.  
Piezoelectric 
Material R L C Co fs fp 
M
a
g
n
it
u
e 
a
t 
fs
 
M
a
g
n
it
u
e 
a
t 
fp
 
5 MHz 
Impulse 
 
0.150 
Ohm 
0.602 
uH 1.93 pF 3.12 pF 
4.67 
MHz 
5.94 
MHz 
0.15 
Ohm 
480 
Ohm 
5 MHz 
Network 
Analyzer 
0.598 
Ohm 
0.938 
uH 1.36 pF 1.73 pF 
4.45 
MHZ 
5.95 
MHz 
0.7 
Ohm 
380 
Ohm 
4 MHz 
Impulse 
 
0.203 
Ohm 1.00 uH 1.54 pF 5.97 pF 
4.06 
MHz 
4.55 
MHz 
0.2 
Ohm 
168 
Ohm 
4 MHz 
Network 
Analyzer 
0.170 
Ohm 1.00 uH 1.65 pF 4.70 pF 
3.92 
MHz 
4.56 
MHz 
0.53 
Ohm 
325 
Ohm 
2 MHz 
Impulse 
 1.06 Ohm 9.36 uH 0.684 pF 2.67pF 
1.98 
MHz 
2.23 
MHz 1 Ohm 
675 
Ohm 
2 MHz 
Network 
Analyzer 1.06 Ohm 9.35 uH 0.684 pF 2.51 pF 
1.99 
MHz 
2.23 
MHz 2 Ohm 
720 
Ohm 
 
Table 2.1 shows component values for the impedance data determined from 
the impulse method and network analyzer.  Resonant and parallel resonant frequencies 
fs and fp, and magnitudes were similar.  
 
2.5 Discussion 
The pulsing circuit comprising the two IC’s, four resistors, three capacitors and 
prototyping board cost ten dollars to build. The simplicity in the design makes it easy 
to construct in 1 hour.  The pulse width can be lengthened or shortened by increasing 
or decreasing the number of gates through which the signal propagates. The 12ns 
pulse from the circuit shown in Figure 2.1 provided sufficient bandwidth to measure 
the impedance of 2-5MHz PED’s.  A shorter pulse would be required to measure 
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higher frequency PED’s. A longer pulse might be sufficient to measure lower 
frequency PED’s.  In practice, we have used the pulsing circuit as presented to 
perform EIS of ultrasonic probes and piezo-materials with impedance in the range 
700kHz to 20MHz. 
By applying a voltage pulse into a component with known impedance in series 
with a PED, and analyzing the transient voltage response across the known component 
in the frequency domain, we were able to use Ohm’s law to accurately measure the 
impedance magnitude and phase of 2, 4 and 5 MHz piezoelectric disks. The impulse 
impedance measurement approach agreed well with measurements from a network 
analyzer system that is often used for these purposes. The resonance and parallel 
resonance frequencies measured by the approaches were found to be within 5% of 
each other. The magnitudes of the impedance were also similar, particularly at 
resonance where the impedance is most important for device design.  
Modeling of the impulse measurement method of impedance in PSpice and AC 
Sweep model agreed closely with the calculated impedance from the piezoelectric 
equivalent circuit. It was easier to determine the equivalent circuit parameters for the 
impedance plots using the impulse method, because it provided a high resolution data 
set (only limited by the length of the recorded signal in time). The network analyzer 
provided an AC Sweep type of measurement approach for a set 401 points per 
window. Depending on the characteristics of the PED, the network analyzer may or 
may not provide enough information to fully characterize the PED. 
The network analyzer system was relatively easy to use and provided 
impedance phase and magnitude curves rapidly. The impulse method required extra 
time to collect the transient response of the PED and then analyze the signal using the 
FFT algorithm. The known impedance Zp in Figure 2.1 may be easily interchanged 
with a capacitor or PED-equivalent circuit. Using an iterative approach, a simple 
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known component such as a resistor, as used in this study, maybe refined into a more 
closely matched impedance to the PED to obtain a more accurate measurement. The 
approach also has the advantage with the simple circuit: to do signal averaging and to 
increase the dynamic range of measurement by using a digital scope/acquisition card 
with higher bit count. Furthermore, the nature of the impulse method may make it 
particularly suitable in certain applications. For example, to measure the impedance of 
a transducer in a water tank, the tank must be lined with acoustic absorbing material. 
Otherwise, reflections from within the tank affect the measured impedance. With the 
impulse method, data are collected before artifacts from reverberant echoes appear. 
 
2.6 Conclusion 
In this chapter a simple pulsing circuit that was used to perform electrical 
impedance spectroscopy (EIS) with ordinary laboratory instrumentation. The 
technique is straight forward and useful to laboratories that do not possess a network 
analyzer or equivalent device. Results showed that, 2, 4 and 5 MHz piezoelectric disk 
impedance spectra were accurately measured using the impulse impedance approach. 
The impulse method has been used in our laboratory to measure electrical impedance 
spectra of ultrasonic transducers and materials from 700kHz-20MHz.      
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CHAPTER 3 
 
DEVELOPMENT OF A PORTABLE THERAPEUTIC AND HIGH INTENSITY 
ULTRASOUND SYSTEM FOR MILITARY, MEDICAL AND RESEARCH 
USE
3,4,5,6 
 
3.1  Abstract 
We have developed a portable high power ultrasound system with a very low 
output impedance amplifier circuit (less than 0.3 Ω) that can transfer more than 90% 
of the energy from a battery supply to the ultrasound transducer.  The system can 
deliver therapeutic acoustical energy waves at lower voltages than those in 
conventional ultrasound systems, because energy losses owing to a mismatched 
impedance are eliminated.  The system can produce acoustic power outputs over the 
therapeutic range (greater then 50 W) from a PZT-4, 1.54 MHz, 0.75 in diameter 
piezoelectric ceramic.  It is lightweight, portable, and powered by a rechargeable 
battery. The portable therapeutic ultrasound unit has the potential to replace “plug-in” 
medical systems and RF amplifiers used in research. The system is capable of field 
service on its internal battery, making it especially useful for military, ambulatory, and 
remote medical applications.  
 
 
                                                 
3 This work has been published as Lewis, G.K., Jr., Olbricht, W.L. (2008). Development of a portable 
therapeutic and high intensity ultrasound system for military, medical, and research use Rev. Sci. 
Instrum. 79, 114302 
4This work has been published as Lewis, G.K., Jr., Olbricht, W.L. (2008). Development of a portable 
therapeutic ultrasound system for military, medical and research use. J. Acoust. Soc. Am. 124 2551 
5This work has been published as Lewis, G.K, Jr., Olbricht, W.L. (2008). Development of a portable 
therapeutic ultrasound system for military, medical and research use. J. Acoust. Soc. Am. POMA 5 
030001 
6 This work has been published as Lewis, G.K., Jr., Olbricht, W.L. (2009). Ultrasound wave generating 
apparatus. United States PTC Patent Application. PCT/US2009/050297 
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3.2 Introduction 
In the last two decades, researchers and clinicians have shown that therapeutic 
ultrasound can be an effective tool in relieving arthritis, improving rehabilitation and 
enhancing wound healing [1-4]. Ultrasound at higher energy has proven useful in 
surgical applications such as prostate therapy and brain tumor and cardiac tissue 
ablation [4-7].  Ultrasound may also be useful in improving a variety of drug delivery 
platforms, including large-molecule transdermal delivery, targeted chemotherapy for 
brain cancer, and cellular gene transfer [8-11]. In addition, the combination of 
ultrasound-based imaging with ultrasound-based therapy has potential for important 
military and medical applications [12-14]. Despite the widespread use of ultrasound, 
the basic idea in producing ultrasound power has not changed significantly in the past 
50 years [6, 13, 15].  Established methods for ultrasound driving systems, such as high 
voltage switching and RF amplifiers, often require bulky and expensive equipment. 
Thus, the development of a cost-effective, portable system for delivering ultrasound 
could greatly enhance the use of ultrasound across a broad range of medical therapies. 
In the late 1920’s initial studies of the biological effects of ultrasound were 
performed by Wood and Loomis [16]. Since then, researchers have proposed systems 
to produce high power ultrasound. In 1942 Lynn et al. introduced an effective 836 kHz 
high voltage (3000-6000 V) low current (900 mAmp) ultrasound driver for biological 
research, which was based on vacuum tube technology and radio transmitter design 
[17]. Since in-house power and very high voltages were used in this design, 
precautions were taken to avoid electrical shock and RF interference. Lynn’s system 
and power outputs were measured crudely by measuring the rise of a conical oil cone 
from the radiation force exerted by the focused ultrasound energy. Fry et al. in 1986 
presented a focused ultrasound system for tissue volume ablation of brain tumors [18]. 
The power of the system was supplied by a 990 kHz tuned (impedance matched) 2 kW 
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amplifier with pre-amplifying circuitry.  Lee et al. in 1999 introduced a 64-channel RF 
driving unit with phase control to produce local hyperthermia in vitro and in vivo [19]. 
The amplifier stage of the system used Transistor-Transistor-Logic (TTL) timing with 
an unspecified in-house built circuit to amplify the drive signal. The 8.0 MHz array 
Lee et al. developed produced acoustic powers from 0-1 W. Owen et al. in 2003 
developed a 12-lb plug-in class D switch-mode amplifier to drive single element high 
intensity focused ultrasound (HIFU) transducers [15]. The system provided 140 W of 
acoustic energy from a 70% efficient PZT transducer with 33mm diameter and 55mm 
radius of curvature. Owen et al. compared the device to products on the market at the 
time and found their device favorable because of its light weight and ability to cause 
hemostasis and tissue necrosis.  
Commercially available ultrasound drivers and RF amplifiers are generally 
built with a 50 Ω output impedance that has high voltage amplification and switching 
of the applied AC signal. To date, many of the developed ultrasound drivers have been 
impedance matched to enhance power transfer as stated in the maximum power-
transfer theorem: to obtain maximum external power from a source with a finite 
internal impedance, the impedance of the load must be made the same as that of the 
source.  The 50 Ω output impedance is matched to the transducer using special 
impedance-matching circuitry to maximize power transfer and minimize reflections 
from the ultrasound transducer [6, 13, 15].  From voltage division, the voltage across 
the transducer is inversely related to the impedance of the source.  Therefore, if the 
source has a 50 Ω output impedance and the transducer has a 10 Ω purly resistive 
impedance, only 17%
 
of the energy from the source will be supplied to the transducer. 
The rest will be reflected or lost as heat.  When impedance-matching circuitry is used, 
half of the power from the source is transferred, and the driver becomes more 
efficient. In matching the characteristic impedance of the driver to the ultrasound 
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probe, which generally has complex impedance, automatic tuning devices are used 
that add to the cost and bulk of the system [15]. 
We have developed a plug-free portable high power ultrasound system with a 
very low output impedance amplifier circuit (less than 0.3 Ω) that is capable of 
transferring more than 95% of the voltage from the battery supply to the transducer. 
Because the output impedance of the drive circuitry and MOSFET switching loss is 
negligible compared with the ultrasound transducer’s impedance, little energy is lost 
as heat. Furthermore, because the batteries can provide high current, much lower 
voltages are required to create therapeutic acoustical energy waves than in 
conventional systems. The system can produce acoustic power outputs over the 
therapeutic range (greater than 50 W). It is lightweight (under 6 lbs), portable (2 x 6 x 
4 in) and powered by a rechargeable battery, which makes it suitable for a variety of 
military, ambulatory, and field medical applications. 
 
3.3 Methods 
The portable therapeutic ultrasound system comprises the low impedance 
ultrasound driver, accompanying circuitry, and the ultrasound transducer probe.  This 
section describes each part of the apparatus and measurements to determine the power 
of the device, acoustical driving efficiency, portability and robustness. 
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Figure 3.1. Circuit schematic of the low output impedance ultrasound driver. A pin 
driver is appropriately timed with a TTL 5 volt signal from a 1.54 MHz crystal 
oscillator that switches the drain of the low output impedance MOSFET from +/- 50 V 
maximum. 
 
3.3.1 Driving Circuit 
The circuit for the low-output-impedance driver is shown in Figure 3.1. A pin 
driver (EL71581SZ, Intersil Inc.) that is capable of driving high capacitive loads is 
supplied with a 5 V square wave transistor-transistor logic (TTL) input at pin 3. The 
input timing signal comes from a 1.54 MHz crystal oscillator (SE1216-ND, Epson 
Toyocom Inc.) that fits the ultrasound probe’s resonant frequency for maximum power 
transfer. Pins 1 and 8 are held at +12 V with 47 µF and 0.1 µF bypass capacitors to 
ground. Pin 2 is connected to pin 1 with a 10 kΩ resistor.  Pins 4 through 6 are 
connected to earth ground.  Pin 7 of the pin driver is the output that provides a 12 V 
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square wave to regulate the switching of the MOSFET’s voltage drain. From pin 7 of 
the pin driver a 2.2 Ω resistor splits off with two 0.1 µF  coupling capacitors into the 
input pins 2 and 4 of the low on resistance N/P channel MOSFET (IRF7350, 
International Rectifier Inc.). Pins 1 and 3 of the MOSFET are held at a maximum of –
50V and +50 V, respectively, with 820 Ω resistors across pins 1-2 and 3-4.  A 47 µF 
and a 0.1 µF bypass capacitors to ground are applied as well to pins 1 and 3 of the 
MOSFET. Pins 5-6 and 7-8 of the MOSFET are tied together and coupled through 1 
Ω, 5 W power resistors with the output drive signal applied to the ultrasound 
transducer through a standard BNC connector. 
 
Figure 3.2. Driving circuit used in portable ultrasound system. The working unit of 
Figure 1 may be applied in parallel stages to reduce the power/heat dissipation in 
each MOSFET to allow for high current driving to the transducer. 
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The Intersil Inc. EL7158ISZ pin driver acts as the logic switch for the 
MOSFETs that supply the power oscillation drive to the ultrasound transducer.  For 
high power continuous wave applications requiring high current, pin drivers are used 
to switch MOSFETs in parallel to lower the current burden on each MOSFET.  As 
shown in Figure 3.2, a single timed pin driver at 5 V drives two pin drivers at 12 V as 
a branching cascade to switch four MOSFETs each for the portable high power 
ultrasound driving system.  Each pin driver/MOSFET unit is wired as shown in Figure 
3.1. The output impedance of the driver was measured directly, and determined from 
manufacturer values of the MOSFETs, and eight 1 Ω parallel resistors to be almost 
entirely resistive and approximately 0.2-0.3 Ω. 
 
Figure 3.3. Wire layout for portable ultrasound system. 
3.3.2 System Design 
Figure 3.3 shows a schematic of the complete system, and Figure 3.4 is a 
photograph of the finished device. Figure 3 is divided into the battery supply and user 
control portion (left),  TTL logic timing signal (middle yellow box), and parallel 
MOSFET ultrasound driving stage (right red box).   The system is housed in a 4 x 6 x 
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2 in watertight plastic enclosure (#073, Serpac Inc.).  The housing holds the circuit 
(1.5 x 2 x 1 in) and six 9.6 V, 1600 mAh NiCad rechargeable battery packs (#23-432, 
Radio Shack Inc.) tied together in series through two single draw rotary switches. The 
user can adjust power delivery to the transducer through the MOSFETs in 9.6 V 
increments over the range ±28.8 V. 
 
  
Figure 3.4. Portable therapeutic ultrasound system with 1.54 MHz ultrasonic probe.  
The unit is 4 x 6 x 2 in and weighs 5.5 lbs. 
 
A blue “on” LED is tied into the on/off switch that supplies power to the 
crystal oscillator and pin driver through 5 V and 12 V 1 amp voltage regulators that 
also have bypass capacitors. The output of the device is terminated in a male BNC 
connector on the front panel.  A battery recharge port at the back of the system is 
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wired to charge the six battery packs in series. To charge the system, the device is 
switched to the off position and the rotary switches are moved to a non-connected 
terminal as labeled on the devices panel.  A parts list for the device is tabulated in 
appendix 3.1 
 
3.3.3 Ultrasonic Probe 
The ultrasound probe is constructed from lead zirconate titanate (PZT-4), 1.54 
MHz, 0.75 in diameter piezoelectric ceramic with a radius of curvature of 1.5 in (EBL 
Products Inc.). The ceramic (air-backed) is housed in a PVC ergonomic plastic 
assembly that was built in-house on a micro lathe and milling system (Sherline 
Products Inc). The clear acrylic front of the transducer acts as a protective cover to the 
ceramic and an in-plane focal alignment standoff for the ultrasound energy. The probe 
is wired with 22 gauge coaxial cable terminated with a female BNC connector. The 
electrical impedance of the ultrasound probe was measured using commonly known 
methods (Figure 3.5), to determine the resonant frequency for high power driving 
efficiency [20].  
 
 
Figure 3.5. Left: Measured impedance and results from a Mason Model of 
transmission lines.  Right: Calculated acoustic conversion efficiency from the Mason 
Model. 
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3.3.4 Measurements and Characterization  
The output waveform and power spectrum of the device were collected using a 
Tektronics Model TDS2002B oscilloscope with the ultrasound probe attached and 
placed in an acoustically insulated water bath. The output impedance, resistance and 
reactance of the device were measured by attaching a 12Ω power resistor across the 
output of the device and measuring the phase and voltage changes across the 
component. The ultrasonic power output was determined with a force balance 
technique in which we measured the force that the ultrasound exerted on an acoustic 
absorbing object [21]. We compared these results to electrical measurements of power, 
using the electrical properties of the probe and a measured ultrasonic power 
conversion efficiency [22].  Battery life was determined for various output powers.  
The device was tested with other ultrasonic probes by interchanging the 1.54 MHz 
crystal oscillator with a function generator.  The system was run with 1.7, 2.2 and 7.5 
MHz transducers, and the output wave form was measured. 
 
3.4 Results 
The waveform of the device output and power spectrum at the 19.2 Vpp-Vpp 
battery setting are shown in Figures 3.6a and 3.6b. Figure 3.6c is the measured output 
waveform from the device while connected to a function generator driving a 7.5MHz 
probe under equivalent power application. Slight ringing at the corners of the 
1.54MHz waveform is shown in Figure 3.6a; however, the driving signal is reasonably 
clean with no oscillations in the waveform and fast rise times between the push-pull 
cycles. The power spectrum, shown in Figure 3.6b, of the signal in Figure 3.6a is 
representative of a typical square-wave drive signal with corner signal spikes. Figure 
3.6b shows the drive signals energy concentration is in the early megahertz 
frequencies. Figure 3.6c shows that the amplitude of the driver is attenuated for the 
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higher frequency of 7.5MHz.  Furthermore, the waveform is asymmetric and exhibits 
small oscillations for positive and negative sides. When the TTL timing frequency is 
increased into the 10MHz range, the MOSFETS saturate and are unable to 
switch/operate at these speeds. The output resistance and reactance of the device was 
measured to be less than 0.3 Ω and almost entirely real with no measurable phase 
shift. 
The electrical impedance for the ultrasound transducer probe of 12 Ω and an 
acoustic conversion efficiency of 63% at 1.54 MHz were obtained from the data 
shown in Figure 3.5, and used to determine power from the voltage measurement 
across the transducer. The ultrasonic power was measured at each power setting and 
results are shown in Table 3.1. The force balance approach gave slightly higher 
acoustic power values compared with the electrical power measurements. Acoustic 
output powers ranged from 5.77 to 51.4 W, with a maximum difference of 23% 
between the two power measurement methods.  
The battery life at each power setting for sustained power output after full 
charge is also tabulated in Table 3.1. Maximum system life was for 1.7 hr at 5 to 6 W 
of acoustic energy.  At the maximum acoustic energy setting, battery life decreased to 
0.7 hr.   
The portability of the system compares well with that of commercially 
available therapeutic systems. Clinical therapeutic systems such as the Therasound® 
medical instrumentation line from Rich Mar Inc. provide a maximum of 4 W of 
acoustical energy to the patient. These systems are comparable in size (7 x 7 x 6 in) 
and in weight (5 to 6 lb) to our system, but they require AC power.  For applications at 
these low power levels, our system could be made considerably smaller, since most of 
the mass is the battery pack.  For high power applications such as HIFU used in 
ultrasound surgery, our system is much smaller and lighter than typical RF amplifiers 
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(usually 12 x 24 x 7 in and 20 lb). Since ultrasound power levels for most surgical 
applications range from 40 to 60 W, the portable system satisfies current requirements. 
The system described here may not be able to deliver, at least on batteries, the higher 
power levels used in some research applications.  However, according to the 
manufacturer’s data, the circuitry in the device can provide 100 V peak to peak.  At 
this voltage, our acoustic efficiency model estimates the device would produce an 
ultrasonic power of 130 W, which is similar to other proposed and bulkier systems. 
 
Adapting the circuitry for other ultrasonic transducers was straightforward. 
The function generator that replaced the crystal oscillator drove 1.7, 2.2 and 7.5 MHz 
PZT-4 focused transducers at powers that produced cavitation and levitation  when 
submerged in degassed water as shown if Figure 3.7. With the 7.5 MHz transducer, 
the MOSFETs began to heat to damage after 2 min at continuous full power.  This was 
not surprising in view of the probe’s low electrical impedance (4 Ω), a current draw of 
7.5 A and greater MOSFET switching losses at the higher freqency.  Thus, operating 
the 7.5 MHz probe continuously would require additional MOSFETs in parallel or the 
use of heat sinks to disipate thermal energy. 
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Figure 3.6. (a) Measured 1.54MHz output waveform from the device with slight 
ringing at the corners. The driving signal is mostly clean with no oscillations in the 
waveform and fast rise times between the push-pull cycles. (b) The power spectrum of 
the 1.54 MHz waveform. The drive signals energy concentration is in the early 
megahertz frequencies. (c) Measured while the timing signal came from a function 
generator, the higher frequency of 7.5MHz lead to attenuated drive voltage and 
asymmetry of the waveform with oscillations on both the positive and negative sides. 
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Table 3.1. Acoustic power measurements and battery life 
Voltage  Setting 
Vpp-Vpp (volts) 
19.2 28.8 38.4 48.0 57.6 
Force Balance 
(watts) 
6.28 10.5 23.5 43.4 55.8 
Electrical 
Measurement 
(watts) 
5.25 11.8 21.0 32.8 47.3 
Power Average 
(watts) 
5.77 11.5 22.5 38.1 51.4 
System Battery 
Life (hours) 
1.7 1.2 1.0 0.8 0.7 
 
 
Figure 3.7. 1.54 MHz ultrasound transducer levitating and cavitating water at full 
system power 
3.5 Conclusions 
The portable therapeutic ultrasound system drives an ultrasound transducer 
with a very low output impedance AC source, so that power from the supply is 
efficiently transferred to the device. The device can operate in the range of 1 to 10 
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MHz, which spans the relevant range for medical therapeutic ultrasound and HIFU 
systems.  
The ultrasound driving circuit has an output impedance of 0.3 Ω and provides 
switching of ±28.8 V.  The device can provide more than 50 W of acoustic energy 
from the 1.54 MHz transducer using no impedance tuning.  Because the device 
consists of multiple battery packs, voltage regulators were wired to the nearest battery 
level to reduce energy waste. Combining the LED on-light, the heating of MOSFETs, 
voltage regulators and resistors, along with a back calculation of the acoustic output 
energy measured, we calculated an energy waste of less than 10% from thermal 
heating. The device is much smaller and lighter than commercially available systems, 
and costs only $150.00, of which 80% was battery costs. 
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CHAPTER 4 
 
DESIGN AND CHARACTERIZATION OF A HIGH-POWER ULTRASOUND 
DRIVER WITH ULTRALOW-OUTPUT IMPEDANCE
7,8 
 
4.1 Abstract 
We describe a pocket-sized ultrasound driver with an ultralow output 
impedance amplifier circuit (less than 0.05 Ω) that can transfer more than 99% of the 
voltage from a power supply to the ultrasound transducer with minimal reflections. 
The device produces high-power acoustical energy waves while operating at lower 
voltages than conventional ultrasound driving systems because energy losses owing to 
mismatched impedance are minimized. The peak performance of the driver is 
measured experimentally with a PZT-4, 1.54 MHz, piezoelectric ceramic and modeled 
using an adjusted Mason model over a range of transducer resonant frequencies. The 
ultrasound driver can deliver a 100 Vpp (peak to peak) square-wave signal across 0-8 
MHz ultrasound transducers in 5 ms bursts through continuous wave operation, 
producing acoustic powers exceeding 130 W. Effects of frequency, output impedance 
of the driver, and input impedance of the transducer on the maximum acoustic output 
power of piezoelectric transducers are examined.  The small size, high-power and 
efficiency of the ultrasound driver makes this technology useful for research, medical 
and industrial ultrasonic applications. 
 
 
                                                 
7This work has been published as Lewis, G.K., Jr., Olbricht, W.L. (2009). Design and characterization 
of a high-power ultrasound driver with ultralow-output impedance. Rev. Sci. Instrum. 80, 114704 
8This work has been published as Lewis, G.K., Jr., Olbricht, W.L. (2009). Ultrasound wave generating 
apparatus. United States PTC Patent Application. PCT/US2009/050297  
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4.2 Introduction 
We present a new amplifier design and printed circuit board schematic for an 
efficient ultrasound driver that can be incorporated easily into acoustic applications in 
science and engineering. The principle underlying the driver design is based on earlier 
work that used a low output impedance driver in a portable high intensity focused 
ultrasound (HIFU) system [1] and in appendix 4.2. Here, we analyze an ultralow 
output impedance driver that delivers high current bursts, continuous wave and 
frequency sweep operation for single element, phased-array, and time-reversal 
acoustic applications.   
Ultrasound has had decades of great success as a diagnostic imaging modality, 
but in recent years studies have shown that the application of ultrasound can be an 
effective therapy or enhance existing therapies in a variety of clinical applications [2-
5]. For example, ultrasound has been used to lyse blood clots and to improve the 
action of thrombolytic agents [5].  It has been used to temporarily break down the 
blood-brain barrier, to enhance the delivery of anti-tumor agents and other drugs, to 
occlude blood vessels, to cauterize wounds, and to enhance wound healing [5-9].  
Furthermore, high-intensity focused ultrasound potentially offers a new way to 
perform ablative surgery on a variety of organs including heart, liver, prostate, and 
brain [10-12]. The acoustic power that is required varies among applications.  Some 
applications require relatively low power levels for acoustic streaming and agitation 
effects [2,4].  Other applications require high power levels, and in these cases tissue 
heating and acoustic cavitation are dominant effects [5, 13-15].   
Despite the potential of ultrasound-based therapies, their translation and 
clinical implementation has been limited in part by the lack of cost-effective and 
convenient ways of generating ultrasound over a wide range of power levels [1].  The 
basic method of producing ultrasound power has not changed significantly in 50 years 
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[11, 16, 17]. Most ultrasound driving systems are based on high-voltage switching 
devices or RF amplifiers that are customarily built with a 50 Ω output impedance. The 
50 Ω output impedance is a historical standard based on the development in the 1930s 
of coax cables for kilowatt radio transmitters [18].  The 50 Ω impedance was chosen 
as a compromise between power handling and low loss in air-dielectric coax 
transmission cable. The 50 Ω output impedance was subsequently used in laboratory 
electronic devices, and it is now an accepted standard for function generators, 
oscilloscopes, rf amplifiers, pulse generators and other electronic instruments.   
A consequence of this standard is that the output impedance of conventional 
ultrasound drivers does not match the characteristic electrical impedance of typical 
ultrasound transducers. The maximum power-transfer theorem states: to obtain 
maximum external power from a source with finite internal impedance, the impedance 
of the load must be made the same as that of the source. Therefore, the output 
impedance of the ultrasound driver is matched to that of the transducer using special 
impedance-matching circuitry and automatic tuning devices [11, 16, 17]. Even then, 
only 50% of the amplifier’s voltage is delivered across the transducer with the other 
50% dissipated as heat. 
Taking a different approach, we have developed a low voltage, high power 0-8 
MHz ultrasound driver with an ultralow output impedance amplifier circuit (less than 
0.05 Ω) that can transfer more than 99% of the voltage from the power supply to the 
transducer. It produces acoustical energy waves at lower voltages than those in 
conventional ultrasound drivers, since energy losses owing to mismatched impedance 
are eliminated.  Since impedance matching circuitry is not required, the driver and 
printed circuit board (PCB) can be built for about $100.  Acoustic energy production 
from the driver was measured experimentally and modeled mathematically using an 
adjusted Mason model over a range of transducer frequencies [19, 20]. The 
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performance of the driver with transducers connected directly to the driver’s output 
was compared with its performance when traditional impedance matching was used.  
Results show that the ultrasound driver can deliver 100 Vpp square-wave signal across 
0-8MHz ultrasound transducers with pulsed current draws in excess of 10 A. 
Modeling and experimental measurements show that maximum acoustic output power 
depends on the impedance of the ultrasound transducer and the output impedance of 
the ultrasound driver.  
 
4.3 Methods 
This section describes the ultrasound driver circuit, printed circuit board (PCB) 
design and construction, modeling and measurements of acoustic energy production, 
and an evaluation of driver performance with and without impedance matching to the 
transducer. Component specifications and part numbers are listed in appendix 4.2. 
 
4.3.1 Circuit Schematic 
The design of the ultralow-impedance, high-current, transistor-transistor logic 
(TTL) ultrasound driver builds on principles that were demonstrated in a simple 
prototype [1]. The prototype used 8 MOSFETs in parallel to deliver 50 W 
continuously without excessive heating of the MOSFETs.  The present design uses 
additional MOSFETs to reduce the current through each MOSFET and to reduce the 
output impedance of the driver, which increases output power, provided there are no 
limitations from the power source. 
Figure 4.1 is a schematic of the driver, which uses 14 MOSFETs in parallel to 
generate the driver output.  A branched tree of pin drivers provides signals to the 
MOSFETs so that they switch synchronously. Each pin driver and MOSFET in Figure 
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4.1 is analogous to the pin driver and MOSFET used in the prototype, except that a 
single pin driver switches multiple MOSFETs in the present arrangement. 
The first pin driver (EL71881SZ), shown at the left in Figure 4.1, is capable of 
driving high capacitive loads.  A 5-10 V square wave from a crystal oscillator or 
function generator is supplied to pin 3 of the pin driver. Pins 1 and 8 are held at +5 V 
with 10 µF and 0.1 µF bypass capacitors to ground (not shown in Figure 4.1). Pin 2 is 
connected to pin 1 with a 10 kΩ resistor.  Pins 4 through 6 are connected to earth 
ground.   The output from pin 7 provides a 5 V square wave to drive the second 
generation of pin drivers.  These pin drivers provide a 5 V square wave to the third 
generation of pin drivers, which regulate switching of the MOSFET’s voltage drain.  
These four pin drivers are held at +12 V instead of +5 V because +12 V is the optimal 
voltage for MOSFET switching. The outputs of these pin drivers are split with two 0.1 
µF coupling capacitors into the input pins 2 and 4 of the low on resistance N/P channel 
MOSFET (IRF7350, International Rectifier Inc.). Pins 1 and 3 of the MOSFET are 
held at a maximum of -50V and +50 V, respectively, with 820 Ω resistors across pins 
1-2 and 3-4.  A 10 µF bypass capacitor to ground is applied as well to pins 1 and 3 of 
the MOSFET (not shown in Figure 4.1).  Pins 5-8 of the MOSFET are tied together 
and connected to the output drive signal through a standard BNC connector. The 
output impedance of ultrasound driver is determined from manufacturer’s values of 
the MOSFETs.  Measurements show it is almost entirely resistive and between 0.01 
and 0.05 Ω. The input capacitance of the P- and N- Channel MOSFETs in parallel is 
5.18 nF. 
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Figure 4.1. Schematic of the ultrasound driver. A TTL timed pin driver is used as a 
branching cascade to switch 14 low output impedance MOSFETs.  
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4.3.2 PCB Design and Construction 
The PCB for the ultrasound driver is shown in Figure 4.2 where components 
are outlined in white and their respective values are given in black. The PCB design is 
created using PCB123® Layout V2 software from Sunstone Circuits Inc. 
 
 
Figure 4.2. PCB layout for the ultralow output impedance ultrasound driver (2 x 3 in). 
Components are shown in white with corresponding values in black text. Extra copper 
visible on the output of components M1-M14 is used for thermal dissipation and 
balancing. 
 
Pin-drivers P1 through P7 and MOSFETs M1 through M14 are soldered to the 
board using an iron at 700ºC. The remaining components, except for the 10μF bypass 
capacitors in-line with the MOSFETs, are added in the same way.  If electrolytic 
capacitors are used, they must be installed with correct polarity. Heat sinks (3-
050305U, Cool Innovations Inc.) with dimensions 4 x 7 x 5 mm are attached to pairs 
of adjacent MOSFETS with thermally conductive Locktight® expoxy (234476, 
Henkel) and activator (2301787387, Henkel).  Thermal epoxy is applied to the bottom 
of the heat sinks, and activator is applied to the top surface of the MOSFETs.  The 
heat sink and MOSFET are pressed together for 2 min. The in-line 10uF bypass 
capacitors are then soldered in place.  MOSFETs M1 through M6 are in parallel on the 
PCB as are MOSFETs M7 through M14.  To make the entire array parallel, three 22 
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gauge copper wires are attached between vias R6 and R7, R5 and R8, and R4 and R9.  
The positive output from the driver at R14 and a ground point on the PCB are 
connected with a BNC connector.  
Pin-drivers P1 through P3 are powered at +5 V, and P4 through P7 are 
powered at +12 V. The input timing signal for the amplifier is supplied to the via 
marked +I in the top right of Figure 4.2. The timing signal may be supplied by a 
crystal oscillator or function generator. The MOSFET switching supply is marked as 
holes +M and –M in Figure 4.2. The voltages supplied to +M and –M determine the 
output voltage range of the MOSFETs. The digital PCB file may be obtained from the 
authors on request. 
 
4.3.3 Driver Modeling 
A Mason two T-port lossy transmission model adapted from Redwood [19] 
and shown in Figure 4.3 is used to characterize the electrical properties of the 
amplifier and piezoelectric transducers. The amplifier is a push-pull amplifier with 
output impedance Rsource. The acoustic energy emitted by the transducer is conducted 
through a water path.  The frequency responses of the transducer and the water path 
are represented as two T-port models.  Each model is composed of transcendental 
periodic functions of frequency that are chosen to be consistent with reflections of 
acoustic energy at intervals corresponding to the time required for signals to travel 
back and forth along the length of the acoustic path.  
Starting from the output of the amplifier at Rsource, the model consists of a 
clamped capacitance of the piezoelectric material Co . 
 
pm
s
o
T
A
C

 33

    (4.1) 
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where  is the clamped dielectric constant for the material, Tpm  is the thickness of 
the piezoelectric material (m),  and A is the radiating area of the piezoelectric element 
(m
2
). Co is placed in parallel to the transformer Φ in the model that converts the 
voltage into a mechanical pressure:  
 
s
pm
opmt Cvk
33

   (4.2) 
 
Figure 4.3. Mason model to study the effect of ultralow output impedance ultrasound 
driver in maximum power driving frequency. Amplifier output resistance Rs is varied 
in this model from 0.03-200 Ω, and the piezoelectric material is modeled as PZT-4 1.5 
MHz and 8.0 MHz transducers. The piezoelectric material and water path are 
considered two port lossy transmission lines. The transformer converts electrical 
energy into pressure for the transducer conversion.  
 
where kt is the thickness coupling coefficient for the material, vpm is the velocity of 
sound in the piezoelectric material (m/sec
2
) and ρpm  is the density of the piezoelectric 
material (kg/m
3
).   
S
33
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The transformer Φ in series with negative capacitance CT, represents the 
pressure output of the piezoelectric transducer, as in Redwood [19] where 
2/oT CC  . 
The piezoelectric material T-port model shown in Figure 4.3 is modeled as  
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 (4.3),  
 
 pmpmpmTrans ThZZ  )(csc2   (4.4), 
 
pmpmpm vAZ      (4.5), 
 
pmpmpm j     (4.6), 
 
m
pm
pm
Q2

      (4.7) 
 
And 
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v

      (4.8) 
where Zpm is the characteristic acoustic impedance of the piezoelectric material, Γpm is 
the material propagation vector, αpm and βpm are the attenuation coefficients in the 
material, ω is the radian frequency variable, and Qm is the mechanical quality factor 
for the piezoelectric material. Values for the constants used in the model are provided 
in Table 4.1. 
The water path T-port model in Figure 4.3 is modeled as 
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and 
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 wmwmwmWater ThZZ  )(csc2   (4.10). 
 
The terms for the water path model impedances ZWater1 and ZWater2 are similar 
to the transducer material (Equations 4.3-4.8) with similar meanings, however with 
different constant values as provided in Table 4.1. 
 
Table 4.1. Compiled constant values and units used in the model presented.  
 
 Symbol Value Units 
Amplifier Properties    
Voltage Supply VSource 10 (v) 
Output Impedance RSource Variable (Ohm) 
Radian frequency variable ω Variable (rads) 
Piezoelectric Properties    
Clamped dielectric 
 
7.17x10
-10 
na 
Thickness of piezoelectric Tpm Variable (m) 
Radiating area A Variable (m
2
) 
Thickness coupling 
coefficient 
kt 0.42 na 
Velocity of sound in the 
piezoelectric material 
vpm 4420 (m/s) 
Density of the piezoelectric 
material 
ρpm 7500 (kg/m
3
) 
Mechanical quality factor 
for material 
Qm 128 na 
Water Path Properties    
Velocity of sound in water vw 1540 (m/s) 
Density of water ρw 1000 (kg/m
3
) 
 
S
33
 65 
The transducer is air-backed, and is included in the model as a small backside 
impedance ZAir  so that mechanical energy is reflected in the forward direction toward 
the water target with its characteristic impedance Zwater .The value of ZAir is chosen to 
match the models prediction of the actual electrical impedance properties of the 
ultrasound transducer used in this study. For the model ZAir = 0.38 x ZWater, where 
wwWater vAZ   . 
From the circuit in Figure 4.3, two node voltages may be defined. By using 
conventional circuit theory and summing the currents at the two node points, two 
equations and two unknowns result. These can be related to the input drive voltage in 
matrix notation. The matrix equation can then be solved for the two unknown 
quantities, and the input and output power may be determined from an examination of 
the circuit model. Thus one can write for the output and input powers:  
 
Water
T
R
P
PowerOut
2)(

  
(4.11),  
where PT is the voltage (or pressure) across RWater , and  
)cos()()( 0   VIPowerIn S (4.12) 
 where  SoSS RVVI /))((   (4.13) and  )()( So IangleVangle  (4.14).            
The efficiency of the amplifier is calculated by  
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

PowerIn
PowerOut
Efficiency  (4. 15). 
The Mason model often is used in ultrasonics to help develop transducer front 
and back matching layers, tune electrical networks, and estimate transducer transmit 
and receive impedances. Here, we use the model to predict the maximum power 
output and efficiency of the ultralow output impedance driver and to compare it with 
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50 Ω and impedance-matched amplifier sources when driving transducers. We varied 
the amplifier source impedance RSource from 0.03 to 100 Ω and predicted the output 
power of four different PZT-4 transducers into a water target impedance RWater . The 
characteristic frequency of the transducer was varied from 1.5 to 8.0 MHz, which 
simulates variations in the thickness of the piezoelectric transducers. The resonant 
electrical impedance of the transducer was varied between 0.37 and 10.6 Ω, which 
simulates variations in the transducer’s cross-sectional area. The drive source Vs is 
taken as 10 V. Parameters for the model transient function constants including ZTrans1, 
ZTrans2, ZWater1, and ZWater2 are compiled in Table 4.1, and were obtained from Redwood 
[19] and EBL Products Inc. for an air-backed PZT-4 transducer into a water bath 
target.  
 
4.3.4 Measurements of Low Output Impedance Ultrasound Driver 
The amplifier is tested by connecting the input (+I hole) to a function generator 
(Tektronix #ARG3102) and powering it with multiple adjustable power supplies 
(Agilent 6613C) for the +5, +12, and +/- MOSFETs power. MOSFET switching 
power is varied from 10 to 50 Vpp.  Current drawn from the circuit is measured using 
the power supply current meter. The amplifier is tested in pulse and continuous wave 
mode by varying the TTL timing signal input. The output waveform and power 
spectrum of the driver are collected using an oscilloscope (Tektronics TDS2002B) 
with a 1.54 MHz lead zirconate titanate (PZT-4) piezoelectric ceramic (EBL Products 
Inc.).  The ceramic is 0.75 in in diameter with a 1.5 in radius of curvature and the 12 Ω 
electrical impedance is measured by impulse impedance spectroscopy.  The ultrasound 
probe is attached to the output and placed in an acoustically insulated water bath [1]. 
The drive waveform is also measured with 12 Ω and 50 Ω power resistors in series 
with the transducer probe to compare impedance matching techniques with the 
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ultralow output impedance driver. The output impedance, resistance and reactance of 
the amplifier are measured by attaching a 12Ω power resistor across the output of the 
amplifier and measuring the phase and voltage changes across the component at drive 
frequencies from 0 to 8 MHz. The ultrasonic power output from the 1.54 MHz 
transducer is determined in continuous wave operation by measuring the force that the 
ultrasound exerts on an acoustic absorbing object [21]. We compare results to 
electrical measurements of power, using measured electrical impedance properties of 
the  1.54 MHz probe [22] and the ultrasonic power conversion efficiency from the 
Mason model [1,19, 20].   
 
 
Figure 4.4. Predictions of the model shown in Figure 3.  (4a) through (4d) show the 
maximum output power as a function of frequency for values of the amplifier source 
impedance Rs in the range 0.03 to 200 Ω . (4a) 1.5 MHz 10.3 Ω transducer. (4b) 1.5 
MHz 1.2 Ω transducer. (4c) 8 MHz 10.6 Ω transducer. (4d) 8 MHz 0.37 Ω transducer  
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4.4 Results 
4.4.1 Model Results 
The predictions of the Mason model are shown in Figure 4.4.  Figures 4.4a 
through 4d show the computed maximum output power from the transducer as a 
function of frequency for two transducers.  Figure 4a and 4b pertain to a 1.5 MHz 
transducer with 10.3 Ω and 1.2 Ω resonant electrical impedance, respectively.  Figure 
4c and 4d pertain to an 8.0 MHz transducer with 10.6 Ω and 0.37 Ω resonant electrical 
impedance, respectively.   
In every case the maximum power delivered to the transducer and, hence, the 
maximum acoustic energy generated by the device, are obtained for the smallest value 
of RSource. The maximum acoustic power is determined by the piezoelectric transducer 
efficiency, which was estimated as 63% from input to output power ratios in the 
model. The electrical impedance of the piezoelectric also affects the maximum 
acoustic power according to:  
 
Z
V
PowerOut o
2

  
 (4.16) 
where PowerOut is the acoustic power from the transducer, VO is the voltage across 
the transducer and Z is the electrical impedance of the transducer. In this case, 
increasing the cross-sectional area of the transducer decreases the electrical impedance 
Z and increases acoustic power. Figure 4 shows that for small RSource, the maximum 
acoustic power is obtained at the transducer’s natural axial resonance frequency.  For 
larger values of RSource, maximum power occurs at frequencies slightly higher than the 
resonance frequency, especially for the 8.0 MHz transducer.  
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4.4.2  Ultrasound Diver Performance 
The output waveform of the ultralow output impedance ultrasound driver at the 
20 Vpp power setting is shown for 1.54 and 8 MHz TTL timing signals in Figure 4.5A 
and 4.5D respectively. Figure 4.5B is the measured output waveform from the driver 
while connected to a PZT-4, 1.54 MHz, and 0.75 in diameter piezoelectric ceramic 
used in this and prior studies [1, 7, 8]. Figure 4.5C is the power spectrum measurement 
from the waveform of Figure 4.5B. The waveform of the 1.54 MHz drive signal 
(Figure 4.5A and 4.5B) shows slight ringing at the corners without and with the 
ultrasound transducer attached to the output. Overall, the 1.54 MHz driving signal is 
reasonably clean with no oscillations in the waveform and fast rise times between the 
push-pull cycles. No measurable voltage drop or phase shift is noticeable between 
Figure 4.5A and 4.5B, showing the amplifier design has a very low output resistance 
and reactance.  The power spectrum in Figure 4.5C is representative of a square-wave 
drive signal with slight corner signal spiking. Figure 4.5D shows that the amplitude of 
the driver is attenuated by approximately 20% for the higher frequency of 8 MHz.  
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Figure 4.5. (A and B) Measured 1.54MHz output waveform from the ultrasound driver 
with slight ringing at the corners without and with the ultrasound transducer attached, 
respectively. (C) The power spectrum of the 1.54 MHz waveform. The drive signals 
energy concentration is in the early megahertz frequencies. (D) Measured 8.0 MHz 
signal shows attenuated drive voltage and asymmetry of the waveform with 
oscillations on both the positive and negative sides. 
 
Furthermore, the waveform is asymmetric and exhibits small oscillations for positive 
and negative sides. When the TTL timing frequency is increased into the 10 MHz 
range, the MOSFETs saturate and are unable to switch at these speeds. The output 
resistance and reactance of the device was measured to be less than 0.05 Ω and almost 
entirely real with no measurable phase shift. 
Figure 4.6 compares the performance of the driver when adjusting the output 
impedance of the driver to match the transducer. Clearly, this is reverse impedance 
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matching, since generally one matches the transducers impedance to the amplifiers 
output impedance. Figures 4.6A and 4.6B show the amplifier output without reverse 
impedance matching.  Figure 4.6A gives the output without a transducer attached, and 
Figure 4.6B gives the output with the 1.54 MHz ultrasound transducer attached to the 
driver at 17 Vpp power setting. The output of the amplifier is effectively transmitted 
with a clean signal and 99% voltage transfer.  Figures 4.6C and 4.6D show output 
waveforms from the driver when a 12 Ω power resistor is attached to the driver in 
series with the 12 Ω ultrasound transducer without and with the transducer attached, 
respectively. Signal distortion is present in Figure 4.6D with 62% voltage transfer 
from driver.  Figures 4.6E and 4.6F show output waveforms from the driver when a 50 
Ω power resistor is attached to the driver in series with the 12 Ω ultrasound transducer 
without and with the transducer attached, respectively. Signal distortion in Figure 4.6F 
is similar to that observed in Figure 4.6D for the 12 Ω resistor, but in this case voltage 
transfer to the transducer is reduced to 22%.  These results show the ultralow output 
impedance driver performs best without matching the drivers’ output impedance to the 
transducer. However, it could be advantageous to match the transducers input 
impedance to the ultralow output impedance of the driver by minimizing Z as 
predicted in Equation 4.16, thereby maximizing the output power from the driver.  
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Figure 4.6. (A and B) Measured 1.54MHz output waveform from the ultrasound driver 
with slight ringing at the corners without and with the ultrasound transducer attached, 
respectively. (C and D) Output waveform from the ultrasound driver with 12 Ω 
impedance matching power resistor attached directly to driver in series to the 12 Ω 
ultrasound transducer without and with the transducer attached, respectively. (E and 
F) Output waveform measured with 50 Ω power resistor in series without and with 
transducer, respectively. 
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Minimizing Z would also result in energy waste across the amplifiers output 
impedance because of voltage division, and may not be appropriate for portable 
battery powered applications. 
The temporal-average acoustic output power from the 1.54MHz ultrasound 
probe while driven at 50 Vpp is 48.0 W as determined from a force balance.  Using 
electrical measurements of power and the electro-acoustic efficiency of 63% from the 
Mason model gives an output power of 33.0 W. The driver has a turn on delay of 10 
ms due to capacitor coupling between pin-driver and MOSFETs. Once on, it is capable 
of providing short bursts of acoustic energy for less than 5 ms and for continuous-
wave operation. The finished driver operating at 28 Vpp with the transducer used in 
this study is shown in Figures 4.7A and 4.7B. Figure 4.7A shows the driver powering 
the 1.54MHz transducer with a clean waveform and visually noticeable acoustic 
energy causing the water to vaporize. Figure 4.7B is a close up of the transducer in the 
water bath levitating and cavitating the water molecules into the air.  
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Figure 4.7. Complete high-power ultralow-output impedance ultrasound driver 
powering a 1.54 MHz ultrasound transducer. (A) Ultrasound driver operating at 28 
Vpp with a clean waveform and high acoustic energy output causing the water to 
vaporize. (B) Close-up of the transducer in the water bath levitating and cavitating the 
water molecules into the air. Cavitation bubbles are visible in the water stream off the 
front face of the transducer. 
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4.5 Discussion 
4.5.1 Amplifier Design 
Managing the heat generated in the ultralow output impedance amplifier is 
essential for its sustained operation. The outputs of the 14 parallel MOSFETS are 
electrically and thermally connected with heat-sinking plains built directly into the 
PCB. The heat-sinking plains dissipate heat generated from switching losses in the 
MOSFETs and balance the temperature distribution between individual MOSFETs to 
prevent thermal runaway and damage to the ICs. Thermal management external heat-
sinks that are attached to the top surface of the MOSFETs in groups of two are not 
necessary for low power applications in the range 0-10 W or for low driver frequency 
in the range 0-3 MHz. However, for high power applications in the range 20-60 W and 
for high driver frequency in the range 4-8 MHz, externally applied heat-sinks are 
necessary for continuous wave operation as shown in Figure 4.7.  
 
4.5.2 Modeling Results of Acoustic Output Power 
The Mason Model predicts that decreasing the output impedance of the driver 
source causes a shift in the drive frequency for maximum acoustic output power, as 
shown in Figure 4.4. The shift can be measured experimentally by using a 50 Ω output 
impedance function generator to drive the PZT-4, 1.54 MHz probe used in this study 
and comparing results with the ultralow impedance amplifier. The shift in maximum 
drive signal power from the actual electrical-resonance of the transducer is 
approximately 85 kHz for the 50 Ω driver.  Although the magnitude of this shift seems 
modest, the results in Figure 4.4 suggest small shifts in the maximum power driver 
frequency can have significant effects on the output power achieved. For example, if a 
system is constructed to produce 1.5 MHz ultrasound with a 1.5MHz piezo-crystal and 
standard 50 Ω driving electronics to complement the frequency, over 50% of the input 
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energy may be lost, as seen in Figure 4.4A by comparing the peak value of the 50 Ω 
curve (approximately 0.5 W) to the power at 1.5 MHz (approximately 0.25 W) . With 
impedance matching circuitry corresponding to the 12.5 Ω curve in Figure 4.4A, the 
power loss in driving at the incorrect frequency is about 20%. With ultralow 
impedance drivers the maximum power drive is closely matched to the electrical-
resonance of the transducer as shown is Figure 4.4a-d, and this problem is mitigated  
 
4.5.3 Ultralow Impedance Ultrasound Driver 
The ultrasound driver is useful in myriad applications that require both low and 
high power acoustic applications. Each amplifier can be constructed for under 
$100.00. Since the ultralow impedance driver delivers 99% of the voltage from the 
power supply to the transducer, batteries may be used to power the system in high and 
low power applications. The International Rectifier’s low on-resistance MOSFET # 
IRF7350  can withstand 100 Vpp operation, according to the manufacturer, which 
could provide more than 10 Amps of current. At a 100 Vpp, our acoustic efficiency 
model estimates that the amplifier could produce an acoustic power of 130 W from the 
transducer used in this study. 
The circuit drives existing transducers more efficiently than typical push-pull 
type amplifiers using impedance matching circuitry and rf amplifiers. If possible, 
however, it is beneficial to use ultralow impedance coax-cabling to connect the 
transducer to the ultralow impedance amplifier to maximize energy transfer and 
minimize waste in the form of heat. This will be important in implementing the 
ultralow impedance amplifier into efficient and portable therapeutic ultrasound 
applications [1, 17 and 23]. 
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4.6 Conclusions 
Modeling and experiments show that the ultralow impedance amplifier delivers 
maximum power close to the electrical-resonance of the ultrasound transducer. This is 
important in designing systems that are efficient at producing ultrasonic energy to 
limit energy waste and maximize energy transfer at low voltages. 
The ultralow impedance ultrasound driver and PCB is considerably smaller (2 
x 3 in ) than typical  rf amplifiers, is significantly less expensive, requires only DC 
power supplies and is 99% efficient at delivering the source voltage across the 
ultrasound transducer. The amplifier can operate in the range from 0 to 8 MHz, which 
spans the relevant range for medical therapeutic ultrasound and HIFU systems. The 
ultralow impedance driver has an output impedance of 0.01-0.05 Ω and provides 
switching of up to 100 Vpp. The amplifier can provide 48 W of acoustic energy from 
the 1.54 MHz transducer using no impedance tuning and has the potential to provide 
over 130 W of power using larger piezo-crystals and higher voltage power supplies. 
Further description and application of the driver in military, medical and research 
applications can be found in appendix 4.2. 
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CHAPTER 5 
 
A PHANTOM FEASIBILITY STUDY OF ACOUSTIC ENHANCED DRUG 
PERFUSION IN NEUROLOGICAL TISSUE
9 
 
 
5.1 Abstract 
To test the feasibility of using 1.1MHz focused ultrasound to increase the 
diffusion of drug through neurological tissue, tissue mimicking agar phantoms and a 
water soluble dye mimicking drug were exposed to 1.1MHz ultrasonic sound fields for 
1 to 4 minutes in duration. Histology was then performed on the phantoms to assess 
the effect of ultrasound on the perfusion of dye. Mathematical analysis was used to 
quantify the extent of perfusion of dye and parametrically fit the experimental data to 
the theoretical diffusion equation. Results show a substantial increase in dye perfusion 
and not diffusion like behavior for the sonicated brain phantoms. 
 
 
 
 
 
 
 
 
                                                 
9This work has been published as Lewis, G.K., Jr., Olbricht, W.L. (2007). A phantom feasibility study 
of acoustic enhanced drug perfusion in neurological tissue. IEEE/NIH Life Science and Systems 
Workshop. © 2007 IEEE.  Reprinted, with permission, from [IEEE, A phantom feasibility study of 
acoustic enhanced drug perfusion in neurological tissue, Lewis, G.K., Jr., Olbricht, W.L.] 
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5.2 Introduction 
Designing effective therapies for brain cancer, including neuroblastoma, 
glioblastoma, and neurofibromatosis remains a significant challenge.  Despite the 
development of drugs that are effective against these malignancies, the prognosis for 
patients remains poor.  One reason for the poor outcome is that malignant cells can 
infiltrate healthy tissue surrounding the tumor, leading to poorly defined tumor 
boundaries.  Migrating cells not only escape removal during tumor resection, but they 
may also avoid radiation and chemotherapy after resection.  As a result, the tumor 
regrows, usually aggressively, and often at a location close to the site of the original 
tumor [1 and 2].  
To address these issues new drug delivery methods have been developed to 
circumvent the blood-brain barrier and deliver drugs directly to brain parenchyma.  
Gliadel wafers impregnated with BCNU are implanted into the resection cavity to 
deliver high concentrations of drug to the surrounding tissue.  However, the diffusivity 
of BCNU in tissue limits its penetration to a few millimeters from the wafer before it 
is eliminated by a variety of mechanisms [3].  This penetration distance is insufficient 
to reach more distant malignant cells.  Similar considerations apply in convection 
enhanced delivery, a technique in which drugs are infused directly into the brain 
through a needle.  Near the infusion site, transport is dominated by convection, but the 
strength of convection decays with distance from the infusion site and diffusion 
becomes important distant from the infusion needle [4 and 5].  Therefore, a method to 
increase the diffusion of compounds in tissue could enhance the therapeutic outcome 
of these drug delivery methods. 
Acoustical techniques have been used in a variety of situations to enhance 
brain cancer treatments. For example, high intensity focused ultrasound (HIFU) has 
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been used to ablate and liquefy neurological tissues, and past and current studies are 
being conducted to assess the use of HIFU as a more complete surgical tool for 
minimally invasive therapy [6, 7 and 8]. Focused ultrasound is beginning to be 
assessed as a feasible way to deliver drugs to neurological tissues via selective 
disruption and permeablization of the blood brain barrier (BBB). Drugs that once 
could not cross the BBB because of molecular weight and hydrodynamic radius are 
now able to permeate into the neurological tissue with the application of ultrasound  [8 
and 9]. Ultrasound has also been used in other applications such as gene therapy and 
drug activation, and for further information on therapeutic ultrasound the authors cite 
[8].    
In this study we explore the use of ultrasound to increase the perfusion of 
locally delivered tracer into an agarose gel that is used routinely as a mimic of brain 
tissue for drug delivery studies [10]. The ultimate goal is to increase the rate of 
transport of pharmaceutical agents relative to their elimination rate, and thereby 
extend the distance that drugs penetrate and maintain therapeutically useful 
concentrations. 
 
5.3 Methods 
Neurological tissue mimicking phantoms were prepared by filling standard 85 
x 15 mm plastic Petri dishes with a solution of 0.6 wt% agar powder in warm distilled 
water. The dishes were then set aside to allow the solution to gel.  Red food coloring, 
diluted in distilled water to 0.5 wt% was used to mimic water soluble drug and apply 
contrast to determine the extent of perfusion. Ultrasound (US) energy in the phantoms 
was generated by a lead zirconate titanate (PZT-4), 1 MHz, 20mm diameter 
piezoelectric ceramic with a radius of curvature corresponding to 40mm (EBL 
Products Inc., Connecticut, USA ).   The ceramic, housed in a PVC plastic assembly, 
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was driven at its center harmonic frequency, determined to be 1.1 MHz, by a +/- 200 
volt, 55 Ohm, RF amplifying circuit. The circuit was constructed from Supertex Inc., 
TC6320 high speed switching MOSFET’s. The RF driving circuit was supplied from a 
function generator (HP 8116A, HP USA) with a sinusoidal 1.1 MHz waveform. It was 
experimentally determined that the transducers input impendence was 65 Ohms at 
resonance, determined by measuring the voltage across the US transducer when 
attached to a 50 Ohm 10 V 1.1 MHz function generator source. A 95% acoustic 
conversion efficiency was estimated (as a high value) from supplied manufactures 
values. Measuring the amplifiers output voltage with and without the US device 
attached, knowing the US device impendence and using voltage division with the 
conversion efficiency of the ceramic a total acoustic output power was estimated to be 
4.5 watts.  
 
 
Figure 5.1. The experimental setup for the phantom study is shown. The sonicated 
phantom is immersed in 0.5 wt% diluted dye and pulse sonicated (15 seconds on and 
off) while simultaneously the transducer is oscillated up and down at 0.25Hz 10mm 
amplitude. The beginning position of the transducer was 40mm above the agar/dye 
interface, so that the US focus was placed on the surface. The control setup was the 
same without US.   
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The experimental setup shown in Figure 5.1, consisted of the control and the 
sonicated phantoms. Four phantoms for the control and experimental were conducted 
at each time point, for a total of 32 experimental measurements. The phantoms and 
dye where allowed to equilibrate to room temperature before the experiment. The 
phantoms were immersed in 500 ml of the dye and secured in position with clamps. 
Phantoms were sonicated on and off (15 seconds each) at their geometric center for 
durations of 1-4 minutes. The location of the focus of the transducer was positioned so 
that the focus at 40mm from the front surface of the US was placed on the agar/dye 
interface. The US was manually oscillated at 0.25 Hz over a 10mm translation to 
increase the sonicated volume (Figure 5.1). This was done for the duration of all 
experiments. For analysis purposes the location of the phantom/dye interface was 
taken to be zero. Histological readings were taken every minute for the control and 
sonicated phantoms. Histology on the phantoms was performed by taking a 1mm 
geometric center slice from the phantom and imaging it with a ccd camera/microscope 
system (Nikon Cool Pix 995, Nikon Inc. USA and Olympus BX51, Olympus Inc. 
USA). The digitally captured image was imported into MatLab® (Math Works Inc. 
USA) to determine the extent of the dye perfusion into the phantoms with and without 
applied US.  By using Red-Green-Blue (RGB) color mapping and converting digital 
pixels into distance (mm) measurements, intensity vs. distance spectral curves of dye 
perfusion into the phantoms were produced. 
We modeled the transport of the dye as one-dimensional diffusion from a 
source.  Experimental data were compared with diffusion profiles for a constant source 
and a limited source as shown: 
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where:  N0 is the source concentration, 
 x is the diffusion distance,  
 Dt is the diffusion time product and 
 erfc is the complimentary error function. 
Q is the total input concentration or integration of Eq. (1) from t=0 to infinity
  
Using a least squares approach, we parametrically fit the experimental data to 
the theoretical equations to compare differences in diffusion between the sonicated 
and control phantoms. The student T-test was used to determine statistical significance 
between control and US groups. 
 
5.4 Results 
Analysis of the experimental data shows that neurological tissue mimicking 
phantoms, that were sonicated, have a substantial increase in dye perfusion when 
compared to the control. Figure 4.2 shows experimental results at time points (TP) 1 
and 4 minutes with a visual and quantifiable increase in dye perfusion into the 
sonicated phantoms (similar results for TP 2 and 3 were also quantified but not 
shown). At 1 and 4 minutes the surface intensity of dye uptake is 25% and 10% 
greater respectively then the corresponding controls, and the sonicated phantoms show 
an overall dye uptake increase of 84% and 25% respectively calculated by the 
difference in area under the color intensity curves at 1 and 4 minutes (p<0.001). 
Shown in the 4 minute intensity profile of Figure 5.2, we see that the control begins to 
follow the same shape of dye perfusion as the sonicated phantom at later TP’s.  
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As expected and predicted by theory (Equation 5.1) we found that the 
perfusion of dye in the control phantom exhibited model diffusion behavior, TP 1 is 
shown in Figure 5.3. Also apparent in Figure 5.3 is that Equation 5.1 did not predict 
the experimental results of the spectral data from the sonicated phantoms at TP1.  
Figure 5.3 shows that sonication plays a role to increase the depth of dye perfusion 
and the method in which it moves into the phantom. Table 5.1 tabulates the diffusion 
coefficients of the sonicated and control phantoms for TP 1-4 and also gives the 
percent error of experimental data compared to the theoretical. We find that the 
diffusion coefficients for the sonicated phantoms are well above those of the control. 
At 1 minute the diffusion coefficient of the sonicated phantom is over 170% of its 
control and over the entirety of the experiment we find a 55% increase in diffusion 
coefficient when sonication is applied, (p<0.001) for all TP’s.   
Table 5.1. A tabulation of diffusion coefficients as determined from parametric fitting 
of experimental data. Note that the diffusion coefficients for No US were obtained 
using Eq. (1), while diffusion coefficients were calculated using Eq. (2) for US groups. 
The general trend is a noticeable increase in diffusion coefficient when US is applied 
to the sample. 
Phantom Diffusion Coefficient 
And Percent Error 
With US 
(cm
2
·sec
-1
)x10
-4
 
No US 
(cm
2
·sec
-1
)x10
-4
 
1 Minute 4.07,       4.69% error
 
2.35,         3.17% error 
2 Minutes 5.40,     11.40% error 3.50,         6.80% error 
3 Minutes 5.72,       4.92% error 3.68,         6.88% error 
4 Minutes 4.83,       4.92% error 3.33,         3.00% error 
Average Over Experiment 5.00,       6.48% error 3.22,         4.96% error 
During the first time point TP1, Figure 5.2 shows that the surface intensity for 
the control is not equivalent to the US experiment. A further experiment was 
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conducted by the authors to address this surface anomaly; why the surface 
concentration of dye in gel for the control phantom did not equilibrate more rapidly. It 
was concluded that gelling surface properties, most plausibly different cross linking 
characteristics of the agar, lead to a mass-transport resistance at the surface of the agar 
phantom. The mass-transport resistance was not apparent when an inner section from 
the agar phantom was used as the surface for dye to diffuse into. Ultrasound therefore 
had an impact on breaking down the surface resistance of the phantom allowing rapid 
perfusion of dye Figure 5.2. 
 
Figure 5.2. Top left and right are histology images taken from phantoms with and 
without applied US TP 1 and 4. Visible is the increase in dye penetration and intensity 
of the sonicated phantom. Bottom left and right are the corresponding RGB color 
intensity maps that correspond with the above images. 
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Figure 5.3. Plot of the theoretical fit to the experimental data for TP 1 and 4. Top left 
we see good agreement with control (No US) and constant source diffusion Eq. (5.1), 
note that US experimental data does not fit Eq. (5.1) well. Bottom left we find that Eq. 
(5.2) fits experimental data with US well but does not fit control. Top right graph 
shows that simple diffusion does not fit control or US phantom well for TP4. Bottom 
right graph shows that Eq. (5.2). fits both control and US phantom well. Overall 
Figure shows a noticeable increase in dye penetration when US is applied. 
 
 
5.5 Conclusions 
In this study we looked at the effect of 1.1 MHz ultrasound on the perfusion of 
dye into neurological tissue mimicking phantoms. We found a clear increase in dye 
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penetration and overall dye density in the sonicated verses control phantoms for all 
TP’s (p<0.001). Most noticeably is the 170% initial increase of spectral intensity from 
dye uptake at the 1 minute TP as shown in Figure 5.2, where US was found to increase 
the surface mass-transfer of dye into agar gel by acoustic radiation pressures and 
agitation of the agar gel matrix. In the mathematical analysis and parametric fitting of 
the data we found good agreement of simple diffusion to the control experiments, 
however simple diffusion processes could not account for the enhanced transport of 
dye into the phantom with the application of US. All of the sonicated phantoms TP 1-4 
data showed excellent agreement with the limited source diffusion equation. Overall 
the control experimental error averaged 4.96% while sonicated phantom groups 
averaged 6.48% error for the entire study. 
From the results presented we find that 1.1 MHz ultrasound is a promising new 
method to increase the penetration of hydrophilic drug into brain tissue. The overall 
goal being the ability to use ultrasound to drive locally delivered chemotherapy agents 
past current diffusion limitations to reach migratory cancer cells. Further research is 
planed to study how changes in ultrasound parameters will affect the rate and level of 
dye perfusion in animal models. Different frequencies, powers, and pulse sequences 
appropriately below the brain tissue damage threshold will be analyzed to create a 
therapeutically useful regimen. 
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CHAPTER 6 
 
ACOUSTIC ENHANCED EVANS BLUE DYE PERFUSION IN NEUROLOGICAL 
TISSUES
10,11 
 
6.1 Abstract 
The success of treating brain cancer such as neuroblastomas neurofibromatosis 
has not been very effective, and is in fact the leading of cancer-related death in 
patients younger than age 35. In the last recent developments in drug delivery methods 
have allowed doctors implant/inject time-release drugs into the tumor cavity that 
allows continuous release of chemotherapy; however results from these have not been 
as successful as anticipated. It is believed that non treated cancerous cells are able to 
migrate from the original tumor and relocate beyond the diffusion range for effective 
drug treatment. this study we utilize high frequency focused ultrasound to increase 
perfusion into phantoms that mimic brain tissue as a method to the rate of drug 
permeation into the tissue before vascular clearance cell migration reduce its 
effectiveness. Using various acoustic sequences we show a substantial increase in 
tracer perfusion into brain mimicking tissue then can be achieved by diffusion alone. 
We could therefore be able to reduce the time of delivery, the amount of drug 
delivered and drugs local impact range. This could significantly increase the success 
of local treatments and reduce systemic effects of chemotherapy. 
In this study 1.58MHz therapeutic ultrasound was used to increase the 
perfusion of Evans blue dye (EBD) through neurological tissue-mimicking phantoms, 
                                                 
10This work has been published as Lewis, G.K., Jr., Lewis, G.K., Sr., Olbricht, W.L. (2007). Acoustic 
targeted drug delivery in neurological tissue. J. Acoust. Soc. Am. 122 3007 
11This work has been published as Lewis, G.K., Jr., Lewis, G.K., Sr., Olbricht, W.L. (2007). Acoustic 
enhanced Evans blue dye perfusion in neurological tissues. J. Acoust. Soc. Am. POMA 2 020001 
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equine brain and avian muscle tissues. We show a substantial increase in EBD 
perfusion into the sonicated tissue then can be achieved by diffusion alone. We are 
therefore able to reduce the time of delivery, the amount of EBD delivered and the 
local impact range. This could significantly increase the success of delivering actual 
therapeutic treatments and reduce systemic effects of chemotherapy. 
 
6.2 Introduction 
The success of treating brain cancer such as neuroblastomas and 
neurofibromatosis has not been very effective, and is in fact the leading cause of 
cancer-related death in patients younger than age 35. Despite the development of 
drugs that combat these malignancies, the prognosis for patients remains poor. One 
reason for the poor outcome is that migrating cells escape removal during tumor 
resection, and in many cases avoid radiation and chemotherapy after resection.  This 
allows the tumor to regrow, usually aggressively, and often at a location close to the 
site of the original tumor [1, 2]. In the last 10 years recent developments in drug 
delivery methods have allowed doctors to implant/inject time-release drugs into the 
tumor cavity that allows for continuous release of chemotherapy; however results from 
these studies have not been as successful as anticipated. Gliadel wafers impregnated 
with BCNU (also called carmustine) are implanted into the resection cavity to deliver 
high concentrations of drug to the surrounding tissue.  However, the diffusivity of 
BCNU in tissue limits its penetration to a few millimeters from the wafer before it is 
eliminated by a variety of mechanisms [3]. 
Convection-enhanced drug delivery has been used to bypasses the blood-brain 
barrier by infusing drugs directly into the brain through a needle or microcatheter.  
The infusion establishes a pressure gradient that induces a flow in the brain away from 
the needle.  Small molecules can be delivered over relatively large distances in the 
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brain, but larger molecules, including certain proteins with proven efficacy against 
malignant cells, are hindered in their transport [4, 5].  As a result, they cannot travel 
sufficiently far to reach migratory malignant cells. Drugs can be packaged inside 
nanoparticles such as polymeric spheres or liposomes, which protects the drug from 
elimination, but transport of these nanoparticles in the interstitium is even more 
hindered than that of proteins [6, 7]. 
The transport of proteins and nanoparticles can be improved by increasing the 
porosity or the effective “pore size” of the brain interstitium.  For example, transport is 
enhanced when the proteins or nanoparticles are infused in a hyperosmolar solution 
that induces tissue swelling locally by drawing fluid into the interstitium from 
surrounding blood vessels and cells.  Infusing an enzyme that temporarily degrades the 
extracellular matrix, which increases the permeability of the interstitium to proteins 
and nanoparticles, also enhances transport [8].  Although these methods work to some 
extent, additional transport enhancement is required to realize the potential of 
convection enhanced drug delivery. 
In this study we utilize 1.58 MHz focused ultrasound to increase the perfusion 
of locally delivered Evans blue dye that is widely used in tissue diffusion experiments 
[9-11] into an agar gel that is used routinely as a mimic of brain tissue for drug 
delivery studies [12], equine brain and avian muscle tissue. The ultimate goal is to 
increase the rate of transport of pharmaceutical agents relative to their elimination rate, 
and thereby extend the distance that drugs penetrate and maintain therapeutically 
useful concentrations. 
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6.3 Methods 
6.3.1 Specimen Setup and EBD Application 
Neurological tissue mimicking phantoms were prepared by filling off-the-shelf 
12 oz Solo Cups (Tops Super Market Brand, Ithaca, NY) with a solution of 0.6 wt% 
agar powder (Product #19461580, MP Biomedicals, Solon, OH). The powder was 
dissolved in 100 degree Celsius distilled water for 5 minutes and poured into the cups 
to a height of 2.5cm. The cups were then covered, set aside, and allowed to cool and 
gel (approximately 20 minutes).  Equine horse brain was harvested from the Cornell 
Vet School two minutes post-mortem and prepared into 3x3x3 cm slices (the cortex 
surface was used for the ultrasound enhanced EBD perfusion). The equine brain 
experiments were conducted within 30 minutes of brain harvesting. Avian muscle 
tissue was purchased fresh from a local supermarket and cut into 3x3x3 cm squares for 
the study. Well characterized Evans blue dye (Product #203163, MP Biomedicals, 
Solon, OH) diluted in distilled water to 0.25 wt% was used to mimic water soluble 
drug and apply contrast to determine the extent of perfusion. During ultrasound 
application, the fresh tissues were placed in 12 oz cups, and all samples were covered 
by 200 ml of EBD and secured in position.  
 
6.3.2 Ultrasound Setup, Dosing and Analysis 
 Ultrasound energy in the samples was generated by a lead zirconate titanate 
(PZT-4), 1.58 MHz, 25.4mm diameter piezoelectric ceramic with a radius of curvature 
corresponding to 40mm. The ceramic, air-backed and housed in a PVC plastic 
assembly, was driven at 1.58 MHz, by a +/- 200 volt amplifying circuit (TC6320 high 
speed ultrasound driver, Supertex Inc., San Jose, CA.). The acoustic source power was 
modeled mathematically using Mason’s model [13-15], and measured directly with a 
calibrated hydrophone (Model #S158, Transducer Engineering Inc., Andover, MA). 
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All samples were sonicated 100% duty cycle at the average intensity of 3.00 watts/cm
2
 
(peak-focus-intensity 15 watts/cm
2
) in the samples geometric center for durations of 1-
4 minutes. The location of the focus of the transducer was positioned so that the focus 
at 40mm from the front surface of the US was placed on the sample/dye interface as 
shown in Figure 6.1. The US was oscillated at 0.25 Hz over a 10mm translation 
perpendicular to the samples surface to increase the sonicated volume for the duration 
of all experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 6.1. The experimental setup for the sample study is shown to the left. The 
sonicated phantom is covered  in 0.25 wt% diluted Evans blue dye and sonicated at 
100% duty  while simultaneously the transducer is oscillated up and down at 0.25Hz 
10mm amplitude. The beginning position of the transducer was 40mm above the 
sample/dye interface. 
 
For analysis purposes the location of the sample/dye interface was taken to be 
zero. Sectional readings of EBD perfusion were taken every minute for the control and 
sonicated samples (four at each time point totaling 12 for each material). The section 
of the sample was performed by taking a 2mm geometric center slice from the sample 
and imaging the location of the US focused energy with a CCD camera/microscope 
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system (Nikon Cool Pix 995, Nikon Inc. USA and Olympus BX51, Olympus Inc. 
USA). The digitally captured images were imported into MatLab® 6.5 (Math Works 
Inc. USA) to determine the extent of the Evans blue dye perfusion into the samples 
with and without applied US.  By using Red-Green-Blue (RGB) color mapping and 
converting digital pixels into distance (mm) measurements, intensity vs. distance 
concentration curves of EBD perfusion into the samples were produced. The four 
spectral intensity curves corresponding to each sectional measurement for each time 
point were averaged, and the area under the concentration curves for the sonicated and 
control were evaluated to quantify the density of EBD  uptake. The areas for control 
and experimental groups was compared using a student T-test for statistical 
significance.  
 
6.4 Results 
Analysis of the experimental data shows the sample tissues have a substantial 
increase in EBD perfusion when compared to the control. Shown in Figure 6.2 are the 
sectional images of the EBD concentration gradient for three samples studied at two 
minutes (1, 3 and 4 minutes not shown). The red curves (peak uptake aprox. 600 for 
all) represents the EBD perfusion into the samples with US applied. The blue curves 
are the controls representing simple diffusion into the sample. Application of US 
enhanced EBD density of 61.5% (phantom), 93.2% (brain) and 52.8% (muscle) 
compared to the control (p<0.001). 
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Figure 6.2. The above Figure shows the sectional images and the results of enhanced 
EBD delivery into a tissue mimicking phantom, equine horse brain and avian muscle 
tissues with the application of Therapeutic Ultrasound for two minutes in red, 
compared with the control in blue. The Figure shows concentration curves of the EBD 
uptake into the samples and that local delivery of EBD in conjunction with the 
application of Therapeutic Ultrasound may significantly enhanced the amount of EBD 
delivery into tissue.  Application of US enhanced EBD density of 61.5% (phantom), 
93.2% (brain) and 52.8% (muscle) compared to the control. 
 
 
During all time points 1-4 minutes and shown in Figure 6.2 the surface 
intensity (x axis=0) for the control is not equivalent to the experimental with 
sonication, this was also noticed in our prior study [16]. We now believe that this edge 
effect and mismatch of concentration in the control and experimental groups is a 
surface mass transport resistance, and the limited diffusion of the dye into the samples 
for the short time points resulting in poor pixel intensity image mapping. 
Experimentally with the phantom, we found that if we removed the phantoms gelling 
surface with a razor, the mass-transport resistance was not apparent and EBD more 
readily perfused the phantom. The focused ultrasound had a sonoporation type effect 
as in transdermal drug delivery, and has an impact on breaking down the surface 
resistance of all samples allowing for quicker perfusion of dye and overall dye density 
uptake in the sonicated phantoms.  
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6.5  Supporting Analysis and Discussion of Results 
To find the concentration profile of a chemotherapeutic diffusing through a 
tissue, the tissue can be modeled as a medium comprising three phases: extracellular 
space (ECS), intracellular space (ICS) and cell membrane (CM) [17-19]. The local 
chemotherapeutic concentration depends on its rate of transport through the tissue, its 
rate of elimination by degradation, metabolism, and permeation into blood capillaries, 
and its rate of binding and internalization. Under these conditions, the 
chemotherapeutic concentration diffusing through tissue is given by 
 
 
C
t
   DECSCECS
O vCECS
O  kECSCECSO  kICSCICSO  1   kMCCMO 
B
t
(6.1) 
where C and B are total concentrations of free and bound chemotherapeutic, 
respectively; 
 
CECS
O , CICS
O , and CCM
O are volume-averaged concentrations in the ECS, ICS 
and CM phases, respectively; t is the time following the beginning of diffusion from 
the source; α and β are volume fractions of ECS and ICS phases; DECS is the diffusion 
coefficient of the drug in ECS; v is the apparent velocity vector of interstitial fluid in 
ECS; and kECS, kICS, and kCM are first-order elimination constants in ECS, ICS and CM 
phases, respectively [17].   
This equation was applied to predict concentrations of BCNU and other 
chemotherapeutics released from polymeric wafers in the rat [18] and monkey brain 
[17]. Comparisons of the predictions with data showed that several assumptions can be 
made in the equation without introducing significant error, including that coefficients 
are independent of position, that free drug is in equilibrium locally with bound drug, 
and that convection is negligible compared with diffusion. Under these assumptions, 
the steady-state profile for total concentration C satisfies the one-dimensional equation 
 
D
2C
x2
- kC = 0  (6.2), where x is distance from the BCNU wafer/tissue interface, D is 
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an apparent diffusion coefficient of drug in the brain, and k is a first-order elimination 
constant that combines the elimination mechanisms mentioned above.  The solution of 
this equation with boundary conditions appropriate for release of drug from an 
implanted BCNU wafer is 
 
C x 
Ci
=
exp -
H - x
L




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 exp
H - x
L




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exp -
H
L




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 exp
H
L




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, where  = L
k
D
.
  (6.3) 
Here, L is the half-thickness of the wafer, Η is the perpendicular distance from the 
wafer/tissue interface to the edge of the brain, and Ci is the chemotherapeutic 
concentration at the wafer/tissue interface. The dimensionless concentration profile 
C(x)/Ci is determined completely by the value of the modulus  , which gives a 
quantitative estimate of the relative rates of elimination and diffusion of the drug in 
brain tissue. Using the results for monkey brain [17], the estimated values of the 
coefficients are D = 14.3 x 10
-6
 cm
2
s
-1
, L = 0.5 mm, k = 0.0028 s
-1
, and H = 5 cm. The 
red curve in Figure 6.3 shows the dimensionless BCNU concentration C/Ci as a 
function of distance x into tissue. The Figure shows that C/Ci decreases significantly 
just a few millimeters away from the wafer.  We found similar results for Evans blue 
dye in the experiments presented. 
Results presented in section 6.3 and in Chapters 6, 8 and 9 shows that exposing 
tissue to ultrasound enhances diffusion in tissue.  The effect of enhanced diffusion and 
its effect on drug penetration into tissue can be anticipated by plotting concentration 
profiles given by the solution above with an apparent diffusion constant D* replacing 
the molecular diffusion constant D. This is shown in the blue curves in Figure 6.3 for 
D* = 5D to 300D. If we define a penetration distance as the distance where C/Ci drops 
to 0.1, then the Figure shows that the penetration distance more than doubles for a 
tenfold increase in the apparent diffusion constant due to ultrasound exposure. For a 
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100-fold increase, the penetration distance would increase by nearly an order of 
magnitude. 
 
Figure 6.3 Dimensionless BCNU concentration profiles in tissue following its release 
from a wafer in monkey brain 
  
Figure 6.4 EBD concentration profiles after 2 min in equine brain tissue without 
ultrasound (red) and with 1W/cm
2
 ultrasound (blue) for 2 min. Ultrasound increases 
the apparent diffusion coefficient by about 40x. 
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Figure 6.4 show example profile with and without exposure of the tissue to 
ultrasound at an intensity of 1 W/cm
2
 for 2 min. The red curve shows the 
concentration profile of EBD in the sample without ultrasound (pure diffusion). The 
blue curve shows the concentration profile for tissue exposed to ultrasound. 
Using the concentration profile, we can estimate that ultrasound exposure 
increases the apparent EBD diffusion coefficient by about a factor of 40 in this case. 
The fluctuations in concentration for the ultrasound case are outside error limits of the 
experiment and are probably due to heterogeneities in tissue structure such as 
transitions between white and gray matter.  Structural variations in tissue influence the 
interaction between ultrasound and tissue, which could affect local EBD transport 
through the tissue. These fluctuations are not observed for experiments involving 
agarose gel brain phantoms. The effectiveness of diffusion based brain cancer 
therapies depends strongly on the penetration of the chemotherapeutic into the peri-
tumoral space. If a 40x increase in the apparent diffusion constant could be realized 
clinically by using ultrasound to assist diffusion based strategies, the penetration of 
chemotherapeutic would be significantly enhanced, which could significantly improve 
outcomes of the therapy for glioblastoma patients. 
 
6.6 Conclusions 
In this study we looked at the effect of 1.58 MHz ultrasound on the perfusion 
of Evans blue dye into neurological tissue mimicking phantoms, equine brain and 
avian muscle tissue. We found a clear increase in EBD penetration and overall dye 
density in the sonicated verses control samples for all times (p<0.001). 
Experimentally, this was noticeable in Figure 6.2 at 2 minutes with enhanced dye 
uptake of 61.5% (phantom), 93.2% (brain) and 52.8% (muscle) compared to the 
controls. Applied therapeutic ultrasound to the sample-dye interface, was found to 
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increase the surface mass-transfer of EBD into the sample and increase the apparent 
diffusion coefficient of EBD in the tissue samples. We hypothesize that the acoustic 
pressures from the peak focal intensity of 15.2 watts/cm
2
 and oscillation of the 
transducer field Figure 6.1, imparted radiation pressures of EBD into the sample, 
while also warming and agitating the porous matrix. These combined effects enhanced 
the perfusion of dye with sonication.   
From the results presented we find that 1.58 MHz ultrasound is a promising 
new method to increase the penetration of hydrophilic drugs into brain tissue. The 
overall goal being the ability to use ultrasound to drive locally delivered chemotherapy 
agents past current diffusion limitations to reach migratory cancer cells. Continued 
research to study how changes in ultrasound parameters will affect the rate and level 
of dye perfusion in animal brain tissues will be our continuing focus. Different 
frequencies, powers, and pulse sequences appropriately below the brain tissue damage 
threshold will be analyzed to create a therapeutically useful regime. 
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CHAPTER 7 
THERAPEUTIC ULTRASOUND ENHANCEMENT OF DRUG DELIVERY TO 
SOFT TISSUES
12 
7.1 Abstract 
 Effects of exposure to 1.58MHz focused ultrasound on transport of Evans Blue 
Dye (EBD) and bovine serum albumin conjugated EBD in soft tissues are investigated 
when an external pressure gradient is applied to induce convective flow through the 
tissue. The magnitude of the external pressure gradient is chosen to simulate 
conditions in brain parenchyma during convection-enhanced drug delivery (CED) to 
the brain. EBD uptake and transport are measured in equine brain, avian muscle and 
agarose brain-mimicking phantoms. Results show that ultrasound enhances EBD 
uptake and transport, and the greatest enhancement occurs when the external pressure 
gradient is applied. The results suggest that exposure of the brain parenchyma to 
ultrasound could enhance penetration of material infused into the brain during CED 
therapy.  
 
 
 
 
 
 
 
                                                 
12This work has been published as Lewis, G.K., Jr., Wang, P., Lewis, G.K., Sr., Olbricht, W.L. (2009). 
Therapeutic ultrasound enhancement of drug delivery to soft tissues. 8th Int. Symp. Theras. Ultras. AIP 
Conf. Proc. 1113, pp. 403-407 
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7.2 Introduction 
Over the last decade, a driving factor in pharmaceutical development and drug 
delivery has been the ability to target disease at the cellular and tissue levels. Local 
delivery of therapeutics often allows higher doses to be delivered without side effects 
that restrict dose levels in systemic delivery. Local delivery can be combined with 
controlled release to provide sustained high concentrations of drug in the immediate 
vicinity of affected tissue [1-3]. Local delivery is especially important in treating brain 
disorders, because most therapeutics administered intravenously do not cross the 
blood-brain barrier. Recent developments in treating brain gliomas, which are 
infiltrative tumors that present poor prognosis for patients, rely on local delivery 
methods. After resection of the tumor, malignant cells that have migrated from the 
tumor remain behind, surrounded otherwise by healthy tissue. These cells continue to 
grow, leading to the recurrence of the disease. CED is a local delivery technique in 
which therapeutics are infused directly into the brain interstitium through an implanted 
needle microcatheter [4, 5]. The infusion induces a convective flow of infusate 
through the interstitium. The infused drugs are subject to elimination via a variety of 
mechanisms. Therefore, the challenge in CED is to enhance penetration of infused 
therapeutics so that they reach migrating malignant cells before they are eliminated. 
Some of the most promising drugs for treating gliomas are large proteins and drugs 
packaged in nanoparticles, which, owing to their size, are especially difficult to move 
through brain interstitium under the convective force of the infusion. Therefore, any 
method to enhance transport of infused drugs could benefit the outcome of the 
therapy. 
The use of ultrasound to enhance drug delivery has evolved over several 
decades. Perhaps the most extensively studied example is the use of ultrasound to 
enhance transdermal drug delivery [6, 7]. Exposure of skin to ultrasound can increase 
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the permeability of the stratum corneum, allowing transport across skin of some 
therapeutic compounds that would otherwise be excluded and enhancing transport 
rates of others. Although a variety of thermal and non-thermal mechanisms could be 
responsible for transport enhancement, acoustic cavitation and microstreaming [8, 9] 
may be the most important.  At lower acoustic power, oscillations of endogenous 
microbubbles or microbubbles added to an infusate may induce similar 
microstreaming, even in the absence of cavitation. 
We present results on the enhancement of Evans blue dye (EBD) and bovine 
serum albumin conjugated EBD transport into soft animal tissues using 1.58 MHz 
ultrasonic powers of 1.3 and 5.25 W in combination with an applied convective flow 
under conditions that simulate convection-enhanced drug delivery [10, 11]. 
 
7.3  Methods 
7.3.1  Sample Preparation 
Neurological-tissue-mimicking phantoms were prepared by filling 12 oz Solo 
Cups with a solution of 0.6 wt% agarose powder (MP Biomedicals, Solon, OH) [12]. 
The powder was dissolved in distilled water at 100º C for 5 min and then poured into 
the cups to a height of 1.5 cm. The cups were covered and allowed to cool and gel 
(about 20 min). Equine horse brain was harvested from the Cornell School of 
Veterinary Medicine immediately post-mortem and cut into 3 x 3 x 1.5 cm cortical 
slices. Experiments were conducted within 30 min of brain harvesting. Avian muscle 
tissue was purchased from a local supermarket and cut into 3 x 3 x 1.5 cm slices. A 
0.25 wt% aqueous solution of Evans blue dye (MP Biomedicals, Solon, OH) was used 
to mimic a water-soluble drug. The EBD solution provided sufficient contrast to 
measure its extent of penetration into the phantom and tissue samples [10, 11, 13, 14].  
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Bovine serum albumin conjugated EBD was prepared by mixing albumin from 
bovine serum (molecular biology, powder, Sigma-Aldrich, OH) with Evans Blue dye 
(Product #203163, MP Biomedicals, Solon, OH)) in the ratio of 1:0.4 (Albumin:Evans 
Blue) by weight. The 5 mg/mL concentration solution was prepared in 0.9% NaCl 
(wt/vl) and sterile filtered through a 0.2 micron syringe filter (Supor® Sterile Syringe 
Filter, 0.2 Micron, 25Mm, Health Care Logistics). The filtrate was then dialyzed 
against 0.9% saline to remove excess Evans Blue with a 10 kDa MWCO Slide-A-
Lyzer (Slide-A-Lyzer Dialysis Cassettes, 10,000 MWCO, 12-30 ml, Thermo Fisher 
Scientific Inc.). The dialysis was carried three times for one hour each at room 
temperature with dialysate 300 times the sample volume. The conjugate dye was 
stored in a cooler prior use. The solution is diluted to 2.5 mg/mL for the experimental 
procedures. 
 
7.3.2  Convection background and setup 
In CED, an infusion into the brain establishes a radial flow outward from the 
needle tip. The average velocity of infusate in the tissue Vc decays as 1/r
2
, where r is 
the distance from the needle tip. For a volumetric infusion rate of 1 µL·min
-1
, a typical 
value in rodent experiments, Vc ranges from 670 to 3.0x10
-7 
m·s
-1
, from the needle tip 
to r = 1.5 cm [16, 17]. The pressure gradient associated with this flow can be 
calculated from Darcy’s law, provided that the porosity Φ and hydraulic permeability 
κ of the tissue can be estimated. For brain tissue, avian muscle, and agarose brain 
phantom estimates are κbrain=5.63 x 10
-12
, κmuscle=5.00 x 10
-14, κagarose=2.05 x 10
-12
 and 
Φbrain=20%, Φmuscle=1.6%, Φagarose=90% [16-19]. To achieve values of Vc that are 
similar to those in CED, pressure gradients were applied across the equine brain, avian 
muscle and brain phantom samples in conjunction with topical application of EBD. 
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A convection chamber was constructed and used to apply pressure gradients of 
1330 kPa·m
-1
 for the brain and phantom samples, and 6650 kPa·m
-1
 for the avian 
muscle samples shown in Figure 7.1.  In this system, the average velocity flow due to 
the applied pressure gradient is unidirectional and constant throughout the sample. The 
sample was held in place at the bottom of a cylindrical chamber, which was filled with 
EBD solution to a height of 5 cm. The bottom of the chamber contained a hole that 
opened into a collection chamber. The tissue sample was placed on a screen that 
covered the hole.  
 
Figure 7.1. Experimental setup for ultrasound-enhanced convection. A 1.58MHz 
transducer sonicated the sample for 1-30 min. The pressure gradient across the 
sample was primarily provided by a vacuum pump, which induced convective flow 
through the sample. 
 
The pressure in the collection chamber was reduced to the appropriate value for each 
sample by drawing a vacuum (Model 2534B-01, Welch Inc., Niles, IL). The resulting 
values of Vc were estimated from the applied pressure difference across the sample, 
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including the hydrostatic pressure from the liquid above the sample.  For the 
specimens in this study we estimated Vc as 3.75 x 10
-5
, 2.02 x 10
-5
 and   2.98 x 10
-6
 
m·s
-1
 for the brain, muscle and phantom samples respectively. 
 
7.3.3  Ultrasound setup and dosing 
Ultrasound (US) energy was generated by a lead zirconate titanate (PZT-4), 
1.58 MHz, 25.4 mm diameter piezoelectric ceramic with radius of curvature 
corresponding to 40 mm (EBL Products Inc., Hartford, CT). The transducer was 
driven at 1.58 MHz. US was applied at 100% duty cycle at the power of 1.30 and 5.25 
W corresponding to a maximum acoustic intensity at the focal zone of 10.3 and 41.8 
W/cm
2
 in the sample’s geometric center for durations of 1 to 30 min. The transducer 
was positioned with its focus at the sample-tracer interface. To increase the sonicated 
volume of tissue, the transducer was translated periodically over a distance of 30 mm 
perpendicular to the sample’s surface at 0.25 Hz. The transducer was driven by a 
custom-built portable system and calibrated using a force balance technique in which 
we measured the force that the ultrasound exerted on an acoustic absorbing object 
[20]. The temperatures of the sonicated samples were recorded with a calibrated 
thermocouple placed 1.5 cm from the focus (Model 52II, Fluke Inc. Everett, WA).  
 
7.3.4 Data analysis 
The experiment was run for the three tissue samples and EBD tracer for 1, 2, 3 
and 4 min with and without the applied pressure gradient and with and without 
exposure to ultrasound. For the phantom samples we collected additional data sets 
with EBD and AcEBD at 1, 2, 4, 6, 8, 10, 15 and 30 min with and without the applied 
pressure gradient and with and without exposure to ultrasound. For data analysis a 3 
mm slice was taken from the geometric center of each sample. The intensity profile 
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was measured as in our previous studies [10, 11]. Area under the curve was calculated 
to quantify the amount of EBD uptake in each case. Phantom samples were further 
analyzed by plotting the dimensionless color intensity concentration profile C(x)/Ci 
where Ci was the optically measured color intensity of the tracer at the sample 
interface and C(x) was the color intensity as a function of distance into the sample as 
discussed in chapter 7. For EBD and AcEBD 1-30 min data sets, background noise is 
reduced to improve data interpretation by fitting the diffusion tail to equation 6.3 as in 
Chapter 6, Figure 6.4. 
 
7.4 Results 
In this section we present results for EBD and bovine serum albumin 
conjugated EBD (AcEBD) distribution in the tissue samples under the experimental 
conditions described in the methods section. 
The distance of tracer penetration into all samples increased in the following 
order: 
No applied pressure gradient and no ultrasound 
Applied pressure gradient and no ultrasound 
No applied pressure gradient and 1.3 W ultrasound 
No applied pressure gradient and 5.25 W ultrasound 
Applied pressure gradient and 1.3 W ultrasound 
Applied pressure gradient and 5.25 W ultrasound 
 
For the two tracers, EBD penetrated further into the samples under test at the 
various time points as compared to AcEBD. Ultrasound exposure led to increases in 
the sample temperature tabulated in Table 7.1. For equine brain and brain phantom, 
temperature changes were similar among the samples. Temperature increases for avian 
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muscle tissue were slightly larger. No tissue damage or changes in tissue morphology 
were observed in any sample.   
Figures 7.2 and 7.3 show the EBD intensity as a function of distance into the 
sample for avian tissue after 4 min, brain tissue after 2 min and brain phantom after 1 
min. The red curve shows the profile with no applied pressure gradient and no 
ultrasound; in this case EBD transport is purely diffusive. The green curve shows the 
profile with an applied pressure gradient but no ultrasound, which simulates CED. The 
blue curve shows the profile for tissue exposed to ultrasound with no applied pressure 
gradient. The yellow curve shows the profile for tissue exposed to ultrasound with an 
applied pressure gradient, which simulates an ultrasound-enhanced CED. For both 
power levels the combined effect of ultrasound and an applied pressure gradient gave 
greatest EBD uptake in all tissues. 
 
 
Figure  7.2. EBD profile of avian muscle tissue after sonication at 1.3 W (top) and 
5.25 W (bottom) for 4 min. US combined with CED provided greatest EBD uptake 
enhancement of 240% (left) and 390% (right) as compared with diffusion alone. 
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Figure 7.3. EBD profile of equine brain tissue (top) and brain-mimicking phantom 
(bottom) after 5.25 W sonication for 2 and 1 min, respectively. US combined with 
CED provided greatest EBD uptake enhancement of 560% (left) and 880% (right) 
compared with diffusion alone. 
 
 
 
Figure 7.4 is a compilation of sectional EBD profile images used to produce 
Figures 7.2 and 7.3. Moving from left to right across the columns in the image shows 
the enhancement of EBD penetration into the three samples. 
As in our previous studies [10, 11], the EBD intensities at the tissue/dye 
interface (x=0 mm) are not identical in the four cases in each Figure. This suggests the 
presence of a mass transfer resistance at the surface of the samples. Apparently, the 
application of ultrasound at 1.3 and 5.25 W decreases this mass transfer resistance at 
the interface and increases uptake into the sample. 
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Figure 7.4. Compilation of sectional profile images to produce EBD profile curves in 
Figures 1 and 2 
 
Table 7.1.  Percent enhancement of EBD uptake into tissue samples as compared with 
diffusion alone. The corresponding temperature changes in the samples during US 
application is also shown.  
Sample and US Power CED US CED and US 
Temperature 
Change 
Avian Muscle 1.3 W 130% 220% 240% 4 ºC 
Avian Muscle 5.25 W 130% 260% 390% 7 ºC 
Equine Brain 5.25 W 185% 450% 560% 1 ºC 
Brain Phantom 5.25 W 310% 590% 880% 2 ºC 
 
The profile curves of Figure 7.5 show the dimensionless EBD and AcEBD 
concentration C/Ci as a function of distance into brain phantoms. The Figure shows 
that C/Ci decrease significantly for diffusion just a few millimeters away from the 
dye/sample interface.  The effect of exposing the tissue to convection and ultrasound 
while the compound diffuses through the sample improves tracer penetration over all 
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time points studied and for the two different size molecules. Ultrasound combined 
with convection improved the perfusion of EBD by 277% and AcEBD by 327% as 
compared to diffusion of the two molecules into the phantom over 30 minutes.   
 
 
Figure 7.5. Dimensionless concentration profiles of EBD (left) and AcEBD (right) for 
brain-mimicking phantom after 5.25 W sonication for 1-30 min. US combined with 
CED provided greatest EBD and AcEBD uptake enhancement of 277% (left) and 
327% (right) compared with diffusion alone at 30 minutes. 
     
 The shapes of the concentration profiles in Figures 7.2, 7.3 and 7.5 for cases with 
ultrasound suggest that ultrasound provides a mass transfer mechanism in addition to 
diffusion. The nearly flat profiles the EBD/sample interface (x=0) suggest a 
convection-dominated regime in this region.  Further into the samples, the steeper 
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concentration gradients that are found are consistent with mass transfer dominated by 
diffusion. 
Temperature rise in the tissue samples from the absorption of ultrasound is a 
possible source of diffusion enhancement. According to the Stokes-Einstein relation, 
the diffusivity is directly proportional to temperature and inversely proportional to 
solvent viscosity. For a 4 and 7 ºC increase in temperature, the diffusivity would 
increase by 11% and 16%, respectively, which is insufficient to explain the observed 
increases in EBD and AcEBD uptake, suggesting that enhanced diffusion due to tissue 
heating is not the dominant mechanism for enhanced EBD and AcEBD uptake.   
 
7.5 Conclusion 
We studied effects of therapeutic 1.58 MHz focused ultrasound at 1.3 and 5.25 
W spatial-average power levels in combination with convective flow on the uptake of 
Evans blue dye into avian muscle, equine brain and  neurological-tissue-mimicking 
phantoms. Furthermore, we evaluated the penetration of Albumin conjugated Evans 
blue dye into phantoms over longer experimental exposure times. Ultrasonic power 
levels were applied below tissue damage thresholds for short sonication times.  
Convection velocities were in the range of typical CED infusions in rodent brain. The 
study showed enhanced penetration effects when ultrasound was combined with CED 
in all samples at both power levels.  The results suggest that CED in combination with 
ultrasound may enhance the penetration of therapeutics in the brain and increase the 
concentration of infused drugs over the penetration distance, which may improve the 
outcome of CED therapy. These promising results support further evaluation and 
examination of ultrasound-assisted CED in vivo. 
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CHAPTER 8 
 
ULTRASOUND ASSISTED CONVECTION ENHANCED DRUG DELIVERY TO 
THE BRAIN IN VIVO WITH A NOVEL TRANSDUCER CANNULA 
ASSEMBLY
13,14 
 
8.1 Abstract 
In traditional convection enhanced delivery (CED), drugs are infused locally 
into tissue through a cannula inserted into brain parenchyma. Transport of the infused 
material is dominated by convection, which enhances drug penetration into tissue 
compared with diffusion mediated delivery. Ultrasound has been shown to assist 
and/or mediate the delivery of pharmaceuticals across membranes and through tissues. 
The purpose of this study was to demonstrate the feasibility of ultrasound-assisted 
convection enhanced delivery (UCED) to the brain in vivo using rats with a novel, low 
profile transducer cannula assembly (TCA), and portable and pocket-sized ultrasound 
system. A total of 40 Sprague–Dawley rats (350 to 450 g) were divided into two equal 
groups and further divided into four equal subgroups (n=5 in each). The rats were 
anesthetized, secured into ear bars on a sterotax, and a craniotomy was performed. The 
caudate of the rodent brain was infused with 0.25 wt% Evans blue dye (EBD) in 
Phosphate-Buffered Saline (PBS) at two different infusion rates of 0.25 µL/min for 
group 1, and 0.5 µL/min for group 2. Infusion flow rate was slowly increased over 10 
minutes from 0.05 to 0.25 µl/min for group 1 n=20 rodents and 0.1 to 0.5 µl/min for 
group 2 n=20 rodents, and maintained at the final flow rate for 20 min thereafter, for a 
                                                 
13This work has been filed as Lewis, G.K. Jr., Olbricht, W.L. (2010). Ultrasound assisted brain drug 
delivery cannula United States Provisional Patent Application. 61311064 
14This work is in preparation for being published as Lewis, G.K., Jr., Schulz, Z., Pannullo, S., Southard, 
T., Olbricht. W.L. (2011). Ultrasound assisted convection enhanced delivery in vivo with a novel 
transducer cannula assembly. 
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total experiment duration of 30 min in both groups. Using the TCA without 
ultrasound, the four control subgroups were infused without and with microbubbles 
(CED and CED+MB). The four UCED subgroups (UCED and UCED+MB) followed 
the same protocol with the addition of simultaneous continuous wave 1.34 MHz 
ultrasound operating at a total acoustic power of 0.11 +/- 0.005 W and peak spatial 
intensity at the cannula tip of I= 49.7 mW/cm
2
. Frozen section and histology was 
performed on the brains, and infusion distribution was three-dimensionally 
reconstructed using MatLab® analysis. Hematoxylin and Eosin (H&E) staining was 
used to assess tissue damage and morphological changes to the brain. The application 
of UCED and UCED+MB improved EBD total volumetric distribution by 2.24 to 3.25 
and 1.16 to 1.70 times, respectively (p<0.001). On gross and histological examination, 
no ultrasound or microbubble related damage to the brain tissue was found. The TCA 
and battery-powered ultrasound device show promise to improve the distribution of 
infusate during CED in clinical practice.  
 
8.2 Introduction 
Convection enhanced delivery (CED) uses a cannula and syringe pump for 
direct infusion of therapeutics into the brain to bypass the blood-brain barrier [1]. The 
infusion takes place through a cannula that is inserted directly into brain parenchyma. 
The infusion establishes a pressure gradient in the tissue that causes material to flow 
outward from the needle tip. Small molecules such as sucrose can be transported 
effectively by convection. However, larger molecules such as proteins may interact 
with components of the extracellular matrix (ECM) and with cell membranes, which 
can inhibit their transport. Furthermore, many therapeutics of clinical interest are 
subject to elimination by several mechanisms, including clearance into capillaries, 
binding to cell membranes, internalization into cells, and enzymatic metabolism. The 
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distance that a therapeutic penetrates into the brain and its concentration profile in the 
interstitium depend on relative rates of convection and elimination. In principle, 
increasing the infusion rate can increase the rate of convection and thereby increase 
the distance that infused molecules penetrate at therapeutically useful concentrations. 
However, brain tissue is poroelastic, and it deforms in response to the local pressure 
associated with the infusion. For sufficiently high infusion rates, the tissue separates 
from the outer surface of the infusion needle, which opens a gap allowing infused 
material to escape the parenchyma [2,3]. Although judicious catheter designs can 
reduce this effect, backflow along the outside of the needle sets an upper limit on the 
infusion rate, which, in turn, sets an upper bounds on the convection rate and 
penetration distance in the parenchyma. 
Extending the penetration distance in CED is essential for the treatment of 
glioblastoma multiforme (GBM), a high-grade glioma that is usually treated with 
tumor resection, external beam irradiation and chemotherapy. However, GBM 
characteristically has diffuse boundaries, and invariably malignant cells have migrated 
away from the main tumor prior to resection, thus limiting the impact of surgery. 
Traditional chemotherapy and radiation therapy administered post-resection are unable 
to eliminate all of the remaining malignant cells. As a result, the malignancy recurs, 
usually within 1 cm of the original tumor. Median survival is approximately one year 
after the diagnosis of GBM [4]. 
In both small and large animal models, convection enhanced delivery (CED) 
has been used to infuse a variety of compounds including small molecules [1,5,6], 
larger molecules [1,7-9], therapeutics encapsulated in liposomes [10] and 
nanoparticles  [11]. In human clinical trials, CED has been used with both single and 
multiple cannula placements to deliver a variety of agents directly into the brain [12-
14]. The results of these studies are highly variable, but some have shown that infused 
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therapeutics can penetrate deep into the brains of small animals with tumor xenografts 
[10], and these studies often show corresponding decreases in mortality. In larger 
animals and human trials, however, delivery of the drug to malignant cells remains a 
major challenge for CED [15,16], as described in recent reviews [17-19]. 
New applications of ultrasound for drug delivery have been evolving over the 
last two decades. Transdermal drug delivery via sonophoresis or cavitation-based 
delivery has been extensively studied in both animals and humans [20-23]. Ultrasound 
exposure of skin to a wide range of frequencies increases the permeability of the 
stratum corneum, increasing and the transport rates of therapeutics through the 
epidermal layers . Although a variety of thermal and non-thermal mechanisms could 
be important, a consensus among investigators who have studied the effect of 
ultrasound parameters on transport enhancement is that the underlying mechanism is 
acoustic cavitation [24, 25]. Large implosion forces and micro jets generated during 
the collapse of cavitation bubbles at the skin surface disrupt the cellular layers, 
opening paths to underlying tissue and capillaries. At lower power levels, ultrasound 
can generate acoustic streaming, which is a local convective motion of liquid due to 
oscillating bubbles. If the liquid contains a concentration gradient of a solute, acoustic 
streaming can enhance mass transfer of the solute without inducing a significant bulk 
motion of the liquid. Recently, high intensity focused ultrasound (HIFU) has been 
shown to be an effective tool to target systemic drug treatments [26, 27]. Where 
ultrasound mediated disruption of the blood brain barrier is being studied to help drugs 
escape the blood stream and enter the brain [27]. Ultrasound has also been shown to 
enhance the convective transport of molecules in agarose, muscle and brain tissue in 
vitro [28-30].  
In this study we demonstrate that ultrasound may be applied in conjunction 
with CED to enhance the penetration of small molecules in the caudate of the rat 
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brain. Additionally, we show that this may be done with a novel 0.64 cm diameter 
1.34 MHz transducer cannula assembly (TCA) developed in our laboratory, powered 
by an ultralow-output impedance hand-held ultrasound generating device that costs 
under $200.00 in parts [32,33,36]. Although we constructed a special TCA for this 
experiment, the results imply that ultrasound may also improve the distribution 
volume for other catheter designs that have been introduced. The ability of ultrasound 
to improve CED, and the portability and low-cost of the ultrasound generating 
technology, suggests great promise in progressing CED in medical applications.   
 
8.3 Methods 
8.3.1 Ultrasound Transducer and Cannula Assembly  
The ultrasound transducer cannula assembly (TCA) consists of three main 
parts: 1. A cylindrical lead zirconate-titanate (PZT-4) ceramic, 2. A 30 gauge infusion 
needle and 3. A sterotaxic guide arm for precision alignment. The TCA is a novel 
axial resonating device that provides a cylindrical therapeutic acoustic field around the 
infusion needle during stereotaxic guided CED treatment.  
As shown in Figure 8.1, a 3x3 cm sheet of polarized 1.34 MHz PZT-4 (EBL-4, 
EBL Products Inc) with gold electrodes was machined into a cylinder with diameter of 
0.64 cm using a CNC milling machine (5400, Sherline Products Inc.) and general 
diamond tipped bore. The center of the cylindrical ceramic was found, and a precision 
diamond grinding point (4376A11, McMaster-Carr Inc.) was used to grind a 0.08 cm 
diameter hole through the center. All of the ceramic machining was conducted under a 
water bath to prevent toxic dust particles and remove heat generated from tooling 
process. The grinding point was also used to remove gold conductor from the top 
(inside) surface around the hole in the ceramic to electrically isolate the brass tube 
from the top surface. 
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Figure 8.1. Construction of the transducer cannula assembly. I. Machine the PZT-4 
into a disk with center hole. II. Connect a brass tube to front face of ceramic using 
solder. III. Place the ceramic in a watertight PVC/aluminum housing with sterotaxic 
guide arm, and connect ground and hot leads to the transducer through the guide arm. 
V-VI. Attach the guide-cannula and infusion cannula to the transducer and secure to 
the popper height with epoxy. VII. Actual finished device. 
 
 
The brass tube was flanged and inserted through the hole in the ceramic, and 
connected to the front face (bottom surface) with solder. The ceramic with brass tube 
was then placed in a low-profile PVC/aluminum assembly (Air-backed) with a 
sterotaxic guide arm as shown. The brass tube (electrical-ground) and top surface 
(electrical-hot) of the ceramic were wired through the stereotaxic guide arm with 5 Ω 
coax-cable (NMEF 1/22-15044 SJ, Cooner Wire Inc.). A 30 gauge cannula-guide and 
11 mm infusion cannula (8IC317I and 8IC317G, Plastics One Inc.) were mounted 
onto the assembly and affixed to the housing with 5-minute epoxy. The infusion 
cannula was positioned through the center of the assembly and perpendicular to the 
face of the transducer, to allow 5 mm of length from the face of the transducer to the 
cannula’s tip. The electrical impedance of the transducer cannula assembly (TCA) was 
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measured using commonly known methods, to determine the resonant frequency for 
efficient ultrasound generation [31]. 
 
8.3.2 Pocket-sized Ultrasound System 
The principles underlying the technology and construction of battery powered, 
pocket-sized ultrasound systems have been described elsewhere [32-36]. Here we 
briefly present a new ultralow output impedance ultrasound driver, based off of a 16-
MOSFET, surface mount component, printed circuit board (PCB) design, and its 
application in ultrasound-assisted convection enhanced delivery to the brain. 
The ultralow output impedance ultrasound driver was constructed on a double-
sided PCB, which was designed and created using PCB123® Layout V2 software 
from Sunstone Circuits Inc. The 3.8 x 7.62 cm PCB has 16 N/P channel parallel 
MOSFETs in a transistor-transistor logic (TTL) timing configuration to provide 
efficient voltage transfer from the driver to the ultrasound transducer. The ultrasound 
driver, 1.34 MHz crystal clock oscillator (ECS-100A-010, ECS Inc.) to time the driver 
at the resonance of the TCA, and three 7.4 V 2400 mAh rechargeable lithium ion 
battery packs (18650, Portable Power Inc.) wired in series are all enclosed in an 
ergonomic 12.2 x 7.9 x 3.3 cm plastic enclosure (PPLX, PacTec Inc). Power from the 
system may be made adjustable by switching between system battery packs to provide 
control of the clamped push-pull square wave drive signal between +/-7.4 or +/- 11.1 
V. For the purpose of this experiment the system was used at +/- 11.1 V setting 
because of the high electrical impedance of the TCA. The ultrasound technology is 
available through contacting the authors.  
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8.3.3 Ultrasound Exposimetry  
The peak ultrasonic intensity of the acoustic field was measured with an 
omnidirectional reference hydrophone (HNR 1000, calibrated July 12
th
 2010, Onda 
Inc.) in parallel planes 0.25 mm from the TCA’s face and at the cannula tip (5 mm 
from the TCA face). The TCA was submerged in a distilled and degassed (2 ppm) 
water tank (30 x 30 x 85 cm in size) that was made almost completely anechoic by 
placing a 1.27 cm thick wall of sound absorbing rubber around its wall (8456K417, 
McMaster-Carr Inc). 
Precise, micromanipulator-controlled positioning of the hydrophone was 
performed by hand using micro milling machine (5400, Sherline Products Inc.). 
Ultrasonic waves detected by the hydrophone were recorded by measured voltages 
using a digitizing oscilloscope (TDS2002B, Techtronix Inc.) and converted into 
intensity measurements using a calibration table provided by Onda Inc. The scanning 
step size for each plane was 1 mm and the scanning area was 10 x 10 mm. Spatial 
peak-temporal peak-intensity were determined for each plane by scanning with the 
hydrophone in 1 mm increments and averaging over 3 measurements [37,38]. The 
total acoustic power was measured with a radiation force balance system (RFB 2000, 
Onda Inc.) using a rubber disk absorbing target (RFB CTK, Onda Inc.) in distilled and 
degassed water. We compared these results with electrical measurements of intensity 
and power using the electrical properties of the TCA and measured ultrasonic power 
conversion efficiency from the Mason transmission line model [32, 33, 36]. 
 
8.3.4  Animal Experiments  
Rats were anesthetized and euthanized by procedures approved by the 
Institutional Animal Care and Use Committee (IACUC) at Cornell University. A total 
of 40 Sprague–Dawley rats (350 to 450 g) were divided into two groups with four 
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subgroups (5 rats in each subgroup). Animals were anesthetized by inhalation of 
isoflurane gas and secured in a stereotaxic frame. The head was shaved, 0.5 ml of 
bupivicaine was applied under the skin as a local anesthetic and an incision was made 
in the skin along the dorsal midline of the skull. A small craniotomy (6-7 mm 
diameter) was made over the left side of the exposed skull using a dental drill. The 
TCA was guided using a micromanipulator to +0 mm anterior, +3 mm lateral and -5.5 
mm ventral from bregma, lowered at 0.25mm per second into the caudate of the rat 
brain and allowed to equilibrate for two minutes. 1-2 ml of artificial cerebral spinal 
fluid (aCSF) and a gel-foam dam was used to couple acoustic energy from the face of 
the TCA into the rodent brain. The TCA was powered on with the pocket-sized 
ultrasound system at the +/-11.1 V setting and infusion began. 
For each rat, the entire experiment lasted a total of 30 min. The control 
subgroups of CED and CED+MB (n=5 in each) were infused using the TCA with no 
ultrasound therapy for 30 min. For the experimental subgroups of UCED and 
UCED+MB (n=5 in each), infusion and ultrasound exposure at an acoustic power of 
0.11 +/- 0.005 W, and TCA face intensity of 0.095 W/cm
2 
which corresponded to a 
cannula tip intensity of 0.0497 W/cm
2 
for 30 min was applied simultaneously.
 
Filtered 
Evan's blue dye (EBD) 0.25 wt% in phosphate buffered saline (PBS) without or with 5 
x 10
5
 stabilized microbubbles per μL with median diameter of 2.5 μm ( TargestarTM-P, 
Targeson Inc.) was infused using a microinfusion pump (Worker Bee
TM
, Bioanalytical 
Systems, Inc.). 
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Figure 8.2. Animal experimental setup for using TCA in rat brain. The rat is secured 
with ear bars in a stereotaxic frame and a small craniotomy is performed on the left 
hemisphere. The TCA is guided 5.5 mm deep into the caudate of the rat brain. 
 
The starting infusion flow rate for the experiments of group 1 was 0.05 μL/min 
for 5 min, the infusion flow rate was then increased to 0.1 μL/min for an additional 5 
min, to the final flow rate of 0.25 μL/min for 20 min. For group 2 the starting infusion 
flow rate was 0.1 μL/min for 5 min, the infusion flow rate was then increased to 0.25 
μL/min for an additional 5 min, to the final flow rate of 0.5 μL/min for 20 min. After 
30 min of simultaneous infusion and ultrasound therapy the experiment was stopped. 
The TCA was left in the tissue for 1-2 min before being removed while euthanasia via 
cardiac urethane injection was performed. The animal was removed from the 
stereotaxic frame and immediately perfused with 200 mL of PBS followed by 200 mL 
4% paraformaldehyde fix. The brain was then promptly removed from the skull using 
bone cutters and prepared for frozen section in 30% sucrose and 4% paraformaldehyde 
solution for one day, and moved to 60% sucrose and 4% paraformaldehyde solution 
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for another day, before being frozen on dry ice in optimal cutting temperature (OCT) 
embedding. 
 
8.3.5 Image, Statistical and Histological Analysis 
Tissue slices were imaged using a CCD camera (Cannon Power Shot G10, 
Cannon Inc.) arranged on a cryostat (Microm HM 550, Thermo Scientific®) during 
frozen section through the brain in the coronal plane. The high resolution 14 Mpix 
Joint Photographic Experts Group (JPEG) image files were captured at the first 
visualization of EBD in the brain tissue and after every fith 50 μm brain slice until 
EBD was no longer distinguishable. The digital image files were cropped to include 
the rodent brain with a white ring of OCT embedding around its outside and resized to 
100 x 70 pixels with a locked aspect ratio using Adobe® Photoshop® for further 
analysis in MatLab® (Mathworks Inc.).  
Each coronal brain section was loaded into MatLab® using the imread() 
function and the pixel to physical length ratio was determined using a calibration ruler 
measure taken in the picture frame windows. The imread() function returned a 100 x 
70 x 3 unit8 matrix of Red Green Blue (RGB) 24-bit color intensity data for each pixel 
in each frame. RGB pixel values making up the white ring of OCT imbedding around 
the brain tissue section were used to adjust for slight lighting variations between image 
frames and samples studied. The white OCT RGB pixel values were measured in the 
top, bottom, left and right quadrants of the image frames, averaged, and used to 
determine a weighting factor. Across samples on average, the standard white OCT 
pixels of the data sets had RGB values of Red=171, Green=175 and Blue=177, 
respectively. These standard OCT values were used to determine each channel’s color 
intensity waiting factor per image frame.  Each RGB waiting factor was then applied 
across the 100 x 70 x 3 unit8 matrix of RGB data frames. For volume distribution 
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analysis of EBD in the brain section the Red, Green and Blue intensity values that 
composed each pixel were added algebraically with additional weight placed on the 
Blue channel (Red channel + Green channel + 2x Blue channel) to generate a 100 x 70 
x 1 summed color intensity matrix. A threshold value of 260 intensity counts was 
experimentally determined to best include all of the EBD pigment image data and was 
applied across the summed color intensity matrix where any matrix component over 
260 was set to 0. The final intensity matrix for each picture frame consisted of 100 x 
70 matrix values ranging from 0-260, with 1 being the darkest pigment, 260 being the 
lightest pigment and 0 acting as an empty matrix space holding component. EBD 
distribution area in each picture frame was measured by whether or not each pixel in 
the 100 x 70 matrix  picture frame held a value greater than 0. The EBD volume 
distribution represented by each brain section was calculated by multiplying each 
frames distribution area by 5 x 50 μm, for a total slice width of 250 μm (to account for 
all sections each individual slice represented). Each analyzed image section was then 
placed into a 3D-stack and summed as a whole to obtain the total brain distribution 
volume of EBD. The 3D stack was additionally compiled using the contourslice() and 
isosurface() functions in MatLab® to generate a 3D visualization of each data set and 
to display the total infusion distribution volume in the rodent brain. The left 
hemisphere and the left caudate of each rat brain were analyzed separately to compare 
EBD distribution in the two regions. In analysis of the left caudate, the 100 x 70 pixel 
image frames of each data set were cropped in Adobe® Photoshop® to include only 
the gray matter track of the caudate region, and then reanalyzed as before. 
Statistical analysis was performed using MatLab
®
. An ANOVA was used to 
analyze the statistical significance of the total infusion distribution volumes in the four 
control and four experiential subgroups. The statistical tests compared if the means 
from the groups were equal, against the alternative that the means were not equal. The 
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p-value was used to determine if the difference between groups was significantly 
greater then chance. 
Histological examination was used to determine any acute and morphological 
changes due to ultrasound-assisted CED. Fixed brain tissue samples from rodents 
undergoing CED, CED+MB, UCED and UCED+MB infusions were delivered to the 
Cornell University Veterinary Pathology Department and 10 µm coronal sections at 
the cannula insertion plane and  were collected using the paraffin method, and saved 
on microscope slides for histology. Histological analysis was conducted by 
hematoxylin and eosin (H&E) staining of 10 µm sections by the Cornell University 
Veterinary Pathology Department, and obtaining an independent review from the 
Pathology Department at Cornell University to determine if any difference between 
subgroups was found. 
 
8.4  Results 
8.4.1  Transducer Cannula Assembly and Ultrasound System 
The construction of the TCA required multiple iterations and careful 
machining because of the fragility of the ceramic. Soldering and final wire 
connections were completed under stereoscope. The electrical impedance magnitude 
of the TCA is shown in Figure 8.3. The TCA resonates at 1.18 MHz with a 380 Ω 
electrical impedance and anti-resonance at 3.1 MHz.  The phase angle (not shown) 
was approximately 0 degrees at resonance. In practice, the TCA was found to operate 
best when driven at 1.34 MHz with the portable ultrasound generator that was used in 
this study. Estimates of the acoustic output power and intensity from the Mason 
transmission line model at 1.34 MHz and the power and intensity measured with the 
hydrophone were within +/- 10% of each other. 
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Figure 8.3. Electrical impedance of TCA. Resonance occurs at 1.18 MHz with 380 Ω 
impedance. The phase angle (not shown) is approximately 0 degrees at resonance. 
Parallel resonance occurs at 3.1MHz. 
 
 
The stereotaxic guided TCA allowed for accurate insertion of the infusion 
cannula into the rat caudate and the portable ultrasound system freed up considerable 
bench-top space as compared to traditional bench-top RF amplifiers that require wall 
power. This allowed the experiment to be conducted in a straight forward and 
repeatable manner. 
 
8.4.2 Ultrasound Dosimetry 
The mechanical index (MI) is a standard measure of the acoustic output in 
ultrasound systems defined as the peak rarefactional pressure of an ultrasound 
longitudinal wave propagating in a uniform medium, divided by the square root of the 
center frequency of the transmitted ultrasound wave.  According to the FDA for 
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diagnostic obstetrics application, the MI should not exceed 1.9, and for ophthalmic 
applications the MI should not exceed 0.2 [39-41]. In order to calculate the maximum 
MI achieved by the TCA using S.I. units (f=1.34 MHz, I=950 W/m
2
), we used the 
intensity (I) and acoustic impedance of soft tissue (Z~1.6e6 kg/m
2
s) [42] in order to 
calculate the pressure (P) and derived the following formula for the TCA to calculate a 
MI of 0.034 according to: 
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Another standard measure is the thermal Index (TI). TI is defined as the ratio 
of the emitted acoustic power to the power required to raise the temperature of tissue 
by 1
o
C. The TI is intended to indicate the likely temperature rise that might be 
produced after long exposure. A larger TI value represents a higher risk of damage due 
to temperature increases. For therapeutic applications, the FDA requires that TI’s over 
6 require further explanation and safety analysis. The calculated soft-tissue thermal 
index (Ts) using the ultrasound power (P) for the TCA
 
was 0.638 as calculated by: 
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The calculated MI was less than 0.2 and the Ts value achieved was less than 6 
for the TCA. The TCA is considered safe according to established FDA guidelines and 
standards developed from the American Institute of Ultrasound in Medicine. 
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8.4.3 In Vivo Ultrasound-assisted Convection Enhanced Delivery 
Typical raw data sets are presented in Figure 8.4 from the CED (4A), 
CED+MB (4B), UCED (4C) and UCED+MB (4D) subgroups of group 2 receiving 
0.5μL per min infusions. A red border is shown around the brain section of the 
cannula insertion point in each of the four subgroups. Image slices in each subgroup 
are 250 μm apart from one another in both anterior and posterior directions. The 
results illustrate EBD distribution volume in the rodent brain for 30 min of treatment. 
Optically quantifiable, EBD pigment is more diffuse and extends over a broader per 
slice area and total number of slices during UCED and UCED+MB as compared to 
CED and CED+MB. Backflow of EBD along the needle track into the corpus 
callosum during 0.5μL per min infusions is also more pronounced in the CED and 
CED+MB subgroups as compared to the UCED and UCED+MB subgroups. In the 
slower 0.25μL per min infusions (not shown) backflow as well as convection of EBD 
into the caudate region was reduced.   
Figures 8.5 shows the three-dimensional reconstructions of EBD distribution 
volumes in the presented brain slices of Figure 4 for the left hemisphere and left 
caudate of the rodent brain, respectively. Figure 8.5 A-D shows the volume 
distribution of group 2 0.5μL per min EBD infusions during CED, CED+MB, UCED 
and UCED+MB, respectively. In the CED and CED+MB controls (5A and B) the 
EBD dye stays in an 810 x 675 x 2500 μm volume around the infusion cannula in the 
gray matter of the caudate and the highly permeable white matter track of the corpus 
callosum. In UCED and UCED+MB treatment (5C and D), the EBD penetrates out of 
the control volume distribution by 2.24 to 3.25 and 1.16 to 1.70 times, respectively 
(p<0.001), and  though the entire left caudate in the case of UCED radiating into the 
ventricles and corpus callosum of the rat brain.  
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Figure 8.4. Brain sections from the four subgroups of group 2 studied after 30 minutes 
of Evans blue infusions at 0.5 μL per minute with a 30 gauge cannula. A. Convection 
enhanced delivery (CED) and B. Convection enhanced delivery with microbubbles 
(CED+MB) provide similar infusion profiles for the rodents in each group. C. 
Ultrasound-assisted convection enhanced delivery (UCED) delivers EBD further into 
the brain and more diffusely spread across the caudate. D. Ultrasound-assisted 
convection enhanced delivery with microbubbles (UCED+MB) shows further EBD 
penetration over CED and CED+MB, but is more localized in the rodent caudate 
versus UCED which spreads EBD out of the caudate region. Backflow of EBD along 
the needle track into the white matter track of the corpus callosum is reduced with 
UCED and UCED+MB as compared to controls. 
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Figure 8.5. 3D Infusion reconstruction of the four subgroups of group 2 brain sections 
from Figure 4. The cannula is in the plane of the Figure and the transducer cannula 
assembly (TCA) is positioned at the top of each Figure. A. Convection enhanced 
delivery (CED). B. Convection enhanced delivery with microbubbles (CED+MB). C. 
Ultrasound-assisted CED (UCED). D. Ultrasound-assisted CED with microbubbles 
(UCED+MB) 
 
MatLab® analysis comparing the total distribution volume of EBD in the 
rodents’ left hemisphere and left caudate for the two 0.25 and 0.5μL per min infusion 
groups and respective subgroups is shown in Figure 8.6. ANOVA analysis between 
the subgroup means was statistically significant p<0.05 and p<0.001 with standard 
deviations of the CED, CED+MB, UCED and UCED+MB groups of 0.29, 1.50, 0.67 
and 1.68, respectively in the left brain, 0.41, 1.95, 0.71 and 0.65, respectively in the 
left caudate for 0.25µL per min infusion of group 1, and 1.90, 5.31, 0.56, 1.25, 
respectively in the left brain, 0.62, 1.99, 0.36, 0.40, respectively in the left caudate for 
0.5µL per min infusion of group 2. UCED and UCED+MB increased the distribution 
volume of EBD by 2.24x and 1.37x (46.3 mm
3 
and 26.9 mm
3
) as compared to CED 
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and CED+MB (20.6 mm
3 
and 19.7 mm
3
)  in the left hemisphere of the rodent brain in 
group 1, respectively. Within the left caudate of group 1, UCED and UCED+MB 
increase the distribution volume of EBD by 2.44x (33.1 mm
3
) and 1.7x (27.0 mm
3
)  as 
compared with CED (13.6 mm
3
) and CED+MB (15.9 mm
3
), respectively. For the 
higher infusion rate of group 2, UCED and UCED+MB increase the distribution 
volume of EBD by 2.96x (111 mm
3
)  and 1.16x (37.1 mm
3
) as compared to CED (37.4 
mm
3
) and CED+MB (31.9 mm
3
)  in the left hemisphere, and 3.25x (70.2 mm
3
) and 
1.54x (30.2 mm
3
)  in the left caudate, respectively. 
 
Figure 8.6. Analysis of total EBD volume distribution in the rodent brain with 
subgroup standard error bars. UCED and UCED+MB increases EBD volume 
distribution by 2.24x and 1.37x in the left hemisphere and 2.44x and 1.70x in the left 
caudate, respectively, as compared with CED and CED+MB receiving 0.25µL per 
min infusions. For 0.5µL per min infusions of group 2,UCED and UCED+MB 
increases EBD volume distribution by 2.96x and 1.16x in the left hemisphere and 
3.25x and 1.54x in the left caudate, respectively.  The left hemisphere and left caudate 
subgroups of groups 1 and 2 are statistically significant with independent means 
p<0.05* and p<0.001*.       
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Figures 8.7 and 8.8 represent the EBD distribution profile in the rodent caudate 
for subgroups of group 1 and group 2. The Figures show the area of EBD in the 
caudate of the rodent brain for each slice as a function of the anterior–posterior (AP) 
distance, defined here as the distance between the slice and the slice containing the 
infusion point. The black lines represent the area of slices averaged over all animals in 
each subgroup. The shaded regions represent the standard deviations of the data within 
each subgroup (n=5). Area measurements below 0.3 mm
3
 in Figures 8.7 and 8.9 are 
subject to artifact from poor signal to noise ratio. Additionally, the TCA provided an 
acoustic field perpendicularly circumferential to the cannula, approximately 3.2 mm in 
radius at the infusion site. Across all groups and subgroups, the maximum area of 
penetration occurs in slices near the infusion point, and the penetration area decreases 
as the distance from the infusion sites increase in both directions. Ultrasound-assisted 
subgroups (UCED and UCED+MB) show greater distribution of EBD in the rodent 
caudate with a larger per slice area of EBD. Ultrasound-assisted subgroups also show 
higher standard deviations of EBD area in each slice as compared to CED alone. The 
area under each curve corresponds to the total volume distribution as presented in the 
bar graph of Figure 8.6. 
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Figure 8.7. Group 1 0.25 µL per min infusion analysis of EBD distribution profile in 
the rodent caudate as a function of the AP distance in the region ±4 mm from the 
infusion site. The black line represents the average area of EBD at the given position. 
The shaded region represents the standard deviation of EBD area (n=5) 
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Figure 8.8. Group 2 0.5 µL per min infusion Analysis of EBD distribution profile in 
the rodent caudate as a function of the AP distance in the region ±4 mm from the 
infusion site. The black line represents the average area of EBD at the given position. 
The shaded region represents the standard deviation of EBD area (n=5) 
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To obtain additional information about the shape of the distribution volume for the 
infusion protocols of group 1 and group 2, the data in Figures 8.7 and 8.8 was redrawn 
in Figure 8.9 as a function of the square of the AP distance, i.e. the distance between 
the slice and slice containing the infusion point. If the infusion of EBD into the rodent 
caudate were isotropic and the shape of the EBD infusion volume was spherically 
symmetrical around the AP direction, then the control subgroups (CED and 
CED+MB) in Figure 8.9 should fall on a straight line with slope of  magnitude π [11], 
and the ultrasound-assisted subgroups (UCED and UCED+MB) could have a different 
distribution profile. The data for the CED, UCED, CED+MB and UCED+MB 
treatments in Figures 8.7 and 8.8 approximate straight lines with slopes close to π, but 
only in the vicinity of the infusion point. This suggests that the distribution volume is 
spherical for these groups close to the infusion point, but that it deviates from 
sphericity away from the infusion point. For UCED and UCED+MB subgroups, the 
magnitude of the slope deceases slower than it does for CED and CED+MB. The 
spherical part of the distribution is smallest for group 2 CED, which has a spherical 
distribution only for the first five or six slices adjacent to the infusion point. For all of 
the data groups, the magnitude of the slope diminishes with increasing distance from 
the infusion point. This indicates preferential transport of EBD in the AP direction, i.e. 
orthogonal to the slices. Of all subgroups studied, ultrasound-assisted infusions 
maintain the largest distribution, particularly in the case of the higher infusion rate of 
group 2. One might expect the UCED and UCED+MB distribution patterns to vary 
beyond the ultrasound field (circularly +/- 3.2 mm perpendicular to cannula tip), 
however due to size limitations of the rodent brain and experimental setup this 
ultrasound field boundary effect is unnoticeable. Additionally, area measurements of 
EBD falling below (0.3 mm
2
) may have image artifact and not enough contrast to 
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obtain accurate signal to noise ratios. For reference, dotted line segments with slope of 
magnitude π are drawn in Figure 8.9. 
 
 
Figure 8.9. The area of EBD in rodent caudate for each slice plotted as a function of 
the square of the AP for group 1 and group 2. Each solid colored line is the average 
area for each treatment at the given position. A dotted line segment with a slope 
magnitude of π is drawn for reference. Data that fall on a line with slope of π or −π 
indicate regions where the infusion of EBD is locally isotropic. Deviations from the 
slope indicate an anisotropic volume distribution. 
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Gross examination of the brain was performed after ultrasound exposure to 
detect visible lesions on the brain surface. Visual examination of the post-UCED 
treated brains did not indicate any noticeable damage or significant change to the brain 
structure as compared with CED. The histological examination for the four groups is 
shown in Figure 8.10. The histology shows CED, CED+MB, UCED and UCED+MB 
subgroups of group 2 after H&E staining in the coronal plane. The arrow with box on 
the slides denotes the area of magnification and position of needle track. Histologic 
changes are similar across all groups and include mild parenchymal disruption, edema 
and hemorrhage around the needle track and injection site.  In some cases, hemorrhage 
extends a short distance within the leptomeninges or along white matter tracts.  Rare 
neurons directly associated with the needle tracks have pyknotic nuclei (necrosis).  
Also, in all groups, cortical neurons are multifocally basophilic and angular (dark 
neurons) and there are occasionally well-circumscribed foci of edema in the 
superficial cerebral cortex.  These changes are not restricted to the injection site and 
are interpreted as artifacts of surgery and/or handling.  Overall, histology for all 
groups show only minor acute damage since cells are distributed evenly and proper 
anatomical structure is maintained for the four groups. 
 
8.5 Discussion 
The goal of this research was to determine if a novel 1.34 MHz ultrasound 
transducer cannula device powered by a portable, light-weight ultrasound system 
could be used for ultrasound-assisted convection enhanced delivery to the brain in 
vivo. Sonicators of various forms have been shown to enhance transport transdermally 
in vitro and in vivo through the skin using low intensities [20-23], as well as various 
other tissues such as muscle and brain [28-30]. 
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Figure 8.10. Hematoxylin and eosin stain of rodent brains (10 um coronal slices) in 
the cannula insertion path. CED, CED+MB, UCED and UCED+MB show similar 
histological results in both the cortex and caudate of the rodent brains. Mild 
parenchymal disruption, edema and hemorrhage around the needle track and 
injection site are equivalent for the group. 
2.5x 20x 20x 
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Considerable amounts of research have been conducted in using pulsed high intensity 
focused ultrasound (HIFU) to open the blood brain barrier and allow systemically 
administered therapy to enter the brain, and HIFU shows great promise as a new 
technique to deliver targeted therapy [26, 27]. Convection enhanced delivery (CED) 
techniques for drug delivery to the brain have also made major strides over the last 10 
years, however the maximum flow rate and therapeutic penetration of drug that can be 
achieved in CED often is determined by the onset of backflow along the outside of the 
infusion cannula [1-19]. Backflow along the tissue cannula interface is directly 
proportional to the volumetric flow rate imposed, the radius of the infusion cannula 
and the permeability/tissue-resistance to convective transport. 
 The transducer cannula assembly (TCA) and portable ultrasound system used 
in this study was utilized to simultaneously sonicate and inject Evan’s blue dye (EBD) 
into the caudate of the rat brain. The application of 1.34 MHz at a total acoustic power 
of 0.11 +/- 0.005 W and peak spatial intensity at the cannula tip of I= 0.0497 W/cm
2
 
was shown to enhance the volume distribution of EBD into the caudate of the rat by 
2.44x and 3.25x at 0.25 µL/min and 0.5 µL/min infusion rates, respectively as 
compared to the controls (p<0.001). Gross and histological examination showed no 
significant cellular damage to the rat brain due to ultrasound exposure. 
 As shown in Figure 8.6, where the volume distribution was calculated for the 
eight subgroups, ultrasound had an overall effect of increasing EBD distribution in the 
brain tissue by approximately 2.24 to 3.25x for UCED, and 1.16 to 1.70x for 
UCED+MB subgroups as compared with controls. This is visualized in Figure 8.4C 
and D and reconstructed in Figure 8.5C and D, where UCED provided extended EBD 
distribution. Figures 8.7, 8.8 and 8.9 also show that ultrasound-assisted infusions 
increase the per slice area of EBD penetration.  Ultrasound may provide a mechanism 
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here to mitigate EBD vascular clearance and elimination from the brain, which 
presents one of the challenges for CED as discussed in the introduction. 
 The effect of increased volumetric distribution in the caudate with stabilized 
microbubbles measured in the UCED+MB infusions of groups 1 and 2 as compared 
with CED+MB controls may have resulted from increased streaming [43, 44] and 
micro-mixing [44, 45] of the microbubbles and EBD at the needle/tissue interface. 
However, an overall reduction of volumetric distribution of EBD was found with the 
addition of microbubbles into the infusate when compared with UCED alone. The 
microbubbles possibly acted as acoustic absorbers and reflectors in the brain 
parenchyma, thereby limiting the ultrasound effect to a smaller region of the brain by 
attenuating ultrasound beyond the infusion volume. The mixing and oscillation of the 
microbubbles in the acoustic field may have had an effect of improving EBD delivery 
into the caudate brain tissue over CED+MB subgroups. The propagation of the 
microbubbles in the direction of the acoustic radiation generated characteristic 
elliptical infusion profiles in the UCED+MB subgroups with the long access of the 
ellipse being parallel to the infusion cannula. Interestingly, CED and CED+MB 
infusions have approximately the same total distribution volume in the caudate as 
shown in Figure 8.6 but have different caudate infusion profiles as shown in Figures 
8.7 and 8.8. CED+MB infusions have higher EBD distribution close to the infusion 
point versus CED infusions.        
 Ultrasound-assisted convection enhanced delivery (UCED) shows advantages 
over traditional CED in the rat brain and warrants further investigation into the 
mechanisms of augmentation. The interaction of the ultrasound field on brain tissue 
permeability during UCED treatment should be assessed and probed real-time under 
parametric sonication intensities. During CED infusions, the pressure at the outlet of 
the needle is sufficiently large to deform the tissue radially, forming a fluid-filled 
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cavity around the needle tip. The interaction of ultrasound with this cavity/tissue 
interface could enhance mass transfer from the cavity into the tissue. Frenkel et al. 
showed that non-destructive low intensity ultrasound widened intercellular spaces 
between epithelial cells at fluid-tissue interfaces [46].  Investigations into the 
phenomenon indicated that the effects were due to transverse waves generated at the 
fluid/tissue interface. These waves increased the penetration and mass transport of 
nanoparticles from the fluid medium into adjacent epithelium, and increased the rate 
of effective diffusion through the tissues [47].  
 Acoustic streaming has been shown to increase the mass transport of 
nanoparticles for improved transdermal delivery [47-49].  The imposed radiation force 
on infusate shows promise to mitigate and prevent backflow along the tissue/cannula 
interface thereby allowing greater infusion rates in CED. At the higher infusion rate of 
group 2, CED subgroups showed backflow and reduction of EBD delivery to the 
caudate whereas UCED subgroups were able to successfully deliver at higher infusion 
rates into the rodents caudate. However due to the small size of the rodent caudate, 
during UCED protocols EBD radiated into the ventricles of the rodent brain. 
Additionally, acoustic cavitation is currently considered to be one of the most 
dominant and vital mechanism for ultrasound mediated drug delivery [26, 27, 49]. 
Numerous in vivo studies have shown that stabilized microbubbles, used as 
cavitational nucleation agents, make ultrasound mediated delivery more efficient, 
useful, and able to be conducted under low acoustic intensities. In some applications, 
microbubbles are shown to enable ultrasound mediated delivery where low-intensity 
ultrasound alone was ineffective [48-49]. Here, we find that microbubbles at the 
concentration and acoustic intensity applied hindered improving the distribution 
volume of EBD, however microbubbles may be particularly useful in improving 
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UCED at different acoustic intensities and pulse sequences, and at lower microbubble 
infusate concentrations. 
  In addition to microbubbles, larger molecular weight infusate molecules and 
nanoparticles that present a greater challenge to CED in clinical practice should be 
studied with UCED administration in vivo. Finally, judicious CED catheter designs 
that have been developed in the past should be tested with ultrasound assistance.  
     
8.6 Conclusion 
 Ultrasound continues to evolve with new uses in a range of medical 
applications from drug delivery to non-invasive surgical techniques. With the price of 
portable and powerful ultrasound therapy equipment decreasing and the uses of 
ultrasound in medicine increasing, many more ultrasound assisted modalities are in the 
pipeline for treatment of human diseases.  In particular, treatment of malignant brain 
tumors, which pose particular challenges due to the obstacles known to limit drug 
delivery in the brain.  This study builds upon our in vitro work in using ultrasound 
with CED to increase the penetration of molecules in equine horse brain [28-30]. Here, 
we show that ultrasound is capable of safely enhancing the permeation and 
distribution of small molecules through the rat caudate in vivo. These early in vivo 
findings suggest that ultrasound energy interactions with tissues and fluids may have a 
broad impact to improve CED treatments; not only with our specially designed 
infusion system, but potentially with any CED cannula design.  
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CHAPTER 9 
 
IN VIVO ULTRASOUND ASSISTED CONVECTION ENHANCED DELIVERY: 
POWER RANGING ANALYSIS AND STANDING WAVE PHENOMENA
15,16 
 
9.1 Abstract 
 Therapeutic ultrasound has been used to enhance and/or mediate drug delivery 
in various applications including convection-enhanced delivery (CED) of tracers to the 
rodent brain. While ultrasound has been shown to increase the delivery volume of 
tracers in neurological tissue safely, the exposure range of safe ultrasound energy 
levels is not well documented and/or explored. This is especially true in the case of 
continuous low-intensity ultrasound therapy to the brain as discussed in Chapter 9, 
since most research has focused on using ultrasound to disrupt the blood-brain barrier 
at much higher acoustic intensities but for much shorter ultrasonic application times. 
To explore the acute effects of ultrasound to the live rodent brain, we applied 
ultrasound using the Transducer Cannula Assembly (TCA) through a small 
craniotomy in vivo under four different acoustic intensities ranging from 0.062 to 
0.155 W/cm
2
 in a total of 4 Sprague–Dawley rats for 30 minutes. After which 
histological analysis was conducted on the brain tissue specimens to asses for neuronal 
damage.  
Additionally, because ultrasound is being used in continuous wave mode for 
ultrasound-assisted CED (UCED), it should be possible to induce standing waves in 
                                                 
15This work is in preparation for being published as Lewis, G.K., Jr., Schulz, Z., Pannullo, S., Southard, 
T., Olbricht. W.L. (2011). Levels of safe ultrasound therapy to improve convection enhanced delivery 
to the brain. 
16This work is in preparation for being published as Lewis, G.K., Jr., Guarino, S. Ghandi, G.,  Olbricht. 
W.L., Sarvazyan, A. (2011). Time-reversal techniques in ultrasound-assisted convection-enhanced drug 
delivery to the brain: Technology development and in vivo evaluation. 
 163 
the brain tissue and generate banding patters of tracers. We show possible results of 
this observed “standing wave phenomena” in the rodent brain in vivo during UCED, 
which suggests low-intensity ultrasound may provide a tool for additional drug 
delivery applications beyond improving the distribution of pharmaceuticals in the 
brain. 
 
9.2  Introduction to Standing Waves 
Standing waves are well documented phenomena formed by the constructive 
interference of two mechanical waves traveling in opposite directions, including 
ultrasound waves propagating in a media. The constructive interference of two equal 
and opposite waves, and the formation of a standing wave results in an interference 
pattern with nodes and anti-nodes that do not move in space temporally. The anti-
nodes represent the maximum displacement and amplitude of the ultrasound wave, 
whereas the nodes represent areas of minimum displacement which experience very 
little acoustic pressure from the ultrasound wave.  Standing waves are commonly 
formed when an ultrasound source of consistent frequency and position, continuously 
generates an incident wave which then interferes with its own reflection off a 
boundary. 
Standing waves have been exploited in a number of applications, both 
biomedical and otherwise.  Some examples include using ultrasonic standing waves to 
immobilize cells in a gel matrix at areas of minimal acoustic pressure (nodes) in the 
standing wave field as well as creating a physical force field filter within microfluidic 
devices [1,2].  However, it is generally believed that standing waves in brain tissue are 
undesirable since localized high energy sites at the anti-nodes could cause damage to 
neuronal tissue. At the 1-2 MHz frequencies in particular, the wavelength resembles 
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the dimension of an artery in the brain, which could prove problematic if high energy 
spots were formed on this scale [3].  
9.3  Methods 
9.3.1 Ultrasound Generator and Ultrasound Exposimetry 
 The ultrasound generator discussed in Chapters 3-5 was powered with two 
adjustable 0-20 V standard lab power supplies to drive the Transducer Cannula 
Assembly (TCA) discussed in Chapter 9, up to the maximum +/- 20 V power setting. 
The acoustic power and intensity was measured using a calibrated hydrophone and 
power meter as in Chapter 9. The four acoustic intensities at the cannula tip and total 
acoustic powers applied to the rodent brains during UCED were 0.062 W/cm
2
 and 
0.12 W +/- 0.005 W, 0.087 W/cm
2
 and 0.16 W +/- 0.005 W, 0.112 W/cm
2
 and 0.23W 
+/- 0.005 W, and 0.155 W/cm
2
 and 0.31W +/- 0.005 W. 
 
9.3.2 Power Ranging Animal Experiments  
Rats were anesthetized and euthanized by procedures approved by the 
Institutional Animal Care and Use Committee (IACUC) at Cornell University. A total 
of 4 Sprague–Dawley rats (350 to 450 g) received UCED at 4 different ultrasound 
intensities ranging from 0.062 to 0.155 W/cm
2
 for 30 min. A small craniotomy was 
made as in Chapter 9 to expose the brain. The TCA was guided using a 
micromanipulator to +0 mm anterior, +3 mm lateral and -5.5 mm ventral from 
bregma, lowered at 0.25 mm per second into the caudate of the rat brain and allowed 
to equilibrate for two minutes. 1-2 ml of artificial cerebral spinal fluid (aCSF) and a 
gel-foam dam was used to couple acoustic energy from the face of the TCA into the 
rodent brain. The TCA was powered on with the ultrasound generator. 
Filtered Evan's blue dye (EBD) 0.25 wt% in phosphate buffered saline (PBS) 
was infused using a microinfusion pump with a starting infusion flow rate of 0.1 
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μL/min for 5 min, the infusion flow rate was then increased to 0.25 μL/min for an 
additional 5 min, to the final flow rate of 0.5 μL/min for 20 min. After 30 min of 
simultaneous infusion and ultrasound therapy the experiment was stopped. The TCA 
was left in the tissue for 1-2 min before being removed while euthanasia via cardiac 
urethane injection was performed. The rodent brains were prepared for histological 
analysis and reviewed by the Veterinary Pathology Department at Cornell University 
as in Chapter 9.  
 
9.4 Histological Results and Conclusions from Power Ranging 
Gross examination of the brain was performed after ultrasound exposure to 
detect visible lesions on the brain surface. Visual examination of the post-UCED 
treated brains did not indicate any noticeable damage or significant change to the brain 
structure. The histological examination for the four groups is shown in Figure 9.1. The 
arrow with box on the slides denotes the area of magnification and position of needle 
track. Histologic changes are similar across all groups as well as rodents receiving 
lower acoustic UCED intensities as discussed in Chapter 9.  Histology showed mild 
parenchymal disruption, edema and hemorrhage around the needle track and injection 
site.  In some cases, hemorrhage extended a short distance within the leptomeninges or 
along white matter tracts.  Rare neurons directly associated with the needle tracks 
show pyknotic nuclei (necrosis).  Also, in all groups presented, cortical neurons are 
multifocally basophilic and angular (dark neurons) and there are occasionally well-
circumscribed foci of edema in the superficial cerebral cortex.  These changes were 
not restricted to the injection site and are interpreted as artifacts of surgery and/or 
handling. 
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Figure 9.1. Hematoxylin and eosin stain of rodent brains (10 um coronal slices) in the 
cannula insertion path. Acoustic intensities of 0.062, 0.087, 0.112 and 0.155 W/cm
2
 
show similar histological results in both the cortex and caudate of the rodent brains. 
Mild parenchymal disruption, edema and hemorrhage around the needle track and 
injection site are equivalent for the group. 
2.5x 20x 20x 
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The results presented here suggest that ultrasound applied below 0.155 W/cm
2 
to the brain for 30 min produces no noticeable neuronal damage to the caudate or 
cortex. Greater acoustic intensity control from the TCA as well as further 
experimentation will be required in order to determine the level of ultrasound 
exposure to the brain that causes acute neuronal damage. Furthermore, the limited 
literature on the continuous application of ultrasound to the brain for drug delivery 
will require parametric analysis to understand the safe operating window for UCED. 
Finally, acute exposure and histology may not be adequate to asses for neurological 
damage from ultrasound exposure since neuronal degeneration may take up to 3-5 
days before detectable by cresyl violet staining [4]. Future UCED research will 
inevitable require survival surgeries to understand post procedural effects to 
ultrasound exposure.   
 
9.5 Standing Wave Findings and Discussion 
The current work of in vivo brain drug delivery utilizes 1.34 MHz ultrasound 
in conjunction with CED to infuse Evans blue dye directly into the rat brain caudate. 
The results are generally a distribution volume of dye with a spherical or ellipsoid 
shape as shown in Figure 9.2A. However, in two rodents during the vast UCED 
experimentation, distinct, non-continuous bands of dye were observed in brain 
sections close to the needle track and directly above the TCA as shown in Figure 9.2B. 
This phenomenon could be attributed to the formation of a standing ultrasound wave 
within the rat brain during the UCED infusion.  This formation is likely the result of 
the incident ultrasound waves interfering with reflections from the rodent skull 
generating a steady spatial field of nodes and anti-nodes. 
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Figure 9.2 UCED Infusion Profiles. The rat brain in (A) shows a relatively uniform 
distribution, while the brain in (B) shows clear banding of the infused dye 
approximately 0.6mm apart. 
 
The observed banding is analagous to other processes whereby material 
accumulates in a standing wave field.  However, the exact mechanism in brain tissue 
has not yet been identified.  One possibility is that the tracer accumulates in the nodes, 
or the areas of least acoustic pressure. The other possibility is that the tracer 
accumulates at the anti-nodes where the ultrasound waves have the greatest amplitude.  
This increased energy could cause increased tissue permeability, causing tracer to 
preferentially accumulate at the anti-nodes.  
To better understand whether tracer is accumulating at the nodes or anti-nodes, 
we calculated the wavelength of ultrasound in brain tissue and compared the result to 
the distance between the bands, 
 

c
f 
   (9.1) 
where ƒ is the frequency, c is the speed of sound in brain tissue (1460 m/s, [5]), and λ 
is the wavelength.  We calculated the wavelength to be 1.09 mm, resulting in a node to 
node distance of 0.545 mm. The distance between the bands in the two experiments 
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experiencing this phenomena are approximately 0.6 mm, which supports the 
conclusion that dye is accumulating at the nodes. 
Though this result runs counter to the objective of maximizing volume 
distribution of an infusate as discussed in Chapter 9, it may have other applications. 
For instance, if various standing wave patterns could be induced during an infusion, 
greater spatial and temporal control over the infusion could be achieved; this control 
could prove especially valuable with highly toxic treatments. Difficulty arises in 
reproducing this in vivo result. Inducing a standing wave depends on correct alignment 
in the desired geometry as well as the correct ultrasound frequency.  Inducing such a 
standing wave field in vivo would likely require real-time imaging and precise 
positioning of the ultrasound source.  However, if standing waves prove harmful to the 
brain, measures can be taken to prevent their formation, such as randomizing 
frequency or moving the source [6]. 
Perhaps the most important implication of this observation of standing waves 
is that it lends supporting evidence showing that ultrasound is not only having an 
effect on brain tissue, but that ultrasound also directly affects the distribution profile of 
the infusate during CED.  Advancing the knowledge of how ultrasound can affect the 
infusion profile will allow for the parameters governing UCED to be optimized as it 
evolves into a clinically relevant therapy for neurological disorders. 
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CHAPTER 10 
 
A LOOK INTO THE FUTURE OF BIOMEDICAL ULTRASOUND 
APPLICATIONS AND ULTRALOW IMPEDANCE DESIGN PRINCIPLES
 
 
 
10.1 Abstract 
Translational research is the hallmark of biomedical engineering with a 
positioned outcome of improving the quality and duration of life for mankind. Our 
team of engineers and clinicians seeks to solve problems that touch close to home and 
affect millions of people every year. Our drive is to quickly innovate and prototype 
ultrasound-based solutions, and place them into clinical hands for evaluation, 
preliminary testing and clinical-feedback as quickly as possible. This rapid, iterative 
approach to our research is possible because we have built the facility and possess the 
talent to develop every piece of an ultrasound based system in our biomedical 
acoustics laboratory. From the onset of every project our team tackles, clinically 
inspired motivation drives engineering design innovation, while our collaborations 
drive technology translation.  
Our team of ultrasound engineers from the Department of Biomedical 
Engineering at Cornell University developed a platform ultrasound technology in 2007 
discussed in chapters 3 and 4 of this dissertation, which reduces the cost and size of 
ultrasound devices by orders of magnitude. The principles behind the technology are 
to reduce the output impedance of the ultrasound generator and the input impedance of 
the ultrasound transducer to zero (ideally), to create zero resistance to energy flow and 
optimize electrical power transfer for battery powered ultrasound devices. This 
pioneering approach of zero output and input impedance pushes the efficiency of 
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ultrasound systems, and provides ultrasound power in a smaller form. Since our 
technology’s inception, motivations from physicians have driven ultrasonic 
innovations to improve drug delivery in glioblastoma brain cancer therapy (Chapters 
5, 6, 7, 8 and 9), develop non-invasive varicose vein treatment systems, and improve 
fetal heart rate monitoring to allow easy and consistent measurements during labor.   
 
 
Figure 10.1 Ultralow output impedance ultrasound power generation technology. A 
10-channel high power ultrasound driver is shown on the lab bench.  
 
10.2  Ultrasound-assisted Brain Cancer Therapy (In Vivo Preclinical Studies)  
Our laboratory has developed and commenced testing of a new ultrasound-
based drug delivery system for pre and post-resection treatment of high-grade 
malignant gliomas. Surgery and adjuvant radiation are standard treatments for these 
malignancies. However, invasive malignant cells migrate into surrounding healthy 
tissue and, as a consequence, are not all removed in surgery, leading to tumor 
recurrence, usually close to the site of the original tumor. Convection enhanced 
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delivery (CED) has emerged as a leading investigational delivery technique for the 
treatment of several disorders, including glioblastoma which presents an especially 
poor prognosis for patients. CED bypasses the blood-brain barrier by infusing 
compounds through a needle or microcatheter directly into the brain parenchyma or 
brain tumor. The clinical trials of CED show mixed results and suggest that the 
outcome of therapy depends strongly on the extent of penetration of drug into the 
brain, which is determined by infusion velocity, and the relative rates of convection 
and elimination during CED. In collaboration with Drs. Susan Pannullo, Mark 
Souweidane and George Lewis Sr. of the Department of Neurosurgery at Weill 
Cornell Medical College (WCMC) and Transducer Engineering Inc., respectively, we 
have developed ultrasound-assisted convection enhanced drug delivery technology 
(UCED) to improve the penetration and spatial control of pharmaceuticals in the brain 
shown in Figure 10.2 
 
Figure 10.2 Ultrasound-assisted CED cannula for improved drug delivery in 
brain cancer therapy. 
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We have developed in vitro and in vivo models of UCED brain tumor 
treatments, and have shown that combining ultrasound with traditional CED improves 
the penetration and distribution of tracer molecules by 2-3 times in vivo. This work 
involves both the basic science of transport mechanisms as well as the translational 
science of scaling the UCED brain cancer therapy into a large animal model at Cornell 
Weill Cornell Medical Hospital. If successful, we will transition the technology to 
human treatment in the next few years.  
Furthermore, we have enlisted new collaborators from Artann Laboratories 
Inc. to combine time-reversal acoustics (TRA) with convection-enhanced delivery 
(CED) to improve the delivery of therapeutics to the interstitium of the brain. Together 
we have developed a novel TRA system that is used to infuse tracers into the brain 
parenchyma while simultaneously exposing the tissue to safe levels of 1-MHz, low 
intensity, ultrasound energy. The system includes a combined infusion needle-
hydrophone, a 10-channel ultralow-output impedance amplifier (Figure 10.1), a broad-
band ultrasound resonator, and MatLab®-based TRA control and user-interface. TRA 
allows easy coupling of ultrasound therapy through the skull without complex phase-
correction and array design. The smart targeting TRA based UCED system has been 
tested in vitro and in vivo and results show it provides 1-mm spatial resolution for 
UCED and improves tracer distribution in the brain over CED alone.   
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Figure 10.3. Delivery and setup of TRA-CED system at Cornell University Biomedical 
Engineering Laboratories. A) Surgical setup of rodent positioned in stereotax device 
and TRA-CED system arranged for preliminary in vivo testing. B) Close up of surgical 
prep, smart ultrasound needle cannula and ultrasound therapy transducer resonator. 
C) First successful TRA-CED focusing in the rodent brain in vivo. D) Artann 
researcher standing next to TRA-CED system in animal surgery suite. 
10.3  Non-invasive High Intensity Focused Ultrasound Varicose Vein Treatment 
(In Vivo Preclinical Studies) 
Varicose veins affect more than 30 million people in the United States each 
year. They cause emotional distress and discomfort for patients and, if left untreated, 
can progress to deep venous thrombosis, skin ulceration, limb loss or death. Clinicians 
perform more than 150,000 varicose vein treatments in the U.S. each year, using 
methods such as vein stripping, sclerotherapy, and endovenous laser and RF treatment, 
which together comprise a $450MM market. Because these methods are invasive, they 
incur added costs in training, equipment, facilities, and staff. In collaboration with Drs. 
Jason Spector and Peter Henderson from the Department of Surgery at WCMC, we 
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have developed and tested the first battery-powered handheld HIFU system to non-
invasively cauterize and occlude varicose veins shown in Figures 10.4 and 10.6. 
 
 
Figure 10.4. Hand held HIFU and its use to non-invasively cauterize and occlude 
veins in vivo. A) Shows the electronic heart of the system and ultrasound transducer 
probes, B and C) Show results from in vivo ablation of rodent inferior vena cava. 
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Figure 10.5. Dr. Peter Henderson, M.D. performing surgical cauterization using 
portable ultrasound device. 
By focusing ultrasound energy to a sharp point with the handheld HIFU 
system, we are able to successfully ablate and occlude veins without damaging 
surrounding tissue. The handheld device has gone through multiple design iterations 
with our team, and we have tested the device in both ex vivo and in vivo platforms. We 
will soon be incorporating low-cost ultrasound image guidance into the system and 
begin testing on large animal porcine models. The technology has potential to be 
utilized similar to a Bovie Pen for tissue cauterization in a range of clinical 
applications.  
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10.4 Improved Fetal Heart Rate Monitoring for Mothers and Doctors (Clinical 
Studies) 
 Doppler ultrasound has been used for over 20 years in measuring the fetal heart 
rate (FHR) during labor and delivery of neonates. However, aside from switching the 
signal processing from continuous-wave Doppler to pulse-wave Doppler FHR 
monitoring in the late 1980’s, few ultrasound advances have improved the field. Our 
collaborator from Cayuga Medical Center, Dr. Steven Gelber, found this frustrating 
and with our Cornell and Transducer Engineering Inc. research team decided to 
improve FHR monitoring as well as uterine contraction monitoring—using ultrasound.  
During labor there is movement from the fetus inside the womb as well as 
from the mother. Due to a very limited detection range, traditional ultrasound 
transducers, which are strapped to the mother’s belly, lose the heart rate signal. The 
transducer must then be repositioned by the nurse to redetect the FHR. Wireless 
telemetry devices for FHR monitoring exist, but FHR detection only works well if the 
mother and fetus do not move. We have designed a custom transducer that improves 
fetal tracking and spatial heart rate detection yet works with existing FHR 
commercially available devices from GE and Philips Healthcare shown in Figure 10.6 
and depicted in Figure 10.7. 
Our team has designed and tested the FHR monitoring transducer in the lab, 
and on 25 patients at Cayuga Medical Center under IRB approval, with an improved 
area detection capability of 2 times across a range of body mass indexes.  
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Figure 10.6. Wide-beam ultrasound transducer developed in comparison to 
traditional commercially available transducer for FHM 
 
 
Figure 10.7. Schematic of improved detection of fetal heart rate by broadening the 
acoustic beam.  
 
Additionally, we have begun development of an ultrasound based solution to 
measure the uterine contraction strength and duration with a signal processing 
approach using the same ultrasound transducer used for FHR monitoring. The overall 
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goal is to provide the doctor a single ultrasound device to perform all heart rate and 
contraction measurements throughout the labor and delivery, and not require 
repositioning or wires tethering the mother. 
 
10.5 The Future Not All Ready In Progress 
The future of ultrasound is truly amazing with unbounded possibilities, and it 
will possibly cover the largest spectrum of medical related applications of any other 
non-ionizing energy source. The potential of low impedance design and the 
development of battery powered ultrasound devices open a new door to possibilities in 
both diagnostic and therapeutic applications. By successfully integrating power, 
electronics and transducer into a single device ultrasound may be geared to medical 
implants, injectable devices and primary healthcare applications. Furthermore, the 
reduction of the cost of these systems affords the translation of ultrasound technology 
to populations where healthcare is not accessible or cost prohibited.   
Over the course of this desertion the ground work has been laid to improve a 
number of healthcare related problems with an ultrasonic twist. Significant focus was 
spent on the development of the core ultrasound generation technology and its 
application to improve transport in brain drug delivery. The ability of ultrasound to 
enhance transport rates in other tissues and across membranes is also well 
documented; however, its applications are not yet in broad clinical practice. This 
dissertation contributes to shifting into a new paradigm in ultrasound engineering “low 
impedance design”, as well as opening new doors to the use of ultrasound in 
ultrasound-assisted convection enhanced delivery, and portable applications.  
 Our collaborative team of engineers and clinicians will continue to extend and 
improve ultrasound into new medical tools while also developing a better 
understanding of the multiplicity of acoustic, drug and tissue interactions. The 
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biomedical engineering answers of the future will not be black on white, but through 
complex and thoughtful analysis, curiosity and creativity, solutions will be found.  
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CHAPTER 11 
 
CROSS-CUTTING THEMES IN BIOMEDICAL ACOUSTICS AND LESSONS 
LEARNED DURING DOCTORAL STUDIES  
 
 
11.1 Introduction 
 
 The American Doctorate of Philosophy (Ph.D.) comes from the Latin term 
philosophiae doctor translating in the English language to “the love of wisdom and 
pursuit of in depth knowledge”. The Ph.D. is one of the most advanced degrees 
awarded to an individual by an academic university after the completion of novel 
independent research and in depth analysis under supervision from a dissertation 
committee. The process of receiving a Ph.D., some may say, is a long and daunting 
task involving research, data analysis, and practical experience. My doctoral training 
has been a combination of all of this, and has been dependent upon the input of 
numerous advisors, collaborators and students who have helped me reach this 
substantial milestone. The scope of doctoral training received from advisory 
committees, departments and universities is an invaluable resource for future 
endeavors. I have found that the value of the degree is not the diploma, but the 
knowledge and lessons learned, and the breadth of experiences obtained opening up 
new doors in creativity, critical thinking and exploration which I bring with me to the 
next phase in my career.      
My dissertation, Medical Ultrasound for Brain Drug Delivery and 
Rehabilitation Medicine was both a unique educational experience covering a 
spectrum of academic and social complexities, as well as a scientific contribution 
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developing new engineering approaches, techniques and ultrasonic applications to 
improve human health. The lessons learned along this educational pathway continually 
prove useful in the conduct of research and the sharing of knowledge. The cross-
cutting themes evolved from an array of biomedical engineering collaborations I have 
forged. This has set the foundation for new applications and better understanding of 
bioacoustics effects of ultrasound.  
My training in acoustics began well over sixteen years ago, starting with my 
early childhood apprenticeship in ultrasound transducer design and 
electrical/mechanical engineering. This experience gave me the foundational 
knowledge I needed to pursue innovations in ultrasound. Over the course of my hands 
on training, I have been afforded the benefit of developing a unique practical 
understanding, insight and instinct into engineering. Combined with my bachelors and 
doctoral studies of human physiology, neurobiology and biomedical acoustics for 
tissue engineering, brain drug delivery and rehabilitation medicine, I have acquired a 
distinctive ability for innovating ultrasound technology, studying and optimizing 
bioacoustics effects and solving challenging medical problems. Furthermore, having 
incredibly supportive advisors, knowledgeable collaborators and enthusiastic students 
has thrust my research quickly forward. 
 
11.2 Cross-Cutting Themes  
 After over 60 years of medical ultrasound applications spanning the diagnostic 
and therapeutic medical realm, ultrasound is still the widely accepted “go-to” tool for 
immediate non-invasive imaging and healing in physiotherapy and rehabilitation. Due 
to the multiplicity and complexity of the interactions ultrasound waves have with 
biological tissues and media in therapeutic applications, it is not surprising that the 
significance of each mechanism of interaction is not clearly understood. In fact, much 
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of the research to date has focused on using therapeutic ultrasound for clinical 
outcomes in randomized placebo controlled trial. Only recently, within the last decade, 
has cellular and small animal research begun to elucidate the mechanisms behind 
therapeutic ultrasound. 
 As discussed in Chapter 1, the interactions of acoustic waves with biological 
media provide a number of effects/mechanisms that can be utilized when various 
ultrasonic energy forms are delivered, and thereby stimulate the media and 
surrounding area. A significant focus of this dissertation included the use of ultrasound 
to improve transport rates in media; this includes drugs in brain and muscle, nutrients 
in tissues, and the washout of pain mediators and inflammatory cytokines at joint 
targets. The therapeutic results obtained are generated from a combination of 
cavitation, micro mixing, thermal, streaming, mechanical oscillation, dispersion and 
other interactions that are highly dependent on acoustic power and mode/repetition of 
delivery. The overall effect in many biological scenarios is that the ultrasound field 
and path of propagation creates a dynamic environment, increasing the kinetics and 
transport rates locally. At a low acoustic intensity regime, micro mixing from stable 
cavitation, acoustic streaming and mechanical oscillation of the media may provide 
the strongest forces for improving transport rates. Evidence from the work presented 
throughout the dissertation in tracer transport with ultrasound, research from other 
groups, as well as future research that is now underway, support this hypothesis. One 
observation at the low acoustic intensity is that cells are not oblivious to the acoustic 
pressure field, and interact and release cytokines in response to mechanical 
stimulation. 
 Recent research conducted by our lab has shown that stimulating osteoarthritis 
synovial fibroblasts in 2D and 3D culture systems with low intensity therapeutic 
ultrasound (LITUS) has a down regulation effect on the level of pro-inflammatory 
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cytokine secretions of Interleukin (IL)-6, IL-8, and Vascular endothelial growth factor. 
Other work conducted in the field has shown that LITUS stimulates neuronal cells, 
bone cells and a number of other cell types under various exposure parameters. The 
role that ultrasound plays in changing the in situ environment as well as the cell-
signaling cascade is still a confounding issue that should be addressed to optimize 
clinically useful LITUS therapies.    
 At higher acoustic intensities the onset of transient cavitation and thermal 
coagulation are the acoustic-tissue interaction mechanisms that clearly dominate in 
this regime. High intensity acoustic fields provide clouds of cavitation activity that 
release tremendous amounts of mechanical energy. Transient cavitation has found 
medical application in transdermal drug delivery and blood brain barrier disruption to 
mediate the delivery of pharmaceuticals across the stratum corneum and brain 
vasculature, respectively. The energy released during cavitation “sonoporates” the 
tissue, thereby disrupting the tissue structure and membranes and allows drug to 
diffuse more readily through the medium. Most ultrasound assisted transient cavitation 
based drug delivery regimes only use cavitation energy for short durations since 
extended treatments would produce significant amounts of heat and cause thermal 
coagulation. On the other hand, high intensity focused ultrasound (HIFU) is used for 
noninvasive thermal ablation of tissues by slowly heating a region of interest and 
raising the focal volume of the acoustic field to a temperature for cell death and tissue 
necrosis.   
 The future of ultrasound applications will utilize the full range of frequencies, 
intensities and treatment durations. Combination devices that sonoporate tissues using 
short cavitation treatments, and then utilize continuous ultrasound to provide acoustic 
streaming and stable cavitation to enhance drug transport could lead to a variety of 
new controlled release systems. Furthermore, the combined drug delivery, cell 
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stimulatory and healing use of ultrasound is a unique field to study requiring a 
multidisciplinary approach with biology, physics, and engineering disciplines. 
 
11.3 Lessons Learned  
I have found that the gravity of every learning experience may never truly be 
appreciated until a letdown becomes a success, or a mishap is bypassed by wisdom. I 
am a leaper, an instinctual persevere who learns from mistakes. This personality has 
driven me since I was a child from disassembling my parents’ prized Bavarian cuckoo 
clock, to running for class president, designing clinical and reach tools, and building 
and leading my own lab. Nothing always goes as planned, the cuckoo clock never 
made it fully back together, it took me over a year to finally be class president, the 
doctor broke my ultrasound device on the first day of use, and the beautiful lab 
provided to me as only a Ph.D. candidate  did not have any equipment. Learning is an 
exciting process and the points I share from my doctoral studies will prove useful for 
any individual wishing to educate and innovate. I share this wisdom to guide 
achievement in academic research.  
 Simplicity and the elegance found in simple proofs and engineering concepts 
has a very important place in science and teaching. Being able to present ideas, convey 
messages and deliver technology in general terms is an invaluable asset for an 
academic career. During my doctoral studies, I learned that presenting clear ideas and 
breaking down concepts into the building block stages is important to understand the 
overall purpose of a project, engineering concept or learning objective. An example of 
this was in developing miniaturized ultrasound systems by starting with the most 
simplistic requirements of power source, amplifier and transducer. By breaking down 
a well-established technology into simplistic terms, new ideas were generated 
resulting in substantial improvements and technological breakthroughs. In ultrasound 
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systems, impedance to energy transfer was one of these barriers. However, by 
minimizing the electrical and mechanical impedance of ultrasound systems, Ultralow 
Impedance Ultrasound Design (UIUD) reduced the opposition to energy transfer from 
power source to ultrasonic vibration. By applying UIUD, lower voltages (less than 4 
V) could be used to generate abundant ultrasonic power. In UIUD, energy transfers 
efficiently because electrical to mechanical conversion losses are reduced; this 
allowed us to design protabl therapeutic ultrasound devices as well as high power 
multichannel arrays for biomedical acoustic research.  
Beyond engineering and research I have learned that teaching new ideas and 
concepts is more effective when the abstract and complex ideas are introduced in 
simple terms. I found this with my students I trained and mentored during my doctoral 
studies. In teaching a new concept, I would first introduce the overarching idea that 
might be out of the comfort area of the student, but shortly thereafter return to 
presenting the idea in basic concepts already grasped by the students. This approach is 
useful since students appreciate the significance of the knowledge/skill to be acquired 
while also building confidence in their ability and hastening the learning process. 
More importantly, teaching in this fashion allows the students to attack new problems 
on their own using the fundamental tools they acquired after mentorship. From 
teaching to research I look to present ideas and develop experiments that are as simple 
and elegant while still conveying the appropriate knowledge and answering the 
scientific question.  
Questioning ambiguity and critical thinking are essential elements to 
conducting good research. Clearly presented ideas allow the audience to understand 
the conveyed message as discussed above. Over the last 4 years I have attended many 
scientific presentations, read and skimmed hundreds of journal articles, and reviewed 
and written research proposals for funding. By participating in this process, I quickly 
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learned that ambiguity in presentations and written language invariably results in 
miscommunication of the experiments and results of them. From the research 
prospective, explicit descriptions and critical presentation of the experimental 
outcomes is respected from the scientific community and is a metric of good research. 
Additionally, the format in which results are presented and conveyed to the audience 
can make or break your research in the eyes of the scientific community. It is therefore 
extremely important to present your research in a coherent fashion in an appropriate 
forum for the target audience. A lay audience may only be interested in the big-impact 
on their lives, while the scientific community would be interested in critical 
assessment of the results, knowledge gained and their impact in designing the next 
round of experiments. 
In developing research experiments and fundable proposals critical thinking 
about the experiments is a must. In most cases, the experiments are generally still in 
the process of design and have not yet been carried out successfully. In designing a 
research proposal and a successful research career, significant time must be spent on 
brainstorming and thinking critically on the experimental protocol and success criteria. 
A poorly thought out proposal will inevitably be ambiguous to the reviewer, and will 
reflect negatively on the aptitude of the investigator, ultimately reducing chances for 
success. Grantsmanship and the ability to clearly convey a research proposal is truly 
an art that matures as different experience shape your background, and in order to be 
successful at it having mentorship in the process is very helpful. Crafting proposals in 
multidisciplinary research in many cases requires collaborators that provide supportive 
insight and are very important to translational research projects. 
Collaborations are ties to knowledge and in order to be a successful teacher 
and investigator it is important to have collaborators who can add breadth to your 
scientific impact and reach. Immersing myself with senior investigators had a 
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tremendous impact on my learning and grantsmanship during my doctoral studies. It 
was important to work with clinicians who were on the front lines with patients, 
particularly for my interest in clinical research and improving healthcare from an 
engineer’s perspective. These collaborators not only brought credentials to my 
research team, but also provided clinical practicality and translational acceptance to 
the research goal. Collaborators of numerous disciplines have brought new ideas and 
tools that proved useful in developing a better understanding of my own research 
objectives. Cross pollination of labs and research agendas in many cases inspired new 
ideas and discoveries.  This was the case for my dissertation work that flourished with 
multidisciplinary collaborates from biology and chemistry to neurosurgeons and 
gastroenterologists. 
Leadership, being thoughtful and mindful of others is an important attribute to 
a leader, particularly one that is trying to educate and inspire. I have been a leader my 
whole life, from hockey captain to student government president. Additionally, I have 
operated small businesses with employees and consulted on a number of occasions, 
yet it was not until my graduate work that I learned how important it was to be 
understanding of my students’ social dynamic and educational goals. In building a 
small student army to help me during my doctoral studies, I found that there was a 
delicate balance between pushing students to reach for their goals as well as my labs 
research agenda, while also supporting my students’ other obligations. At first this was 
somewhat difficult for me because of the university dynamic with the constant turn 
over and limited retention time of students. It was frustrating and difficult to train each 
student over and over again, and this was disheartening when trying to move my 
experimental goals forward. However, I found that being a good leader required me to 
able to position students into roles that they could flourish in while simultaneously 
reducing my required retraining efforts on individuals in the group. 
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In my last 2 years of doctoral work I found that was able to balance the passing 
of knowledge from group member to group member, while keeping students 
motivated and self-resilient on their projects. A key to the smooth transitions were to 
appoint research leaders who had the duty of passing on key knowledge to the new 
student members who entered the lab. This allowed the more senior members to have 
a supervisory role in training the new students. Each student, whether senior or new, 
still had their own individual project that they designed and carried out under the core 
research themes of my research. I found that this approach gave the students a sense of 
project ownership and for most of the students this resulted in successful research and 
students who enjoyed working on the project: A win-win scenario.  
Finally, leadership roles require the building of camaraderie between the team 
and confidence of the individual members. I learned that student teams seem to work 
the best to carry out the research goals, especially in projects requiring significant 
patience and focus. In some cases, the individual students on the team may have 
independent projects, but still work together on additional, supplementary projects that 
would be difficult for any one person to carry out alone. The idea of team research and 
shared responsibility is important for group camaraderie and synergy, and invaluable 
in the students’ future careers. 
 
11.4 Concluding Remarks 
 My doctoral study at Cornell University under the mentorship of Dr. William 
Olbricht, Dr. Ronald Booker and Dr. Lawrence Bonassar was a remarkable 
experience. I developed an in-depth understanding of biomedical acoustic applications 
and bioacoustics tissue interactions. I gained invaluable mentoring, laboratory 
management and collegiate teaching skills. Additionally, I formed a vast array of 
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relationships with clinicians and scientific investigators who have interest in similar 
biomedical research applications. 
 Now I am starting my independent research career and taking all the lessons 
learned and applying them to new biomedical problems and developing a deeper 
understanding of the mechanisms of ultrasonic interactions with biological media. By 
applying critical thinking and looking for the underlying building blocks to unravel the 
complexity of problems, I will be able to overcome unmet needs to better human 
health. Furthermore, providing strong leadership and mentorship to my students and 
lab, and tying in collaborators across disciplines will make for an exciting, innovative 
and multifaceted research agenda. From cell to tissue to human, I will conduct cross 
cutting research that applies basic mechanisms and state-of-the-art design concepts to 
treat and prevent disease for a happier, healthier life.  
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APPENDIX  
 
3.1  Appendix  
 
Parts list for amplifier components 
 
1. Low output impedance MOSFET, quantity 8 (#IRF7350, International 
Rectifier Inc. or #FDS4559, Fairchild Semiconductor Inc.)  
2. Pin driver, quantity 3 (#EL7158ISZ, Intersil Inc.) 
3. 1.54 MHz TTL Crystal Oscillator, quantity 1 (#SE1216- ND, Epson Toyocom 
Inc.) 
4. 10kΩ,+/-5%, ¼ watt resistor, quantity 3 (General) 
5. 820Ω, +/-5%,  ¼ watt resistor, quantity 16 (General) 
6. 2.2Ω, +/-5%, ¼ watt resistor, quantity 8 (General) 
7. 1Ω, +/-5%, 5 watt resistor, quantity 8 (General) 
8. 47uF, +/-20%,  50 volt electrolytic capacitor, quantity 12 (General) 
9. 0.1uF, +/-20%, 50 volt electrolytic capacitor, quantity 12 (General) 
Parts list for housing and miscellaneous parts 
 
1. Plastic enclosure, quantity 1 (#073, Serpac Inc.) 
2. Rotary switch, quantity 2 (#275-1386, Radio Shack Inc.) 
3. SPST 3-way switch, quantity 1 (#275-612, Radio Shack Inc.) 
4. LED, quantity 1 (#276-316, Radio Shack Inc.) 
5. Voltage regulator 5 volts, quantity 1 (#276-1770, Radio Shack Inc.) 
6. Voltage regulator 12 volts, quantity 2 (#276-1771, Radio Shack Inc.) 
7. Prototyping board, quantity 1 (#276-150, Radio Shack Inc.) 
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8. DC power connector, quantity 1 (#274-1563, Radio Shack Inc.) 
9. NiCad 9.6 volt battery with charger, quantity 6 (#23-432, Radio Shack Inc.) 
4.1 Appendix  
Parts list for amplifier components 
1. PCB Circuit Board, quantity 1 (Sunstone Circuits Inc.)  
2. Low output impedance MOSFET, quantity 14  (#FDS4559, Fairchild 
Semiconductor Inc of #IRF7350, International Rectifier Inc..)  
3. Pin driver, quantity 7 (#EL7158ISZ, Intersil Inc.) 
4. 10kΩ,+/-5%, ¼ watt resistor, quantity 7 (General) 
5. 820Ω, +/-5%,  ¼ watt resistor, quantity 14 (General) 
6. 2.2Ω, +/-5%, ¼ watt resistor, quantity 8 (General) 
7. 10uF, +/-20%,  50 volt electrolytic capacitor, quantity 19 (General) 
8. 0.1uF, +/-20%, 50 volt electrolytic capacitor, quantity 19 (General) 
9. BNC connector, quantity 2 (General) 
10. Heat-sinks, quantity 7 (#3-050305U Cool Innovations Inc)  
11. Thermal conductive epoxy, quantity 25ml (Locktight® idh#234476 3873 
Henkel Inc.) 
12. Activator, quantity 13ml (Locktight® idh#230178 7387 Henkel Inc.) 
 
 
 
 
 
 
 
 
  
194 
 
4.2 Appendix  
ULTRASOUND WAVE GENERATING APPARATUS
17 
 
4.2.1 Abstract 
In one embodiment, there is provided in an ultrasound wave generating 
apparatus a low output impedance transistor based driver circuit that has the ability to 
apply a drive signal at a frequency corresponding to an ultrasound transducer’s 
resonant frequency. The low output impedance of the driver circuit allows for a 
substantial portion of the energy to be delivered to the ultrasound transducer and 
converted to ultrasound energy. The power transfer efficiency of the presented circuit 
allows ultrasound drivers to be powered by portable battery packs, while still 
delivering high ultrasound acoustic power. The ultrasound driver can provide energy 
in sufficient amounts making it suitable for a range of ultrasound driving applications 
including but not limited to therapeutic low and high power clinical systems, high 
intensity focused ultrasound HIFU, acoustical welding, industrial inspection, and other 
various forms of low-to-high power acoustic devices. Other embodiments of 
ultrasound transducer drivers and of other components of portable ultrasound 
generator apparatus in various embodiments are set forth herein. 
 
4.2.2 Field of the Invention 
This invention relates to transducer provisioned apparatuses in general and in 
particular to ultrasound wave generating apparatuses for use in a wide variety of 
applications. 
 
                                                 
17This work has been published as Lewis, G.K., Jr., Olbricht, W.L. (2009). Ultrasound wave generating 
apparatus. United States PTC Patent Application. PCT/US2009/050297 
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4.2.3 Background of the Invention 
In the last two decades therapeutic ultrasound has received attention from the 
medical community as a tool to relieve arthritis, to improve rehabilitation, and to 
enhance wound healing processes. Ultrasound at higher energies plays a role in 
surgical applications such as prostate therapy, and brain tumor and cardiac tissue 
ablation. Therapeutic ultrasound and its effects on tissue properties are currently being 
studied in research. For example, researchers are assessing the ability of ultrasound for 
large molecule transdermal drug delivery, in targeted chemotherapy delivery to brain 
cancer, and in cellular gene transfer applications. The potential of a combined portable 
ultrasound imaging and therapeutic system is currently being studied to great lengths 
for military, industrial, and medical applications. Despite the widespread use of 
ultrasound, the basic hardware has not changed significantly in the past 50 years. 
The ability to drive ultrasound transducers for therapeutic, surgical, 
mechanical, military, and other applications is of importance to medical doctors and 
acoustical engineers and professionals in numerous additional fields. 
 
4.2.4 Summary of the Invention 
In one embodiment, there is provided an ultrasound wave generating apparatus 
having a low output impedance transistor based driver circuit that has the ability to 
apply a drive signal at a frequency corresponding to an ultrasound transducer’s 
resonant frequency. The low output impedance of the driver circuit allows for a 
substantial portion of the energy to be delivered to the ultrasound transducer and 
converted to ultrasound energy. The power transfer efficiency of the presented circuit 
allows ultrasound drivers to be powered by portable battery packs, while still 
delivering high ultrasound acoustic power. The ultrasound driver can provide energy 
in sufficient amounts making it suitable for a range of ultrasound driving applications 
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including but not limited to therapeutic low and high power clinical systems, high 
intensity focused ultrasound HIFU, acoustical welding, industrial inspection, and other 
various forms of low-to-high power acoustic devices. Other embodiments of 
ultrasound transducer drivers and of other components of portable ultrasound 
generator apparatus in various embodiments are set forth herein. 
In another embodiment, a low output impedance power supply can be 
incorporated in a portable ultrasound sensing apparatus. Various embodiments of an 
ultrasound sensing apparatus are set forth herein. 
 
4.2.5 Brief Description of the Drawings 
The features described herein can be better understood with reference to the 
drawings described below. The drawings are not necessarily to scale, emphasis instead 
generally being placed upon illustrating the principles of the invention. In the 
drawings, like numerals are used to indicate like parts throughout the various views.  
 
Figure 4.2.1 is a schematic block diagram of an ultrasound wave generating apparatus; 
 
Figure 4.2.2 is a schematic diagram of a driver circuit in combination with a timing 
circuit; 
 
Figure 4.2.3 is a block diagram of a driver circuit in combination with a timing circuit, 
wherein the driver circuit includes a plurality of transistor pairs arranged in parallel 
pairs; 
 
Figure 4.2.4 is a schematic diagram of a power supply having a driver circuit with a 
plurality of transistor pairs arranged in parallel; 
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Figure 4.2.5 is a schematic diagram of a power supply having a plurality of series 
connected power supply stages; 
 
Figure 4.2.6 is a plot of resonant frequency (expressed as a point value) versus driver 
circuit output impedance for illustrating an effect of driver circuit output impedance 
on resonant frequency; 
 
Figure 4.2.7 is a depiction of an exemplary user interface component of an ultrasound 
wave generating apparatus, wherein actuator virtual control buttons are displayed on a 
display of an ultrasound wave generating apparatus;  
 
Figure 4.2.8 is a Mason model power output chart for an ultrasound transducer in one 
embodiment; where the ultrasound transducer is provided by a 10.3 Ohm ultrasound 
transducer having a nominal frequency of resonance of 1.5 MHz; 
 
Figure 4.2.9 is a Mason model power output chart for an ultrasound transducer in one 
embodiment; where the ultrasound transducer is provided by a 1.2 Ohm ultrasound 
transducer having a nominal frequency of resonance of 1.5 MHz; 
 
Figure 4.2.10 is a Mason model power output chart for an ultrasound transducer in one 
embodiment; where the ultrasound transducer is provided by a 10.6 Ohm ultrasound 
transducer having a nominal frequency of resonance of 8 MHz; 
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Figure 4.2.11 is a Mason model power output chart for an ultrasound transducer in one 
embodiment; where the ultrasound transducer is provided by a 0.37 Ohm ultrasound 
transducer having a nominal frequency of resonance of 8 MHz; 
 
Figure 4.2.12 is an impedance versus frequency plot for a selected ultrasound 
transducer in one embodiment; 
 
Figures 4.2.13-4.2.18 are signal plots illustrating specific output drive signals, each 
being associated with a particular candidate transducer assembly of a set of candidate 
transducer assemblies; 
 
Figure 4.2.19 is a diagram showing a single transducer element ultrasound transducer; 
 
Figure 4.2.20 is a diagram showing a plural transducer element ultrasound transducer; 
 
Figure 4.2.21 is a physical form view of an ultrasound wave generating apparatus in 
one embodiment; 
 
Figure 4.2.22  is a front view of probe for an ultrasound wave generating apparatus; 
 
Figure 4.2.23  is a photograph of probe for an ultrasound wave generating apparatus; 
 
Figure 4.2.24  is a top view of a printed circuit board carrying components of a power 
supply in one embodiment; 
 
Figure 4.2.25  is a bottom view of the printed circuit board as shown in Figure 5.24; 
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Figure 4.2.26  is a photograph of a transmission line for an ultrasound wave generating 
apparatus having a braided coaxial cable transmission line; 
 
Figure 4.2.27  is a diagram of a transmission line for an ultrasound wave generating 
apparatus having a twisted coaxial cable transmission line;  
 
4.2.6 Detailed Description of the Invention 
A high level schematic diagram of an ultrasound wave generating apparatus is 
shown and described with reference to Figure 4.2.1. Ultrasound wave generating 
apparatus 1000 can include a power supply 10, and an ultrasound probe 80 having a 
transducer 90 operative for emission of ultrasound waves. Ultrasound probe 80 can 
emit waves at a frequency within the ultrasound frequency range of from about 20 
kHz to about 200 MHz. In some embodiments, ultrasound wave generating apparatus 
1000 can also include a transmission line 70. 
Referring to power supply 10, power supply 10 can include driver circuit 20, 
timing circuit 30, power distribution and control circuit 40, and power source 50. 
Driver circuit 20 can be operative to have low output impedance, e.g. of under 0.5 
Ohms. Power supply 10 can be housed in a housing 12 as is represented by dashed in 
border 12. Power supply 10 and its associated housing 12 in one embodiment can be 
portable and in one embodiment power supply 10 and housing 12 can be hand held. 
Probe 80 can include an ultrasound transducer 90 which emits ultrasound waves in 
response to electrical signals received thereby. Transducer 90 can be housed in a probe 
housing 82 as is represented by dashed in border 82. 
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Figure 4.2.1 is a schematic block diagram of an ultrasound wave generating 
apparatus 
 
Probe 80 and its associated housing 82 in one embodiment can be portable and 
in one embodiment probe 80 and associated housing 82 can be hand held. 
In one embodiment, transmission line 70 can be deleted and ultrasound wave 
generating apparatus 1000 can include a single housing. For example, transducer 90 
can be housed in housing 12, or power supply 10 can be housed in housing 82 of 
probe 80.  
Ultrasound wave generating apparatus 1000 can be conFigured to be operative 
in a single, or alternatively in multiple operating modes. A drive signal output by 
power supply 10 can have a different set of characteristics for each operating mode. 
Further, ultrasound wave generating apparatus 1000 can be operative so that an 
operating mode of apparatus 1000 and therefore output drive signal changes in 
response to control inputs that are input into apparatus 1000 by an operator. In some 
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possible operating modes, power supply 10 outputs a continuous drive signal at a 
steady state frequency. A mode of operation where power supply 10 outputs a 
continuous drive signal is useful, in a wide range of applications e.g., in ultrasound 
therapy medical applications, imaging applications, industrial applications, automobile 
applications, fuel cell applications, water purification applications, filtering 
applications, food industry applications, industrial applications, ultrasound therapy 
medical applications, commercial cutting applications, small particle removal 
applications, industrial and/or commercial mixing applications, and liquid 
vaporization applications. In another mode of operation, power supply 10 is operative 
to output a short burst drive signal. Such mode is useful in a wide range of 
applications, e.g., in ultrasound therapy medical applications, imaging applications, 
and industrial applications. The emission of ultrasound waves by apparatus 1000 
either in a continuous mode or a burst mode can also be useful, e.g., for cooling of 
electric motors by recycling bubbles in a coolant, aiding in cooling of batteries, 
preparation of substrates for fermentation, assisting in distillation of mixed bio-fuels 
and waste, assisting the converting of plant oils to biodiesel by cavitation, desalinating 
and purifying water, and preparing of crude oils. 
Driver circuit 20 in one embodiment can include a transistor pair having 
associated first and second clamping voltage terminals, where the clamping voltage 
terminals have voltages that are alternatingly passed to an output of the driver circuit. 
The transistor pair can be controlled with an oscillating timing signal for controlling 
timing of the switching of the transistors of the transistor pair so that the transistors of 
the transistor pair alternate between conducting and non-conducting states. With the 
transistors of the transistor pair alternating between conducting and non-conducting 
states, the voltages of the first and second clamping voltage terminals can be 
alternatingly applied to the output of the driver circuit. The driver circuit can be 
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provisioned to include a low output impedance that is mismatched with respect to the 
impedance of the transducer. The provisioning of the driver circuit to include a low 
output impedance provides numerous advantages as will be set forth further herein. 
In one embodiment, a plurality of the described transistor pairs can be 
connected in parallel for reduction of an output impedance of the driver circuit, and for 
increasing an output current capacity of the driver circuit. The driver circuit can be 
conFigured to have an output current capacity of more than 50 Amperes while being 
capable of outputting an output drive signal of relatively low voltage. Outputting an 
output signal of low voltage, e.g., 50V or lower is advantageous in a variety of 
applications where a higher output voltage can pose a risk to humans. 
In another aspect, the output drive signal output by the driver circuit for 
driving the ultrasound transducer can be a bipolar signal having alternatingly positive 
and negative polarities. Configuring a driver circuit to output a bipolar drive signal 
provides variation in the forces imparted to transducer 90 for causing vibration 
thereof, thus increasing an expected lifetime and performance of transducer 90. In 
another aspect, an applied bipolar drive signal can be an imbalanced bipolar signal so 
that compression forces are imparted to transducer in greater magnitudes than 
expansion forces. 
In one embodiment, ultrasound wave generating apparatus 1000 is conFigured 
to be a single mode apparatus so that at all times, when operative to output a drive 
signal, the ultrasound wave generating apparatus 1000 outputs a drive signal having 
the same set of characteristics. However, in one embodiment, the ultrasound wave 
generating apparatus 1000 can include enhanced control features configuring the 
ultrasound wave generating apparatus so that an operator, e.g., via actuation of control 
actuator of a user interface of the apparatus, can adjust one or more characteristics of 
an output drive signal to change a mode of operation of the apparatus. Drive signal 
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characteristics that can be subject to adjustment can include such characteristics as 
amplitude, frequency, maximum positive voltage, minimum negative voltage, and the 
pattern (e.g., “continuous pattern,” “burst pattern”) of the apparatus's output drive 
signal. Apparatus 1000 can be operative so that an operator can adjust one or more 
characteristics of a drive signal via actuation of a user interface actuator. Apparatus 
1000 can also be operative so that an operator can adjust one or more characteristics of 
a drive signal via replacement of a transducer assembly, as is set forth herein. 
In one embodiment, ultrasound wave generating apparatus 1000 can be 
provisioned so that a transducer assembly of apparatus 1000 is replaceable and further 
so that differently conFigured candidate transducer assemblies can be associated to 
power supply 10. In one example, each of plurality of candidate transducer assemblies 
can include a probe 80 and a transmission line 70 terminating in a detachable 
connector 72 that can be detachably coupled with a connector 220 (see Figure 4.2..21) 
of power supply 10. The ultrasound wave generating apparatus 1000 can be 
conFigured so that each candidate transducer assembly that can be associated to power 
supply 10 has an associated output drive signal having a predetermined set of 
characteristics well suited for driving the transducer of the particular associated 
transducer assembly. The ultrasound wave generating apparatus 1000 can be 
conFigured so that the specific output drive signal output by driver circuit 20 is 
responsive to which of a plurality of transducer assemblies is presently attached to the 
power supply 10. In one embodiment, apparatus 1000 can be conFigured so that an 
output drive signal that is specific to a particular transducer assembly can be subject to 
adjustment via control inputs that are input to apparatus 1000 by an operator using a 
user interface of apparatus 1000. 
Referring now to Figure 4.2.2, a schematic diagram of driver circuit 20 in 
combination with timing circuit 30 in a particular embodiment is shown and described. 
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In general, in one embodiment, an output of driver circuit 20 can be responsive to a 
timing signal output by timing circuit 30 which controls a timing of an output drive 
signal. As shown in Figure 4.2.2, driver circuit 20 can include at least one transistor 
pair 204 and 206 having associated first and second clamping voltage terminals. A 
timing signal output by timing circuit 30 can be operative to cause switching between 
transistors of the transistor pair for output of a signal that varies between output of the 
voltage at the first clamping voltage terminal and the voltage at the second clamping 
voltage terminal. In the embodiment of Figure 4.2.2, driver circuit 20 is provided by a 
transistor push pull pair having first and second clamping terminal voltages. In the 
embodiment described, the first clamping voltage terminal 220 can be clamped to 
+50V and the second clamping voltage terminal 222 can be clamped to -50V. 
Referring to timing circuit 30, an oscillating timing signal can be output by timing 
circuit 30 for causing alternating switching of transistor 204 and transistor 206. In the 
embodiment of Figure 4.2.2, transistor 204 and 206 are provided by metal oxide 
semiconductors field effect transducers (MOSFETs). First transistor 204 clamped to 
the first clamping voltage terminal (+50V) is provided by a PMOS transistor, while the 
second clamping voltage terminal (-50V) is provided by an NMOS transistor. Timing 
circuit 30 in the particular embodiment of Figure 4.2.2 includes a pin driver integrated 
circuit 302 that outputs at pin 7 thereof a unipolar 0V-12V timing signal. In another 
embodiment, transistors 204 and 206 can be provided by bipolar junction transistors 
(BJTs). Driver circuit 20 in the embodiments set forth herein can have inactive and 
active states. An active state of driver circuit 20 is defined when there is a time 
varying voltage present at the output of the driver circuit 20. 
  
205 
 
 
Figure 4.2.2 is a schematic diagram of a driver circuit in combination with a timing 
circuit 
 
In the particular embodiment as shown in Figure 4.2.2, a transistor pair 204, 
206 of driver circuit 20 can include a plurality of Metal Oxide Semiconductor Field 
Effect Transistors (MOSFETs) arranged in a particular configuration. In the 
embodiment of Figure 4.2.2, a pair of MOSFETs namely, PMOS transistor 204 and 
NMOS transistor 206 are provided on a common integrated circuit 202 and are 
arranged in a push pull configuration. In the particular embodiment, a timing signal 
output of timing circuit 30 is commonly applied as a gate drive signal to the gates of 
transistors 204 and 206 through a capacitive coupling circuit. Further regarding 
MOSFET push pull pair 204 and 206, an oscillating timing signal having a timing 
controlled by the output of the timing circuit 30 can be commonly applied to gates of 
the respective push pull pair and respective sources of the pair can be clamped to first 
and second respective terminal voltages. With the noted oscillating timing signal 
applied to the MOSFET pair, (PMOS and NMOS) the pair can oscillate between a first 
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state in which PMOS transistor 204 conducts and NMOS transistor 206 is cut off and 
a second state in which NMOS transistor 206 conducts and PMOS transistor 204 is cut 
off. 
With further reference to features of timing circuit 30 as shown in the 
embodiment of Figure 4.2.2, pin 7 of the pin driver integrated circuit 302 in the 
embodiment of Figure 4.2.2 is the output that provides a 0 to 12V square wave to 
regulate the switching of the MOSFET's voltage drain. As is detailed in Figure 4.2.2, 
the unipolar square wave output of pin driver integrated circuit 302 can be converted 
into a bipolar square wave with use of capacitive coupling circuit. In the embodiment 
of Figure 4.2.2, a capacitive coupling circuit is provided by coupling capacitors 210 
and 214 in combination with resistors 212 and 216. From pin 7 of the pin driver 302 in 
the embodiment of Figure 4.2..2, a 2.2 Ohm resistor splits off with two 0.1mF 
coupling capacitors 210 and 214 into the input pins 2 and 4 of the low on resistance 
N/P channel MOSFET integrated circuit 202. MOSFET integrated circuit 202 can be 
provided by an IRF7350 MOSFET integrated circuit of the type available from 
International Rectifier Corporation. Further, resistor 212 is connected between pin 2 
and the positive terminal voltage and resistor 216 is connected between the negative 
terminal voltage and pin 4 of MOSFET integrated circuit 202. Resistors 212 and 216 
function to allow for a voltage differential from gate to source. MOSFET integrated 
circuit 202 in one embodiment can be provided by an IRF7350 MOSFET integrated 
circuit of the type available from International Rectifier Corporation. In another 
embodiment, MOSFET integrated circuit 202 can be provided by an FDS4559 
integrated circuit of the type available from Fairchild Semiconductor Corporation. 
Pins 1 and 3 of MOSFET integrated circuit 202 are held at a maximum of - 50V and + 
50V , respectively, with 820 Ohm resistors across pins 1−2 and 3−4. Bypass capacitors 
230 and 232 are applied as well to pins 1 and 3 of the MOSFET. Capacitor 230 and 
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capacitor 232, which are tied to ground function to remove noise from the gate drive 
signal. Pins 5−6 and 7−8 of MOSFET integrated circuit 202 are tied together and 
coupled. The output drive signal can be applied to the ultrasound transducer through a 
standard BNC connector 220 as shown in Figure 4.2.10. In one embodiment, (not 
shown) the pins 5-6 and 7-8 of MOSFET integrated circuit 202 can be tied together 
and coupled through 1 Ohm 5W power resistors. 
The use of a unipolar timing signal in combination with the capacitive 
coupling circuit (in the described embodiment of Figure 4.2.2 including capacitors 210 
and 214, and resistors 212 and 216), for converting the unipolar timing signal into a 
bipolar output for input to transistors 204 and 206 provides significant advantages. Pin 
driver integrated circuits of the type of pin driver integrated circuit 302 having 
unipolar outputs are mass produced and are available at low cost as off-the-shelf 
component parts. Thus, use of a unipolar timing signal allows use of a low cost 
component part. Further, as a unipolar output component pin driver integrated circuit 
302 can be powered using a single terminal voltage, the use of a unipolar output 
timing circuit reduces overall power supply complexity and cost.  
Referring to MOSFET integrated circuit 202, MOSFET integrated circuit 202 
can include PMOS transistor 204 and NMOS transistor 206 forming a transistor pair 
for driver circuit 10. In the example shown, the transistors are connected in a push pull 
pair. An output from pin driver integrated circuit 302 as described in the embodiment 
of Figure 4.2.2 can be capacitively coupled with use of a capacitive coupling circuit 
and input into gates of PMOS transistor 204 and NMOS transistor 206. When a square 
input wave 0 -12V signal is capacitively coupled for output of a bipolar input signal, 
and where the bipolar input signal is applied to the gates of PMOS transistor 204 and 
NMOS transistor 206 with the source of PMOS transistor 204 clamped at a suitable 
clamping voltage, e.g., at + 50V , and the source of NMOS transistor 206 clamped at - 
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50V , the MOSFET pair will alternate between conditions of (a) NMOS cut off, with 
PMOS conducting and (b) PMOS cut off and NMOS conducting. Operating as 
described, a transducer driving output signal of the MOSFET pair will be a ± 50V 
square wave. ConFigured as described, it will be seen that the amplitude of the output 
drive signal output by driver circuit 20 will be dependent essentially only on the 
voltages at clamping voltage terminal 220 and at clamping voltage terminal 222 but 
will not be dependent on an amplitude of a timing signal output by timing circuit 30. 
In the particular embodiment of Figure 4.2.2, an output of timing circuit 20 can control 
a timing of switching of driver circuit 20; however, an amplitude of the output timing 
signal can have essentially no effect on an output drive signal output by driver circuit 
20. 
Referring to further aspects of timing circuit 30, timing circuit 30 in the 
embodiment of Figure 4.2.2, pin driver integrated circuit 302 can be selected to be 
capable of driving high capacitive loads. Pin driver integrated circuit 302 can be 
provided by an EL71581SZ pin driver available from Intersil Corporation. Pin driver 
integrated circuit 302 can be supplied with a 5V square wave transistor-transistor logic 
(TTL) at pin 3. In one embodiment, the input timing signal 304 can be provided by a 
crystal oscillator (not shown) having an output frequency that is selected to correspond 
to the ultrasound probe's resonant frequency (the resonant frequency of transducer 90) 
for maximum power transfer. Selecting a crystal oscillator of timing circuit 30 to have 
an output frequency corresponding to the resonant frequency of transducer 90 provides 
certain advantages. An oscillator (not shown in Figure 4.2.2) can be included by an 
SE1216-ND crystal oscillator integrated circuit of the type available from EPSON 
Toyocom Corporation. Pins 1 and 8 are held at +12V with 10mF and bypass capacitor 
312 (e.g., 10mF,47uF) and bypass capacitor 314 (e.g., 0.1mF ) to ground. Pin 2 is 
connected to Pin 1 with a 10k Ohm resistor. Pins 4 through 6 are connected to earth 
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ground. Driver circuit 20 as shown in Figure 4.2.2 has a measured low output 
impedance of about 0.5 Ohms when integrated circuit 202 is provided by an IRF750 
integrated circuit available from International Rectifier Corporation (1.5 Ohms if 1 
Ohm series power resistor is included). Where the driver circuit 20 as shown in Figure 
4.2.2 is devoid of an output series power resistor, driver circuit 20 has a current output 
capacity of about 10 Amperes. Schemes for decreasing an output impedance of and 
increasing a maximum current output capacity of driver circuit 20 are set forth herein. 
Referring to the embodiment with reference to the block diagram of Figures 
4.2.3 and 4.2.4 and the circuit diagram of Figure 4.2.4, the embodiment of Figure 4.2.3 
is a scaled up version of the circuit of Figure 4.2.2, scaled up by providing a plurality 
of transistor pairs as set forth in the embodiment of Figure 4.2.2 in parallel. As shown 
in the embodiment of Figures 4.2.3 and 4.2.4, driver circuit 20 can include a plurality 
of such push pull transistor pairs arranged in a parallel configuration. In the 
embodiment of Figures 4.2..3 and 4.2.4, driver circuit 20 includes eight (8) transistor 
pairs. However, it will be understood that driver circuit 20 can include 1 to N 
transistor pairs in parallel, substantially as conFigured in Figure 4.4.2. Providing a 
plurality of MOSFET push pull pairs reduces an output impedance of driver circuit 20 
and increases the power delivery efficiency of driver circuit 20. With driver circuit 20 
provisioned to have an output impedance of less than about 0.5 Ohms, and with 
transducer 90 having an appropriate impedance 95%-100% of the energy from the 
power supply 10 can be delivered to transducer 90. 
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Figure 4.2.3 is a block diagram of a driver circuit in combination with a timing 
circuit, wherein the driver circuit includes a plurality of transistor pairs arranged in 
parallel pairs; 
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Figure 4.2.4 is a schematic diagram of a power supply having a driver circuit with a 
plurality of transistor pairs arranged in parallel 
 
Referring to the embodiment of Figures 3 and 4, the Intersil Corporation 
EL7158ISZ pin driver integrated circuit 302 including a pin driver acts as the logic 
switch for the MOSFETs that supply the power oscillation drive to the ultrasound 
transducer. For high power continuous wave applications requiring high current, pin 
drivers are used to switch MOSFETs in parallel to lower the current burden on each 
MOSFET. As shown in Figures 4.2.3 and 4.2.4, a single timed pin driver at 5V drives 
two pin drivers at 12V as a branching cascade to switch four MOSFETs each for the 
portable high power ultrasound driving system. Each pin driver/MOSFET unit is 
wired as shown with respect to the single transistor pair embodiment of Figure 4.2.2. 
Referring to the circuit of Figure 4.2.2, 1 Ohm power output series resistors (not 
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shown) can optionally be included at the output of each transistor pair. With the series 
resistors, the output impedance of the driver circuit 20 was measured directly, and 
determined from manufacturer values of the MOSFETs, and the eight 1 Ohm parallel 
power output series resistors (which can optionally be deleted) to be almost entirely 
resistive and approximately 0.2 – 0.3 Ohms. The output impedance can be reduced by 
removing the power output series resistors. Where driver circuit 20 includes a plurality 
of transistor pairs, the effective output impedance of the driver circuit 20 can be given 
by the formula 
   
  
 
 
where RP is the output impedance of an individual transistor pair. Thus, where each 
transistor pair has an output impedance of about 0.5 Ohms, and there are eight (8) 
pairs, the total output impedance can be expected to be about 0.06 Ohms. Where the 
output impedance associated with each pair is about 1.5 Ohms, and there are eight (8) 
pairs, the output impedance of driver circuit 20 would be expected to be about 0.19 
Ohms. By scaling up driver circuit 20, via arranging additional transistor pairs in 
parallel, an output impedance of driver circuit 20 can be reduced to continually lower 
levels. For example, where an output resistance of an individual transistor pair is 0.5 
Ohms, an output impedance resulting by including 16 pairs to parallel would be about 
   
  
          . Referring to the circuit of Figures 4.2.3 and 4.2.4 in an additional 
aspect, a timing of a first set of four transistor pairs is provided by first pin driver 
integrated circuit and a timing for a second set of four transistor pairs is provided by a 
second pin driver integrated circuit. Providing such a balanced configuration, where 
each pin driver integrated circuit that outputs a timing signal that is coupled to a 
transistor pair, is coupled to an equal number of transistor pairs reduces noise relative 
to an imbalanced configuration (e.g. one in which a first pin driver integrated circuit 
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provides timing for four transistor pairs, and a second pin driver integrated circuit 
provides timing for two transistor pairs. Referring to the circuit of Figures 4.2.3 and 
4.2.4, while a particular chip layout is described embodying a particular degree of 
integration, it is understood that alternative scales of integration are possible. For 
example, the dual MOSFET integrated circuits described can be replaced with four 
MOSFET integrated circuits. In one embodiment the entirety of circuit components of 
the driver circuit 20, timing circuit 30, and power distribution and control circuit 40 
can be provided on a common integrated circuit.  
In the development of apparatus 1000, it was determined that including 
additional transistor pairs can increase an input capacity of driver circuit 20, thereby 
decreasing the frequency bandwidth of driver circuit 20. For expanding a frequency 
bandwidth of power supply 10, power supply 10 can be provisioned as shown in 
Figure 4.2.5.  
In the embodiment of Figure 4.2.5, power supply 10 can include a plurality of 
power supply stages 11-1, 11-2, 11-3. Each stage, 11-1, 11-2, 11-3 can include a 
driver circuit 20, a timing circuit 30, power distribution circuit 40, an associated power 
source 50, e.g., a battery power source or AC to DC converter and an associated stage 
ground 5. Providing each stage to have an associated power source that can be isolated 
from the power sources of remaining stages can be advantageous for a variety of 
reasons. For example, such arrangement mitigates ground coupling and looping, 
provides isolated power supply stages for multiple channel transducer drive, and 
provides power supply backup protection. In the embodiment of Figure 4.2.5, there are 
three (3) power supply stages. However, power supply 10 could also have 1, 2, or N 
power supply stages. For connecting the stages, an output of a driver circuit 20 of a 
first stage, e.g., 11-1 is input into the stage ground 5 of the succeeding stage. That is, 
an output of stage 11-1 is input into ground 5 of stage 11-2, and the output of driver 
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circuit 20 of stage 11-2 is input into the stage ground 5 of stage 11-3. The stage 
ground 5 of a first stage 11-1 in the described example can be connected to earth 
ground. 
 
 
Figure 4.2.5 is a schematic diagram of a power supply having a plurality of series 
connected power supply stages 
 
Providing a plurality of series connected power supply stages as shown in 
Figure 4.2.5 operates to sum the voltages of the various stages. For example, if each 
stage is similarly conFigured and the first stage has an output voltage of ± MV, the 
output of power supply would be ± NMV where N is the number of stages, and M is 
the voltage output of each stage. Accordingly, the multiple stage power supply set 
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forth herein is operative to provide the function of a voltage transformer without 
design complexities and manufacturing obstacles sometimes posed by transformers. In 
some applications, the incorporation of a transformer is advantageous.  
The providing of multiple power supply stages increases a frequency 
bandwidth of power supply 10 and allows a bandwidth restriction problem associated 
with disposing transistor pairs in parallel to be overcome. An input capacitance of 
power supply 10 is reduced as stages are added. For example, if each stage is similarly 
conFigured and the first stage has an input capacitance C1, the input capacitance of 
multiple series power supplies would be N/C where N is the number of stages and C is 
the input capacitive of each stage. 
An effective output impedance of driver circuit 20 of the third stage 11-3 will 
be the sum of the output impedance of each driver circuit 20 of power supply 10. 
However, it will be seen that the value of the effective in output impedance can be 
maintained at a low impedance level by configuring each stage’s driver circuit 20 to 
have a low output impendence. It is seen that where each stage has an output 
impedance of 0.03 Ohms, (e.g., as in the 16 transistor pair example set forth herein) an 
effective output impedance of the last stage driver circuit will be under 0.1 Ohms, still 
providing excellent voltage transfer to the load, even in cases where a transducer has 
low impedance (e.g., even where the load has an impedance of 1.0 Ohms, a voltage 
ratio between load and source would be above 90% (90.9%)). 
In another aspect, power supply 10 including multiple stages 11-1, 11-2, 11-3 
in series can include a master timing control unit 35. Master timing control unit 35 can 
be isolated from each stage. Master timing control unit 35 can operate to control a 
frequency at which each power supply stage 11-1, 11-2, 11-3 switches. Master timing 
control unit 35 can be operative to switch each stage at a certain frequency or at 
different frequencies. It has been mentioned that each stage 11-2, 11-2, 11-3 can be 
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similarly conFigured. For example, each stage 11-1, 11-2, 11-3 can have the same 
number of transistor pairs arranged in parallel. In another example, each stage 11-1, 
11-2, 11-3 can have a different number of transistor pairs, each stage having a number 
of transistor pairs ranging from 1 to N.  
The power supply drive circuits set forth in Figures 4.2.2-4.2.4 generally 
feature low output impedance, a relatively low voltage output signal, and high output 
current capacity. It has been described that an output impedance of driver circuit 20 
can be decreased by providing a plurality of transistor pairs in parallel as shown in the 
embodiment of Figures 4.2.3-4.2.4. Also, an output current capacity of drive circuit 20 
can be increased by providing transistor pairs as shown in the circuit of Figure 4.2.2 in 
parallel. The output current capacity of driver circuit 20 is approximately the sum total 
of the output MOSFET output current capacity for each individual transistor pair. For 
example, in the driver circuit of Figure 4.2.2, the single transistor pair driver circuit, 
having a transistor pair formed on integrated circuit 302 has an output current capacity 
of about 10 Amperes. In the embodiment of Figures 4.2.2-4.2.3 having eight (8) 
transistor pairs arranged in parallel where the pairs are formed on a smaller 
conFigured MOSFET integrated circuit, the output current capacity is about 80 
Amperes. The output current capacity of driver circuit 20 can be increased or 
decreased by increasing or decreasing the number or transistor pairs that are arranged 
in parallel in driver circuit 20. Similarly, an output impedance of driver circuit 20 
decreases as additional transistor pairs are added driver circuit 20. In the embodiment 
of Figure 4.2.2 where driver circuit 20 shows a single transistor pair driver circuit, 
driver circuit 20 has an output impedance of 0.5 Ohms. In the embodiment of Figures 
4.2.2-4.2.3, where driver circuit 20 has eight (8) transistor pairs arranged in parallel 
and the integrated circuits that are set forth herein, driver circuit 20 has an output 
impedance of about  
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The output impedance of driver circuit 20 can be adjusted to a desired output 
impedance by increasing or decreasing a number of parallel arranged transistor pairs 
in driver circuit 20.  
According to the maximum power theorem, maximum power is delivered to a 
load where an impedance of a load is matched to an output impedance of a source. In 
some embodiments, apparatus 1000 can be conFigured so that an impedance of a load 
is matched to an impedance of driver circuit 20. In other embodiments however, load 
impedance can be mismatched with respect to an impedance of driver circuit 20, 
which can be provisioned to have a low output impendence (e.g., less than 0.5 Ohms), 
and apparatus 1000 can be provisioned so that a ratio of an output impedance of driver 
circuit 20 to a load impedance is less than 1/10. Provisioning an output impedance to 
be low (e.g., less than 0.5 Ohms) and further so that an output impedance to load 
impedance ratio is less than 1/10 provides a number of advantages. For example, 
configuring driver circuit 20 to have a low output impedance and low (e.g., 1/10 or 
less impedance ratio) results in high energy conversion efficiency. A substantial 
majority of energy is delivered to the load, (i.e., the transducer 90). As such, very little 
energy is lost as heat in the driver circuit 20. Such result is particularly advantageous 
in, e.g., medical applications where heat generated by apparatus 1000 can pose danger 
to a patient. For any application where power source 50 is provided by one or more 
batteries, high energy conversion efficiency embodiments set forth herein yield 
significant advantages in terms of battery life. Maintaining a low driver circuit output 
impedance and impedance ratio also assures that a source voltage closely corresponds 
to a load voltage, thus improving the controllability and ease of use of the apparatus. A 
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voltage delivered to a transducer 90 can substantially be set by establishing a source 
voltage. 
Driver circuit 20 as set forth herein can include an associated source voltage 
when driver circuit 20 is in an active state and when driver circuit 20 outputs a drive 
signal having a frequency, e.g., to a resonant frequency of transducer 90. A driver 
circuit source voltage can be measured directly by measuring voltage across output 
terminal of a driver circuit in an open circuit condition (without current flow there is 
no voltage drop across the driver circuit's impedance contributing components). 
Further, with a load attached across the output terminals of a driver circuit, and with 
the driver circuit driving the load, e.g., at a frequency corresponding to the resonant 
frequency, the voltage at the load can be expressed as  
 
      
            
              
                          
where RSource is the output impedance of driver circuit 20. Accordingly, the ratio of a 
voltage across a load (the transducer), to a source voltage can be expressed as 
 
     
       
 
     
             
                            
Thus, it is seen that as the output impedance of the driver circuit 30 tends to zero, the 
load voltage more closely approximates the source voltage. Further, it is seen that by 
configuring apparatus 1000 so that the ratio of the source output impedance to the load 
impedance is maintained at or below 1/9, the amplitude of voltage across the load 
relative to the amplitude of the source voltage at the driver circuit will remain at or 
above 90 percent. Various embodiments of apparatus 1000 having such ratio are set 
forth herein. In other embodiments set forth herein, a voltage ratio of load to source is 
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at or above 95% and in other embodiments is at or above 99%. Prospective examples 
with expected associated data are set forth in Table 4.2.1 below. 
Table 4.2.1 Impedance of driver and transducer load to source voltage ratio 
Embodiment 
Driver Circuit 
Output Impedance 
Transducer 
Impedance 
Load To Source 
Voltage Ratio 
1 0.5 Ohms 8 Ohms 94.1% 
2 0.03 Ohms 1 Ohm 97.1% 
3 0.5 Ohms 5 Ohms 90.9% 
4 0.09 Ohms 3 Ohms 97.1% 
5 0.03 Ohms 10 Ohms 99.7% 
 
Another advantage of configuring driver circuit 20 to include a low output 
impedance and low impedance ratio is that such configuration reduces an amount of 
shift in a resonant frequency of transducer 90. Referring to Figure 4.2.6, there is 
shown a plot of the resonant frequency of transducer 90 (the frequency of a drive 
signal output by driver circuit 20 at which maximum power is output by ultrasound 
transducer 90) versus source output impedance of driver circuit 20. As the source 
output impedance increases, the resonant frequency shifts significantly (from about 
1.51 MHz to about 1.63 MHz in the described example). Reducing the amount of 
resonant frequency shift by reducing the source output impedance improves 
controllability and ease of use of apparatus 1000 for the reason that a resonant 
frequency that is observed for a particular transducer is more proximate a nominal 
frequency of resonance for the particular transducer (normally provided by a 
manufacturer of the transducer and determined based on material properties of 
transducer 90). 
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Figure 4.2.6 is a plot of resonant frequency (expressed as a point value) versus driver 
circuit output impedance for illustrating an effect of driver circuit output impedance 
on resonant frequency 
 
Referring to additional advantages of the low output impedance high output 
current configuring driver circuit 20, a high output current capacity at driver circuit 20, 
about 50 Amperes or more in some embodiments (while low current output capacity 
embodiments are advantages in certain applications) allows high energy output at 
transducer 90 (about 50 Watts or more in some embodiments) with modest voltages of 
less than 100V, and in several embodiments, about 50V or lower or 25V or lower. Such 
functionality (high energy output with only modest voltages) is advantageous in 
numerous applications, including in medical applications where risk of harm to a 
patient or caregiver in proximity to transducer 90 is posed by exposure to high 
voltages, e.g. of 100V or more. In some applications, however, an output of over 100V 
is advantageous. 
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In one embodiment, ultrasound wave generating apparatus 1000 can be a 
single mode apparatus, which has a fixed (non-interchangeable) transducer 90 and 
which outputs a drive signal of the same characteristic each time it is activated for 
output of a drive signal. In another embodiment, ultrasound wave generating apparatus 
1000 can be a multiple mode apparatus capable of output of drive signals of different 
characteristics at different times. Apparatus 1000 can be operative so that apparatus 
1000 outputs a drive signal having a different set of characteristics in response to an 
operator input control that is input into a user interface of apparatus 1000. Apparatus 
1000, where provisioned so that a transducer assembly thereof is one of a plurality of 
replaceable candidate transducer assemblies, can be operative so that apparatus 1000 
outputs a different output drive signal having a different set of characteristics 
responsively which of the candidate transducer assemblies is presently associated to 
power supply 10. 
Power distribution and control circuit 40 in the embodiment of Figure 4.2.4 
can include a three-way switch integrated circuit 404. Switch integrated circuit 404 
can be manually moved by an operator to switch the switch integrated circuit 404 
between an OFF position and an ON position. In the ON position, power from power 
source 50 is coupled to the clamping voltage terminals of driver circuit 20. Power 
supply ground can be used to isolate +5V and +12V supplies, thus reducing a wiring 
burden. In another aspect, power distribution and control circuit 40 can include a 
control unit 410. Control unit 410 can be provided by a microcontroller or a 
microprocessor. Control unit 410 can be associated with memory 412, which can store 
various data, program data, and setup data for determining characteristics of an output 
signal output by driver circuit 20. Control unit 414 can be in communication with 
display 414, which can be conFigured to have user interface capability. 
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For illustrating additional features including control features of apparatus 
1000, Figure 4.2.4 shows a further detailed schematic of a power supply shown in the 
block view of Figure 4.2.3. In Figure 4.2.4, there is shown driver circuit 20, timing 
circuit 30, power distribution and control circuit 40, and power source 50. Power 
source 50 in one embodiment can include a plurality of 9.6V, 1600 mA h NiCad 
rechargeable battery packs. Power source 50 in another embodiment can include an 
AC to DC converter for coupling to an AC wall outlet power source. The battery 
packs can be, e.g. No. 23-432 battery packs available from RadioShack Corporation. 
Power supply 10 can also include rotary switches 402 and three-way switch 404 
forming power distribution and control circuit 40. The user can adjust power delivery 
to the transducer through the MOSFETs in 9.6V increments over the range ± 28.8V. 
Additional batteries can be included for increasing the voltage range of power source. 
A blue “on” LED 306 in the embodiment of Figure 4.2.4 is tied into the on/off switch 
that supplies power to the crystal oscillator integrated circuit 304 and pin driver 
integrated circuits 302 through 5V and12V 1A voltage regulators that also have bypass 
capacitors. The output of the device is terminated in a male Bayonet Neill Concelman 
(BNC) connector on the front panel. A battery recharge port at the back of the system 
(not shown) is wired to charge the six battery packs in series. To charge the system, 
the device is switched to the off position and the rotary switches are moved to a non-
connected terminal as labeled on the devices panel. 
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Figure 4.2.7 is a depiction of an exemplary user interface component of an ultrasound 
wave generating apparatus, wherein actuator virtual control buttons are displayed on 
a display of an ultrasound wave generating apparatus  
 
A user interface of ultrasound wave generating apparatus 1000 can be partially 
provided by switch 402 and switch 404 which can be used by an operator to control 
voltages at clamping voltage terminals 220, 222 and can be partially provided by 
switch 406. A user interface of ultrasound wave generating apparatus 1000 can also 
include additional control actuators. For example, apparatus 1000 can be conFigured 
so that display 414 displays various virtual control buttons which can be actuated by 
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an operator. One example of apparatus 1000 where display 414 is conFigured to 
include an interface control button is shown in Figure 4.2.7. 
In the example at Figure 4.2.7, apparatus 1000 can be operative so that buttons 
430, 432 can be used to adjust a voltage at first clamping voltage terminal 220, buttons 
438, 440 can be used to control a voltage at second clamping voltage terminal 222, 
buttons 444, 446 can be used to control a frequency of a drive signal output by driver 
circuit 20, and buttons 450, 452 can be used to control a pattern of low output drive 
signal, e.g., to select between a “continuous pattern” or a “burst pattern.” In the 
embodiment set forth herein, control unit 410 can be in communication with switches 
402 and 404 so that a voltage at clamping voltage terminals 220, 222 can be adjusted 
either with use of voltage switches 402, 404 or buttons 430, 432, 438, 440. In preview 
area 460, there can be displayed a representation of the output drive signal expected to 
be output when the present set of control parameters is applied. For control of output 
drive signal frequencies with use of a user interface, control unit 410 can be 
communicatively coupled to timing device 304 as is indicated in the schematic 
drawing of Figure 4.2.4. Timing devices such as the crystal oscillator integrated circuit 
specifically set forth can be selected to be programmable, so that a frequency within a 
range of frequencies can be selected via input of a control to the device. For expansion 
of the range of selectable frequencies, a plurality of timing devices having overlapping 
frequency of ranges can be included in timing circuit 30. Appropriate multiplexing 
circuitry (not shown) can be provided for allowing selection of an appropriate timing 
device based on a selected frequency. 
In some embodiments of apparatus 1000 where transducer 90 is one of a 
plurality of candidate replaceable transducers incorporated in one of a plurality of 
respective transducer assemblies, an output drive signal of apparatus 1000 can be 
responsive to which transducer assembly (e.g. with reference to Figure 4.2.1, 
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transducer assembly A or transducer assembly B), is presently associated to power 
supply 10. In the specific embodiment described replaceable transducer assemblies A 
and B incorporate transmission line 70 and probe 80. However, in another 
embodiment, replaceable parts of apparatus 1000 that incorporate a transducer (i.e., 
the transducer assembly) can incorporate probe 80 only with transmission line 70 
being a fixed component part. In another embodiment, a transducer assembly 
incorporating transducer 90 can comprise essentially only transducer 90. A transducer 
assembly that consists essentially only of transducer 90 can be provided as a plug in 
component of a circuit board. To the end that apparatus 1000 can adjust characteristics 
of an output drive signal responsively to which of a plurality of candidate transducer 
assemblies is presently associated to power supply 10, each candidate transducer 
assembly can have an associated memory 900 (see Figure 4.2.1) storing an identifier 
for the transducer, e.g., in the form of a text based alpha numeric identification 
number. As shown in Figure 4.2.1 memory 900 can be housed within housing 82 of 
probe 80. 
Apparatus 1000 can be operative so that when a new transducer assembly (e.g., 
A, B and another assembly, C, etc.) is associated to power supply 10, the transducer 
assembly identifier information stored in memory 900 is communicated to control unit 
410, via appropriate communication apparatus 902. For example, control unit 40 and 
memory 900 can be in communication via a communication apparatus 902 provided 
by a two wire interface, e.g., a Phillips I2C bus. Control unit 410 can be operative so 
that responsively to identification data being communicated between memory 900 and 
control unit 410, control unit 410 establishes appropriate settings for output of a drive 
signal having a specific set of characteristics for driving the ultrasound transducer of 
the specific transducer assembly presently associated to power supply 10. 
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Hereinabove, it has been described that output drive signal characteristics of an 
output drive signal can be made responsive to an associated transducer assembly by 
way of communicating of data respecting an identity of a transducer assembly. In 
another embodiment, apparatus 1000 can be operative so that output drive signal 
characteristics output by driver circuit 20 are responsive to an associated transducer by 
way of being controlled with use of specific timing circuitry associated to the 
transducer assembly of a set of candidate transducer assemblies. 
In one example, as explained with reference to Figure 4.2.1, each transducer 
assembly of a set of candidate transducer assemblies (which may or may not be the 
full set of candidate transducer assemblies) can be provided with an associated timing 
device. As shown in Figure 4.2.1, a crystal oscillator integrated circuit 304 can be 
associated to transducer assembly A, and crystal oscillator integrated circuit 304 can 
be associated to transducer assembly B. Each crystal oscillator integrated circuit 304 
can have associating communication apparatus 305 for communicating with remaining 
components of timing circuit 30. Communication apparatus 305 can comprise a 
copper wire. Apparatus 1000 can be operative so that when a new transducer assembly 
is associated to power supply 10, a timing device associated to the new transducer 
assembly is made active to control one or more output characteristics of the output 
drive signal. Referring to the example in Figure 4.2.1, apparatus 1000 can be operative 
so that when transducer assembly A is associated to a power supply 10, timing device 
304 of transducer assembly A controls a timing of the output drive signal. Apparatus 
1000 can also be operative so that when the transducer assembly B is associated to 
power supply 10, timing device 304 disposed with transducer assembly B controls a 
timing of the output drive signal output by drive circuit 20. 
Reference will now be made to ultrasound transducer 90 of probe 80. 
Ultrasound transducer 90 of probe 80 can be provided by a PZT-4, 1.54 MHz, and 
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0.75 in. diameter piezoelectric ceramic with a radius of curvature of 1.5 of the type 
available from EBL Products, Inc. Such transducer by EBL Products, Inc. is given a 
nominal frequency of resonance of 1.5 MHz by the manufacturer. Housing 82 can be 
provided by a polyvinyl chloride (PVC) ergonomic plastic assembly. Such assembly 
can be custom built using a micro-lathe and milling system of the type available from 
Sherline Products, Inc. The clear acrylic front of the housing 82 acts as a protective 
cover to the ceramic transducer 90 and also functions as an in-plane focal alignment 
standoff for the ultrasound energy emitted by transducer 90. Regarding referenced 
elements herein, a reference to element “90” herein will be regarded as a reference to 
any of specific transducers referenced herein, e.g., transducer 90, 90A, 90 90B, and so 
forth. 
Transducer 90 can be wired with use of a transmission line 70 provided by a 22 
gauge coaxial cable terminated with a connector 72 (Figure 4.2.21) which can be 
provided by female BNC connector. Transducer 90 can have power output 
characteristic as shown in Figures 4.2.8, 4.2.9, 4.2.10, and 4.2.11, and impedance 
characteristics as shown in Figure 4.2.12. In Figures 4.2.8, 4.2.9, 4.2.10, and 4.2.11, 
there is shown a maximum power output curve, for various transducers calculated 
using the Mason Model, while being driven by differently conFigured driver circuits 
having different output impedances over a range of frequencies. Figure 4.2.8 is a 
power output plot for a transducer having a nominal frequency of resonance of 1.5 
MHz and an impedance of 10.3 Ohms. Figure 4.2.9 is a power output plot for a 
transducer having a nominal frequency of resonance of 1.5 MHz and an impedance of 
1.2 Ohms. Figure 4.2.10 is a power output plot for a transducer having a nominal 
frequency of resonance of 8 MHz and an impedance of 10.6 Ohms. Figure 4.2.11 is a 
power output plot for a transducer having a nominal frequency of resonance of 8 MHz 
and an impedance of 0.37 Ohms. A resonant frequency of ultrasound transducer 90 
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can be regarded as the frequency at which the ultrasound transducer emits maximum 
power when driven by the output drive signal output by driver circuit 20 that is to 
drive the transducer.  
Referring to Figure 4.2.6, and again with reference to power output plots of 
Figures 4.2.8, 4.2.9, 4.2.10, and 4.2.11, it is seen that a resonant frequency will shift 
slightly as an output Impedance of driver circuit 20 is increased. Regarding “resonant 
frequency” as referred to herein, it is understood that a number of factors can 
contribute to a transducer’s resonant frequency, e.g., the output impedance of the 
driver circuit 20, the impedance of transmission line 70. Nevertheless, as the primary 
determinants of the frequency at which transducer 90 resonates are the material 
properties of transducer, the reference to “resonant frequency of the transducer” is 
appropriate. Also, if an output impedance of driver circuit 20 and transmission line 70 
are maintained at approximately low levels, the contribution of the driver circuit 
output impedance, and the impedance of transmission line impedance will be 
negligible. 
 
Figure 4.2.8 is a Mason model power output chart for an ultrasound transducer in one 
embodiment; where the ultrasound transducer is provided by a 10.3 Ohm ultrasound 
transducer having a nominal frequency of resonance of 1.5 MHz 
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Figure 4.2.9 is a Mason model power output chart for an ultrasound transducer in one 
embodiment; where the ultrasound transducer is provided by a 1.2 Ohm ultrasound 
transducer having a nominal frequency of resonance of 1.5 MHz 
 
 
Figure 4.2.10 is a Mason model power output chart for an ultrasound transducer in 
one embodiment; where the ultrasound transducer is provided by a 10.6 Ohm 
ultrasound transducer having a nominal frequency of resonance of 8 MHz 
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Figure 4.2.11 is a Mason model power output chart for an ultrasound transducer in 
one embodiment; where the ultrasound transducer is provided by a 0.37 Ohm 
ultrasound transducer having a nominal frequency of resonance of 8 MHz; 
 
In Figure 4.2.12, there is shown an impedance versus frequency curve for the 
noted PZT-4, 1.5 MHz (nominal frequency of resonance), 8 Ohm transducer. 
Impedance characteristics of a ceramic transducer can be measured, e.g., with use of a 
standardly known meter method for measuring impedance. In the described example 
for transducer 90, an impedance of transducer 90 is at its lowest value of about 8.0 
Ohms at an impedance measurement equipment frequency of about 1.5 MHz. The 
impedance measuring equipment frequency at which an impedance of transducer 90 is 
at its lowest value with reference to Figure 4.2.12 can be regarded as a measurement 
of the resonant frequency of transducer 90. 
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Figure 4.2.12 is an impedance versus frequency plot for a selected ultrasound 
transducer in one embodiment; 
 
However, as noted, the resonant frequency of transducer 90 when driven by 
driver circuit 20 can be expected to be dependant, in part, on characteristics of driver 
circuit 20. By definition, when driven at the resonant frequency power output of 
transducer 90 is at its highest level. A resonant frequency can be expressed as a point 
value (e.g., 1.54 MHz) or as a range of frequencies at which power output is above a 
predetermined percentage (e.g., 90%) of a maximum power output value. A drive 
frequency corresponding to the resonant frequency can be regarded as a frequency of 
about the resonant frequency as expressed at a point value. A drive frequency 
corresponding to the resonant frequency can also be regarded as a frequency within a 
resonant frequency range, where a resonant frequency is expressed as a frequency 
range. 
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It has been noted that power supply 10 can be operative so that an output drive 
signal for driving transducer 90 can have a frequency corresponding to the resonant 
frequency of transducer 90. In another aspect, power supply 10 can be conFigured so 
that an output drive signal output by power supply 10 for driving transducer 90 can 
oscillate between a positive and negative voltage. 
Provisioning power supply 10 to output a drive signal for driving transducer 90 
that includes both positive and negative polarity provides significant advantages. 
Referring to transducer 90, transducer 90 in general will compress when a voltage of a 
first polarity is applied thereto and will expand when a voltage of a second polarity is 
applied thereto. Accordingly, applying a drive signal with positive and negative 
polarity provides variation in the stresses that are applied to transducer 90 for causing 
emissions of ultrasound waves, thereby increasing the life of transducer 90. In another 
aspect, providing a driver signal with oscillating positive and negative polarity results 
in any standing voltages of transducer 90 cancelling and thereby reducing a magnitude 
of standing voltages. Still, further use of a bipolar output drive signal allows use of 
both positive and negative channels of a transistor pair (e.g., transistor 204, transistor 
206 as shown in Figure 4.2.2) reducing thermal fatigue of the transistor pair and 
increasing the current output capacity of the transistor pair, thereby allowing higher 
power output with reduced voltage below hazardous levels. (It will be seen that a ± 
50V signal applied to a load produces the same output power as a ± 0 - 100V drive 
signal, but with substantially safer voltage levels). 
In another aspect, power supply 10 can be operative to output an imbalanced 
bipolar signal for driving transducer 90. An “imbalanced” bipolar signal herein can 
have, in one embodiment, an amplitude difference between first and second polarities 
of 1V or greater (e.g., a +10V to -9V imbalanced bipolar signal); in another 
embodiment, 5V or greater (e.g., a +5V to -10V imbalanced bipolar signal); in another 
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embodiment, 20V or greater (e.g., a +100V to -80V imbalanced bipolar signal); and in 
another embodiment, 40V or greater (e.g., a +30V to -70V imbalanced bipolar signal ). 
In the development of apparatus 1000, it was determined that the capacity of 
transducer 90 to withstand forces imparted thereto is increased with reference to 
compression forces relative to expansion forces. Transducer 90 will be compressed 
when a negative voltage drive signal is applied thereto and expanded when a positive 
voltage drive signal is applied thereto (or alternatively, depending on the setup, 
compressed when a positive voltage drive is applied and expanded when a negative 
voltage drive signal is applied). Nevertheless, driving transducer 90 with both positive 
and negative voltage drive signals advantageously produces variations of the range of 
motion of transducer 90. By provisioning power supply 10 to output an imbalanced 
bipolar drive signal, both compression and expansion forces can be imparted to 
transducer 90, and yet compression forces can be imparted to transducer 90 in greater 
magnitude than expansion forces. 
Referring again to Figure 4.2.4, the provisioning of apparatus 1000 so that both 
positive clamping terminal voltage and a negative clamping terminal voltage can be 
independently adjusted via operator input controls input using a user interface of 
apparatus 1000, allows the output drive signal output by drive circuit 20 to be 
precisely tuned to the limits imposed by the physical properties of transducer 90 
without exceeding such levels.  
Referring to Table 4.2.2, various prospective examples of transducer 
assemblies are summarized in connection with exemplary drive signals associated 
with each transducer assembly. 
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Table 4.2.2 Examples of transducers with various drive signals 
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A 90A 1.54 MHz 1.47-1.58 MHz 1.5 MHz 8 Ohms 
Continuous Imbalanced 
Bipolar Square Wave at 
about 1.54 MHz 
B 90B 1.01 MHz 0.95-1.09 MHz 1 MHz 14 Ohms 
Continuous Balanced 
Square Wave at 1.01 
MHz 
C 90C 2.60 MHz 2.45-2.68 MHz 2.5 MHz 5 Ohms 
Continuous Unipolar 
Sinusoidal Wave at 2.60 
MHz 
D 90D 3.11 MHz 3.01-3.22 MHz 3 MHz 7 Ohms 
Continuous Imbalanced 
Bipolar Sinusoidal at 
3.11 MHz 
E 90E 7.55 MHz 2.51-11.56 MHz 7.5 MHz 15 Ohms 
Burst Balanced Bipolar 
Square Wave at 7.55 
MHz 
F 90F 1.52/4.15/6.51 
1.45-1.59/3.85- 
4.35/6.37-6.62 
MHz 
1.5/4/6.5 3 Ohms 
Continuous frequency 
sweeping signal at 1.52 
MHz (bipolar 
imbalanced), 4.15 MHz 
(bipolar imbalanced), 
6.51 MHz (bipolar 
imbalanced) 
 
Characteristics of a suitable output drive signal associated with the transducer 
assemblies A, B, C, D, E, and F are summarized in Figures. 4.2.13, 4.2.14, 4.2.15, 4.2. 
4.2.16, 4.2.17, and 4.2.18. In the illustrative Table B and in associated Figures. 4.2.13-
4.2.18, the output drive signal is shown as being identical (to two decimal points) to 
the resonant frequency of transducer 90 It will be understood that due to tolerances, an 
actual drive signal can correspond to a resonant frequency without being identical to 
the resonant frequency. 
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Figure 4.2.13 are signal plot illustrating specific output drive signals, being 
associated with a particular candidate transducer assembly A 
 
Referring to Figure 4.2.13, imbalanced bipolar output drive signal is shown 
having a possible voltage peak of +30V and a negative voltage peak of -70V. The 
output drive signal of Figure 4.2.13 is operative to result in compression force being 
imparted to transducer 90 in greater magnitude than expansion forces. Apparatus 1000 
can be provisioned so that the characteristics of the drive signal of Figure 4.2.13 can 
be set either responsively to operator control using a user interface of apparatus 1000 
or responsively to a particular transducer assembly being associated to power supply 
10. In the case where apparatus 1000 is operative to output a drive signal of particular 
characteristics responsively to association of a particular transducer assembly, e.g., A, 
B, C, D, E, F, apparatus 1000 can further be operative so that characteristics of the 
drive signal can be further subject to change via control inputs that are input by an 
operator using a user interface of apparatus 1000 after the association is completed. 
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Figure 4.2.14 are signal plot illustrating specific output drive signals, being 
associated with a particular candidate transducer assembly B 
 
 
Figure 4.2.15 are signal plot illustrating specific output drive signals, being 
associated with a particular candidate transducer assembly C 
 
 
 
Figure 4.2.16 are signal plot illustrating specific output drive signals, being 
associated with a particular candidate transducer assembly D 
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Figures 4.2.13, 4.2.14, 4.2.15, 4.2.16, 4.2.17, and 4.2.18 illustrate drive signals 
that can be set responsively to control inputs that are input by an operator using a user 
interface of apparatus 1000 and/or responsively to a particular transducer assembly 
being associated to power supply 10. Characteristics of the drive signal of Figure 
4.2.13 have been characterized herein above. Referring to the output drive signal of 
Figure 4.2.14, the output drive signal of Figure 4.2.14 is a balanced bipolar output 
drive signal suitable for driving transducer assembly B transducer assembly having 
transducer 90, 90b. Referring to Figure 4.2.15, the output drive signal of Figure 4.2.15 
is a unipolar sinusidal output drive signal suitable for driving transducer assembly C 
having transducer 90, 90c. Referring to Figure 4.2.16, the output drive signal of Figure 
4.216 is an imbalanced bipolar sinusoidal drive signal suitable for driving transducer 
assembly D having transducer 90, 90d. Referring to the output drive signals of Figures 
4.2.13-4.2.16, the output drive signals of Figures. 4.2.13-4.2.16 can be regarded as 
“continuous” drive signals by virtue of their lack of repeated null periods between 
periods of oscillation. The drive signal of Figure 4.2.17 can be regarded as a burst 
signal by virtue of it having null periods, pn, intermediate of periods of oscillation. In 
some applications, e.g., imaging, apparatus 1000 can be operative to output null 
periods, pn, intermediate of periods of oscillation for purposes of conserving power, 
where null periods, pn, will not negatively impact function of apparatus 1000. In some 
imaging apparatuses, for example, it is only necessary that periods of oscillation be 
timed with exposure periods. 
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Figure 4.2.17 are signal plot illustrating specific output drive signals, being 
associated with a particular candidate transducer assembly D 
 
 
Figure 4.2.18 are signal plot illustrating specific output drive signals, being 
associated with a particular candidate transducer assembly D 
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It is seen that apparatus 1000 can be conFigured so that a switching between 
transducer assemblies of apparatus 1000 causes switching between modes of operation 
of apparatus 1000. For example, with transducer assembly A associated, apparatus 
1000 can operate in a mode in which apparatus 1000 outputs an imbalanced bipolar 
drive signal. Apparatus 1000 can further be conFigured so that a mode of operation of 
apparatus 1000 changes responsively to a presently associated transducer assembly 
being switched, e.g., to a mode of operation in which bipolar balanced drive signal 
(when transducer assembly B is associated), or to a mode of operation in which a 
unipolar drive signal is output (when transducer assembly C is associated). 
In one embodiment, as shown in Figure 4.2.19, transducer 90 can be provided 
by a single transducer element, e.g., a single transducer disk 91 having a certain 
impedance and nominal frequency of resonance. In one embodiment, as shown in 
Figure 4.2.20, transducer 90 can include plural transducer elements, e.g., a plurality of 
transducer disks arranged in series. In a particular embodiment, each of transducer 
elements (e.g., ceramic disks) can have a particular associated nominal frequency of 
resonance and a particular resonant frequency when driven by a driver circuit 20 of a 
certain configuration. In the example of Figure 4.2.20, transducer 90 includes three (3) 
transducer elements 91. However, transducer 90 could also include, e.g., two (2) 
transducer elements, or N transducer element.  
 
 
Figure 4.2.19 is a diagram showing a single transducer element ultrasound 
transducer; 
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Figure 4.2.20 is a diagram showing a plural transducer element ultrasound 
transducer 
 
 
  
Figure 4.2.21 is a physical form view of an ultrasound wave generating apparatus in 
one embodiment 
 
Referring to Table 4.2.2, transducer assembly F illustrates the use case where a 
transducer assembly includes a transducer comprising a plurality of transducer disks, 
each having a different nominal frequency resonance and resonant frequency. Each of 
the elements can comprise a transducer disk of the PZT series of transducer elements 
available from EBL Products. Such a transducer can be advantageously driven with a 
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drive signal as shown in Figure 4.2.18. The drive signal of Figure 4.2.18 is a 
frequency sweeping drive signal having a changing frequency. During period p1, the 
drive signal has a frequency of 1.52 MHz corresponding to the resonant frequency of 
the first transducer element. During period p2, the drive signal has a frequency of 4.15 
MHz corresponding to the resonant frequency of the second transducer element. 
During period p3, the drive signal has a frequency of 6.51 MHz corresponding to the 
resonant frequency of the third transducer element of transducer 90F. 
A physical form view of ultrasound generator 1000 is shown in Figure 4.2.21. 
Power supply 10 can be small and lightweight, e.g., about 5 pounds. Housing 12 for 
power supply 10 can have dimensions of about 4 ´ 6 ´ 2in.3 . Housing 82 for probe 80 
can be provided by a polyvinyl chloride (PVC) ergonomic plastic assembly. Referring 
to housing 82, ultrasound transducer 90 (shown dashed in) can be housed at a distal 
end of housing 82 as shown in Figure 4.2.21 and standoff component 84 can be 
disposed to extend from the distal end of housing 82. Standoff component 84 can 
define a cavity 86. Cavity 86 can be adapted to receive a coupling medium. A 
coupling medium such as ultrasound fluid or water can be disposed within cavity 86. 
A suitable ultrasound fluid coupling medium is No. NTNMAA001X ultrasound fluid 
available from The National Medical Association (NMA). In some applications, probe 
80 of apparatus 1000 can be adapted so that standoff component 84 can be replaceably 
removed from housing 82. Further, standoff component 84 can be provided as one of a 
family of candidate standoff components which can include, e.g., component 84' and 
84''. Standoff component 84 can include a light transmissive wall 85. As is best seen in 
the view of Figure 4.2.23, light transmissive wall 85 can be light transmissive to allow 
visual viewing into an interior of cavity 86. As shown in the front view of Figure 
4.2.22, with transducer periphery 91 dashed in, a periphery of standoff component 84 
can be substantially aligned with a periphery of standoff component 84 at the interface 
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between the transducer 90 and standoff component 84. Light transmissive wall 85, as 
best seen in Figure 4.2.23 permits an operator to view an interior of cavity 86 to 
determine, e.g., the quality of a coupling medium disposal within cavity (e.g., whether 
the coupling medium is substantially free of bubbles). Light transmissive wall 85 can 
be formed partially about the periphery of standoff component 84. In the embodiments 
of Figure 4.2.23, light transmissive wall 85 is formed entirely about the periphery of 
standoff component 84. Transmission line 70 can have a length of about 1m. In 
another embodiment, transmission line 70 can be deleted and power supply 10 and 
transducer 90 can be housed in a common housing. 
 
 
Figure 4.2.22  is a front view of probe for an ultrasound wave generating apparatus; 
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Figure 4.2.23  is a photograph of probe for an ultrasound wave generating apparatus 
 
Additional housing and packaging features of apparatus 1000 in one 
embodiment are set forth with reference to Figures 4.2.24 and 4.2.25. Figures 4.2.24 
and 4.2.25 show top and bottom views of a printed circuit board 15 carrying MOSFET 
integrated circuits 202 of driver circuit 20. In the views of Figures 4.2.24 and 4.2.25, 
the dashed in border 12 indicates a location of housing 12 when printed circuit board 
15 is disposed in housing 12. In the embodiment of Figure 4.2.24, MOSFET 
integrated circuits 202 can be distributed at an outer periphery of circuit board 15 so 
that integrated circuits 202 are more proximate a periphery of printed circuit board 15 
than a longitudinally extending imaginary center axis 17 of printed circuit board 15. In 
the embodiment of Figures 4.2.24 and 4.2.25, each MOSFET integrated circuit 202 of 
driver circuit 20 is so located. Distributed as described proximate housing boundary 12 
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heat generated by integrated circuits 202 is more likely to be conducted to an exterior 
of housing 12, thus removing heat from integrated circuits 202 and increasing the 
power output capacity of MOSFET integrated circuits 202 and of driver circuit 20. 
 
Figure 4.2.24  is a top view of a printed circuit board carrying components of a 
ultrasound power supply in one embodiment 
 
 
Figure 4.2.25  is a bottom view of the printed circuit board as shown in Figure 5.24 
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Referring to the circuit diagrams of Figures 4.2.24 and 4.2.25, an output of 
driver circuit 20 can include an output from each of a plurality of MOSFET integrated 
circuits co-located at a common node 250. As seen in the physical form view of 
Figures 4.2.24 and 4.2.25, common node 250 can be physically constituted by a planar 
conFigured output voltage plane. Common node 250 conFigured as an output voltage 
plane can be distributed over a two dimensional area of printed circuit board 15 to 
partially define one or more surfaces of printed circuit board 15. In the embodiment of 
Figures 4.2.24 and 4.2. 25, the output voltage plane is distributed to partially define 
each of a top surface and a bottom surface of printed circuit board 15. As shown, the 
common node 250 where provided by an output voltage plane can include a planar 
surface exposed to an exterior or printed circuit board 15. The common node 250 
where provided by an output voltage plane as shown in Figures 4.2.24 and4.2. 25 can 
be formed from a printed circuit board copper surface laminate that is appropriately 
etched and provided to commonly connect the respective outputs of the various 
transistor pairs of driver circuit 20. With a common node 250 being constituted with a 
planar conductor defining a surface of printed circuit board 15 significant heat is 
removed from the circuit components of apparatus 1000 including from MOSFET 
integrated circuits 202 of driver circuit 20 thus increasing a power output capacity of 
MOSFET integrated circuits 20. Common node 250 where provided by an output 
voltage plane can be distributed such that the output voltage plane is in thermal 
contact or near thermal contact with an electrically insulative portion of a plurality of 
(and in one embodiment each) MOSFET integrated circuits 202. With such 
configuration, there is encouraged a distribution of thermal energy to the end that each 
of a plurality of MOSFET integrated circuits 202 and in one embodiment each 
MOSFET integrated circuit has approximately a common operating temperature. 
Configuring driver circuit 20 so that each MOSFET integrated circuit 200 has 
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approximately a common operating temperature reduces noise output by driver circuit 
20. Specifically, configuring driver circuit 20 so that each 
MOSFET integrated circuit 200 has approximately a common operating temperature 
can be expected to reduce differences in oscillating and switch timing operations that 
would create ripple and noise in an output of driver circuit 20. 
The system in one embodiment is housed in a housing 12 provided by a 4´ 6´ 
2in.3watertight plastic enclosure, No. 073 of the type provided by Serpac, Inc. The 
housing holds the circuit (1.5´ 2´1in.3 ) and six 9.6V , 1600 mA h NiCad rechargeable 
battery packs (No. 23−432 available from RadioShack Corporation) tied together in 
series through two single draw rotary switches. 
Referring again to Figure 4.2.1, the various impedances of driver circuit 20, 
transmission line 70, and transducer 90 can be coordinated in a specific manner. In 
one embodiment, driver circuit 20 has an output impedance of about 0.5 Ohms. 
Provisioning driver circuit 20 to have an output impedance that is not matched with 
the impedance of transducer 90 improves energy transfer efficiency of apparatus 1000. 
By provisioning driver circuit 20 to have a low output impedance very little energy is 
dissipated as heat in driver circuit 20. Accordingly, driver circuit 20 will be 
maintained in a state that is safe to the touch throughout operation of driver circuit 20. 
An impedance of transmission line 70 can also be coordinated with the output 
impedance of driver circuit 20 and an impedance of transducer 90. In one example, 
transmission line 70 can be provisioned to have an impedance of value that is about 
the output impedance of driver circuit 20 so that the impedance of transmission line 70 
matches the output impedance of driver circuit 10, but, like driver circuit 20, is 
mismatched with respect to transducer 90. 
In developing apparatus 1000 it was determined that advantages are exhibited 
by configuring the impedance of transmission line 70 to be low, e.g., about 5 Ohms or 
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lower and in other embodiments, 1 Ohm or lower. In one example, transmission line 
70 where provided by a coaxial cable is provided by a 5 Ohm coaxial cable, part 
number 1/22-15044 available from Cooner Wire, Inc. of Chatsworth, CA. The 
impedance of transmission line 70 can be reduced by providing a plurality of coaxial 
cables in parallel. Where a plurality of coaxial cables are provided in parallel in the 
formation of transmission line 70, an impedance of transmission line 70 can be 
expressed as  
      
  
 
                                     
where RC is the impedance of each individual cable and N is the number of cables. 
Thus, a transmission line impedance where transmission line 70 includes six (6) of the 
referenced coaxial cables would be less than 1 Ohm. A plurality of cables can be 
arranged in a specific configuration. In the embodiment of Figure 4.2.25, transmission 
line 70 is provided by a plurality of braided coaxial cables arranged in parallel. In the 
embodiment of Figure 4.2.26, transmission line 70 is provided by a plurality of twisted 
coaxial cables arranged in parallel. The specific configurations as shown in Figure 
4.2.25 and Figure 4.2.26 operate to reduce noise. 
 
 
Figure 4.2.26  is a photograph of a transmission line for an ultrasound wave 
generating apparatus having a braided coaxial cable transmission line 
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Figure 4.2.27  is a diagram of a transmission line for an ultrasound wave generating 
apparatus having a twisted coaxial cable transmission line  
 
A small sample of systems methods and apparatus that are described herein is as 
follows: 
A1. An ultrasound wave generating apparatus comprising: 
a power supply having a power source, a timing circuit, and a transistor based 
driver circuit for output of a drive signal, wherein the driver circuit includes a 
transistor pair including first and second transistors, and first and second clamping 
voltage terminals, the first and second transistors having respective first and second 
gates, wherein the timing circuit is operative to output a timing signal for controlling 
timing of the drive signal output by the driver circuit; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein a frequency at which the 
ultrasound transducer emits maximum power when driven by the output drive signal 
defines a resonant frequency of the ultrasound transducer; 
 wherein the driver circuit is operative to output a drive signal having a 
frequency corresponding to the resonant frequency; and 
wherein the apparatus is conFigured so that the transducer has an associated 
load voltage when the driver circuit outputs the drive signal to drive the transducer at a 
frequency corresponding to the resonant frequency, wherein the apparatus is further 
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conFigured so that the driver circuit has an associated source voltage when the driver 
circuit outputs the drive signal at a frequency corresponding to the resonant frequency, 
and wherein the apparatus is conFigured so that the amplitude of the load voltage is at 
least 90 percent of the amplitude of the source voltage when the driver circuit outputs 
a drive signal at a frequency corresponding to the resonant frequency. 
 
A2. The ultrasound wave generating apparatus of claim A1, wherein the ultrasound 
transducer is operative so that compression force is imparted to the ultrasound 
transducer when the drive signal is of a first voltage polarity, and further so that an 
expansion force is imparted to the ultrasound transducer when the drive signal is of a 
second voltage polarity, and further so that the drive signal is a continuous bipolar 
drive signal so that both of compression forces and expansion forces are imparted to 
the ultrasound transducer.  
 
A3. The ultrasound wave generating apparatus of claim A1, wherein the ultrasound 
transducer is operative so that compression force is imparted to the ultrasound 
transducer when the drive signal is of a first voltage polarity, and further so that an 
expansion force is imparted to the ultrasound transducer when the drive signal is of a 
second voltage polarity, and further so that the drive signal is an imbalanced 
continuous bipolar drive signal so that both of compression forces and expansion 
forces are imparted to the ultrasound transducer, and further so that the compression 
forces are of greater magnitude than the expansion forces. 
 
A4. The ultrasound wave generating apparatus of claim A1, wherein the driver circuit 
is operative so that the drive signal has an output current capacity of greater than 50 
amperes. 
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A5. The ultrasound wave generating apparatus of claim A1, wherein the power supply 
includes a capacitive coupling circuit coupling the timing signal to the first and second 
gates of the transistor pair, wherein the timing signal is a unipolar timing signal, and 
wherein the capacitive coupling circuit converts the unipolar timing signal into a 
bipolar input signal for input into the driver circuit. 
 
A6. The ultrasound wave generating apparatus of claim A1, wherein the transistor 
based driver circuit includes a plurality of transistor pairs connected in parallel, each 
of the transistor pairs having first and second transistors, wherein each of the transistor 
pairs is coupled to the first and second clamping voltage terminals. 
 
A7. The ultrasound wave generating apparatus of claim A1, wherein the ultrasound 
wave generating apparatus includes a user interface and is operative so that at least 
one characteristic of the drive signal can be changed in response to an operator control 
input that is input utilizing the user interface. 
 
A8. The ultrasound wave generating apparatus of claim A1, wherein the ultrasound 
wave generating apparatus is adapted so that the ultrasound transducer is incorporated 
in a replaceable ultrasound transducer assembly that is one of a plurality of candidate 
ultrasound transducer assemblies that can be associated to the ultrasound wave 
generating apparatus, and wherein the ultrasound wave generating apparatus is 
operative so that the drive signal has at least one characteristic that is responsive to 
which of the plurality of candidate ultrasound transducer assemblies is presently 
associated to the ultrasound wave generating apparatus.  
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A9. The ultrasound wave generating apparatus of claim A1, wherein the ultrasound 
wave generating apparatus includes a user interface and is adapted so that the 
ultrasound transducer is incorporated in a replaceable ultrasound transducer assembly 
that is one of a plurality of candidate ultrasound transducer assemblies that can be 
associated to the ultrasound wave generating apparatus, wherein the ultrasound wave 
generating apparatus is operative so that the drive signal output by the driver circuit is 
responsive to each of (a) a switching of a candidate transducer assembly, and (b) a 
control input that is input by an operator utilizing the user interface.  
 
A10. The ultrasound wave generating apparatus of claim A9, wherein each of the 
plurality of candidate transducer assemblies includes a timing device disposed therein 
for controlling a timing of the driver circuit. 
 
A11. The ultrasound wave generating apparatus of claim A1, wherein the ultrasound 
wave generating apparatus is operative in a first mode of operation and in a second 
mode of operation, wherein the ultrasound wave generating apparatus in the first mode 
of operation outputs an imbalanced bipolar output drive signal, wherein the apparatus 
in the second mode of operation outputs an output drive signal that is selected from the 
group consisting of a unipolar output drive signal and a balanced output drive signal. 
 
A12. The ultrasound wave generating apparatus of claim A11, wherein the ultrasound 
wave generating apparatus includes a replaceable transducer assembly incorporating 
the transducer, the transducer assembly being one of a plurality of candidate 
transducer assemblies, wherein the ultrasound wave generating apparatus is operative 
so that the ultrasound wave generating apparatus switches operation from the first 
mode of operation to the second mode of operation responsively to the transducer 
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assembly being replaced with another of the plurality of candidate transducer 
assemblies. 
 
A13. The ultrasound wave generating apparatus of claim A1, wherein the apparatus 
further includes a housing for housing the ultrasound transducer, the housing having a 
distal end at which the ultrasound transducer is disposed, wherein there is further 
disposed at the distal end a standoff component defining a cavity for carrying 
ultrasound coupling medium, the standoff component having a light transmissive wall 
adapted to permit visual viewing of an interior of the cavity through the light 
transmissive wall. 
 
A14. The ultrasound wave generating apparatus of claim A1, wherein the apparatus 
includes a transmission line coupling the driver circuit and the transducer, the 
transmission line including a plurality of coaxial cables arranged in parallel, and 
further being arranged in a braid configuration. 
 
A15. The ultrasound wave generating apparatus of claim A1, wherein the apparatus 
includes a transmission line coupling the driver circuit and the transducer, the 
transmission line including a plurality of coaxial cables arranged in parallel, and 
further being arranged in a twisted configuration.  
 
A16. The ultrasound wave generating apparatus of claim A1, wherein the transducer 
comprises a single transducer element having a first associated nominal frequency of 
resonance. 
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A17. The ultrasound wave generating apparatus of claim A1, wherein the transducer 
comprises a plurality of transducer elements. 
 
A18. The ultrasound wave generating apparatus of claim A1, wherein the transducer 
comprises first and second transducer elements, the first transducer element having a 
first resonant frequency, the second transducer element having a second resonant 
frequency. 
 
A19. The ultrasound wave generating apparatus of claim A1, wherein the ultrasound 
transducer comprises first and second transducer elements, the first transducer element 
having a first resonant frequency, the second transducer element having a second 
resonant frequency, and wherein the apparatus is conFigured so that the driver circuit 
is operative to output a frequency sweeping drive signal, the frequency sweeping drive 
signal having a frequency corresponding to the first resonant frequency during a first 
period, the frequency sweeping drive signal having a frequency corresponding to the 
second resonant frequency during a second period. 
 
A20. The ultrasound wave generating apparatus of claim A1, wherein the power 
supply has a plurality of power supply stages, each power supply stage having an 
associated driver circuit and power source, wherein the plurality of the power supply 
stages include first and second power supply stages, the second power supply stage 
being successive in relation to the first power supply stage, and wherein an output of 
the first of the power supply stages is input into a stage ground of the second power 
supply stage.  
 
  
254 
 
A21. The ultrasound wave generating apparatus of claim A1, wherein the power 
supply includes a user interface conFigured to permit an operator to independently 
adjust the first terminal clamping voltage and the second terminal clamping voltage 
via input of control inputs utilizing the user interface.  
A22. The ultrasound wave generating apparatus of claim A1, wherein the power 
source includes a battery power source. 
 
A23. The ultrasound wave generating apparatus of claim A1, wherein the power 
source includes an AC/DC converter. 
 
A24. The ultrasound wave generating apparatus of claim A1, wherein the driver 
circuit includes a MOSFET integrated circuit, and wherein the apparatus includes a 
housing and printed circuit board for carrying the MOSFET integrated circuit, the 
printed circuit having a peripheral edge that is proximate the housing when the printed 
circuit board is disposed in the housing, wherein the MOSFET integrated circuit is 
disposed on the printed circuit at a location that is more proximate the peripheral edge 
of the circuit board that a longitudinal centerline of the printed circuit board. 
 
A25. The ultrasound wave generating apparatus of claim A1, wherein the driver 
circuit includes a plurality of transistor pairs and a plurality of pin drivers for 
providing switching of the plurality of transistor pairs, wherein the driver circuit is 
conFigured so that each of the plurality of pin drivers for providing switching drives a 
common number of transistor pairs.  
 
A26. The ultrasound wave generating apparatus of claim A1, wherein the apparatus 
includes a printed circuit board carrying the first and second transistors of the driver 
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circuit and wherein an output of the driver circuit includes common node that 
combines outputs of the first and second transistors, wherein the common output node 
is constituted by an output voltage plane having a planar surface area partially defining 
a surface of the printed circuit board. 
 
B1. An ultrasound wave generating apparatus comprising: 
a power supply having a power source, a timing circuit, and a transistor based 
driver circuit for output of a drive signal, wherein the driver circuit includes a 
transistor pair including first and second transistors, and first and second clamping 
voltage terminals, the first and second transistors having respective first and second 
gates, wherein the timing circuit is operative to output a timing signal for controlling 
timing of the drive signal output by the driver circuit; 
a hand held housing for housing the power supply; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein a frequency at which the 
ultrasound transducer emits maximum power when driven by the output drive signal 
defines a resonant frequency of the ultrasound transducer; 
wherein the driver circuit is operative to output a drive signal having a 
frequency corresponding to the resonant frequency; and 
wherein the apparatus is conFigured so that the transducer has an associated 
load voltage when the driver circuit outputs the drive signal to drive the transducer at a 
frequency corresponding to the resonant frequency, wherein the apparatus is further 
conFigured so that driver circuit has an associated source voltage when the driver 
circuit outputs the drive signal at a frequency corresponding to the resonant frequency, 
and wherein the apparatus is conFigured so that the amplitude of the load voltage is at 
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least 90 percent of the amplitude of the source voltage when the driver circuit outputs 
a drive signal at a frequency corresponding to the resonant frequency; 
wherein the ultrasound transducer is operative so that compression force is 
imparted to the ultrasound transducer when the drive signal is of a first voltage 
polarity, and further so that an expansion force is imparted to the ultrasound 
transducer when the drive signal is of a second voltage polarity, and further so that the 
drive signal is an imbalanced continuous bipolar drive signal so that both of 
compression forces and expansion forces are imparted to the ultrasound transducer, 
and further so that the compression forces are of greater magnitude than the expansion 
forces; 
wherein the driver circuit is operative so that the drive signal has an output 
current capacity of greater than 50 amperes. 
wherein the power supply includes a capacitive coupling circuit coupling the 
timing signal to the first and second gates of the transistor pair, wherein the timing 
signal is a unipolar timing signal, and wherein the capacitive coupling circuit converts 
the unipolar timing signal into a bipolar input signal for input into the driver circuit; 
wherein the transistor based driver circuit includes a plurality of transistor pairs 
connected in parallel, each of the transistor pairs having first and second transistors, 
wherein each of the transistor pairs is coupled to the first and second clamping voltage 
terminals; 
wherein the ultrasound wave generating apparatus includes a user interface and 
is adapted so that the ultrasound transducer is incorporated in a replaceable ultrasound 
transducer assembly that is one of a plurality of candidate ultrasound transducer 
assemblies that can be associated to the ultrasound wave generating apparatus, 
wherein the ultrasound wave generating apparatus is operative so that the drive signal 
output by the driver circuit is responsive to each of (a) a switching of a candidate 
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transducer assembly, and (b) a control input that is input by an operator utilizing the 
user interface; 
wherein the apparatus further includes a housing for housing the ultrasound 
transducer, the housing having a distal end at which the ultrasound transducer is 
disposed, wherein there is further disposed at the distal end a standoff component 
defining a cavity for carrying ultrasound coupling medium, the standoff component 
having a light transmissive wall adapted to permit visual viewing of an interior of the 
cavity through the light transmissive wall; 
wherein the apparatus includes a transmission line coupling the driver circuit 
and the transducer, the transmission line including a plurality of coaxial cables 
arranged in parallel, and further being arranged in one of a braid or twisted 
configuration; 
wherein the power supply has a plurality of power supply stages, each power 
supply stage having an associated driver circuit and power source, wherein the 
plurality of the power supply stages include first and second power supply stages, the 
second power supply stage being successive in relation to the first power supply stage, 
and wherein an output of the first of the power supply stages is input into a stage 
ground of the second power supply stage. 
wherein the user interface is conFigured to permit an operator to independently 
adjust the first terminal clamping voltage and the second terminal clamping voltage 
via input of control inputs utilizing the user interface; 
wherein the power source includes a battery power source; 
wherein the driver circuit includes a MOSFET integrated circuit, and wherein 
the apparatus includes a housing and printed circuit board for carrying the MOSFET 
integrated circuit, the printed circuit having a peripheral edge that is proximate the 
housing when the printed circuit board is disposed in the housing, wherein the 
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MOSFET integrated circuit is disposed on the printed circuit at a location that is more 
proximate the peripheral edge of the circuit board that a longitudinal centerline of the 
printed circuit board; 
wherein the driver circuit includes a plurality of transistor pairs and a plurality 
of pin drivers for providing switching of the plurality of transistor pairs, wherein the 
driver circuit is conFigured so that each of the plurality of pin drivers for providing 
switching drives a common number of transistor pairs; and 
wherein the apparatus includes a printed circuit board carrying the first and 
second transistors of the driver circuit and wherein an output of the driver circuit 
includes common node that combines outputs of the first and second transistors, 
wherein the common output node is constituted by an output voltage plane having a 
planar surface area partially defining a surface of the printed circuit board. 
 
C1. An ultrasound wave generating apparatus comprising: 
a power supply having a timing circuit for outputting a timing signal, and a 
transistor based driver circuit for output of a drive signal, wherein the driver circuit 
includes a transistor pair including first and second transistors, and first and second 
clamping voltage terminals, the first and second transistors having respective first and 
second gates, wherein the timing circuit is operative to output a timing signal for 
controlling timing of the drive signal output by the driver circuit; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein the ultrasound transducer 
includes an impedance rating and a frequency rating and wherein the driver circuit is 
operative to output the drive signal at a frequency of about the frequency rating of the 
ultrasound transducer; and 
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wherein the driver circuit includes an output impedance and wherein the 
apparatus is conFigured so a value of the output impedance of the driver circuit is less 
than 10 percent of a value of the impedance rating of the ultrasound transducer. 
 
C2. The ultrasound wave generating apparatus of claim C1, wherein the ultrasound 
wave generating apparatus is operative to output more than 50 Watts of ultrasound 
energy. 
 
C3. The ultrasound wave generating apparatus of claim C1, wherein the power supply 
includes a capacitive coupling circuit coupling the timing signal to the first and second 
gates of the transistor pair, wherein the timing signal is a unipolar timing signal, and 
wherein the capacitive coupling circuit converts the unipolar timing signal into a 
bipolar input signal for input into the driver circuit. 
 
C4. The ultrasound wave generating apparatus of claim C1, wherein the transistor 
based driver circuit includes a plurality of transistor pairs connected in parallel, each 
of the transistor pairs having first and second transistors, wherein each of the transistor 
pairs is coupled to the first and second clamping voltage terminals. 
 
C5. The ultrasound wave generating apparatus of claim C1, wherein the apparatus 
includes a battery power source. 
 
C6. The ultrasound wave generating apparatus of claim C1, wherein the power supply 
includes a user interface conFigured to permit an operator to independently adjust the 
first terminal clamping voltage and the second terminal clamping voltage via input of 
control inputs utilizing the user interface. 
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D1. An ultrasound wave generating apparatus comprising: 
a power supply having a timing circuit for outputting a timing signal, and a 
transistor based driver circuit for output of a drive signal, wherein the driver circuit 
includes a transistor pair including first and second transistors, and first and second 
clamping voltage terminals, the first and second transistors having respective first and 
second gates, wherein the timing circuit is operative to output a timing signal for 
controlling timing of the drive signal output by the driver circuit; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein the ultrasound transducer 
includes an impedance rating and a frequency rating and wherein the driver circuit is 
operative to output the drive signal at a frequency of about the frequency rating of the 
ultrasound transducer; 
wherein the driver circuit includes an output impedance and wherein the 
apparatus is conFigured so a value of the output impedance of the driver circuit is less 
than 10 percent of a value of the impedance rating of the ultrasound transducer; 
wherein the ultrasound wave generating apparatus is operative to output more 
than 50 Watts of ultrasound energy; 
wherein the power supply includes a capacitive coupling circuit coupling the 
timing signal to the first and second gates of the transistor pair, wherein the timing 
signal is a unipolar timing signal, and wherein the capacitive coupling circuit converts 
the unipolar timing signal into a bipolar input signal for input into the driver circuit; 
wherein the transistor based driver circuit includes a plurality of transistor pairs 
connected in parallel, each of the transistor pairs having first and second transistors, 
  
261 
 
wherein each of the transistor pairs is coupled to the first and second clamping voltage 
terminals; 
wherein the apparatus includes a battery power source; and 
wherein the power supply includes a user interface conFigured to permit an 
operator to independently adjust the first terminal clamping voltage and the second 
terminal clamping voltage via input of control inputs utilizing the user interface. 
 
While the present invention has been described with reference to a number of specific 
embodiments, it will be understood that the true spirit and scope of the invention 
should be determined only with respect to claims that can be supported by the present 
specification. Further, while in numerous cases herein wherein systems and 
apparatuses and methods are described as having a certain number of elements it will 
be understood that such systems, apparatuses and methods can be practiced with fewer 
than the mentioned certain number of elements. 
 
4.2.7 Claims 
1. An ultrasound wave generating apparatus comprising: 
a power supply having a power source, a timing circuit, and a transistor based 
driver circuit for output of a drive signal, wherein the driver circuit includes a 
transistor pair including first and second transistors, and first and second clamping 
voltage terminals, the first and second transistors having respective first and second 
gates, wherein the timing circuit is operative to output a timing signal for controlling 
timing of the drive signal output by the driver circuit; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein a frequency at which the 
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ultrasound transducer emits maximum power when driven by the output drive signal 
defines a resonant frequency of the ultrasound transducer; 
wherein the driver circuit is operative to output a drive signal having a 
frequency corresponding to the resonant frequency; and 
wherein the apparatus is conFigured so that the transducer has an associated 
load voltage when the driver circuit outputs the drive signal to drive the transducer at a 
frequency corresponding to the resonant frequency, wherein the apparatus is further 
conFigured so that the driver circuit has an associated source voltage when the driver 
circuit outputs the drive signal at a frequency corresponding to the resonant frequency, 
and wherein the apparatus is conFigured so that the amplitude of the load voltage is at 
least 90 percent of the amplitude of the source voltage when the driver circuit outputs 
a drive signal at a frequency corresponding to the resonant frequency. 
 
2. The ultrasound wave generating apparatus of claim 1, wherein the ultrasound 
transducer is operative so that compression force is imparted to the ultrasound 
transducer when the drive signal is of a first voltage polarity, and further so that an 
expansion force is imparted to the ultrasound transducer when the drive signal is of a 
second voltage polarity, and further so that the drive signal is a continuous bipolar 
drive signal so that both of compression forces and expansion forces are imparted to 
the ultrasound transducer. 
 
3. The ultrasound wave generating apparatus of claim 1, wherein the ultrasound 
transducer is operative so that compression force is imparted to the ultrasound 
transducer when the drive signal is of a first voltage polarity, and further so that an 
expansion force is imparted to the ultrasound transducer when the drive signal is of a 
second voltage polarity, and further so that the drive signal is an imbalanced 
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continuous bipolar drive signal so that both of compression forces and expansion 
forces are imparted to the ultrasound transducer, and further so that the compression 
forces are of greater magnitude than the expansion forces. 
 
4. The ultrasound wave generating apparatus of claim 1, wherein the driver circuit is 
operative so that the drive signal has an output current capacity of greater than 50 
amperes.  
 
5. The ultrasound wave generating apparatus of claim 1, wherein the power supply 
includes a capacitive coupling circuit coupling the timing signal to the first and second 
gates of the transistor pair, wherein the timing signal is a unipolar timing signal, and 
wherein the capacitive coupling circuit converts the unipolar timing signal into a 
bipolar input signal for input into the driver circuit. 
 
6. The ultrasound wave generating apparatus of claim 1, wherein the transistor based 
driver circuit includes a plurality of transistor pairs connected in parallel, each of the 
transistor pairs having first and second transistors, wherein each of the transistor pairs 
is coupled to the first and second clamping voltage terminals. 
 
7. The ultrasound wave generating apparatus of claim 1, wherein the ultrasound wave 
generating apparatus includes a user interface and is operative so that at least one 
characteristic of the drive signal can be changed in response to an operator control 
input that is input utilizing the user interface. 
 
8. The ultrasound wave generating apparatus of claim 1, wherein the ultrasound wave 
generating apparatus is adapted so that the ultrasound transducer is incorporated in a 
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replaceable ultrasound transducer assembly that is one of a plurality of candidate 
ultrasound transducer assemblies that can be associated to the ultrasound wave 
generating apparatus, and wherein the ultrasound wave generating apparatus is 
operative so that the drive signal has at least one characteristic that is responsive to 
which of the plurality of candidate ultrasound transducer assemblies is presently 
associated to the ultrasound wave generating apparatus. 
 
9. The ultrasound wave generating apparatus of claim 1, wherein the ultrasound wave 
generating apparatus includes a user interface and is adapted so that the ultrasound 
transducer is incorporated in a replaceable ultrasound transducer assembly that is one 
of a plurality of candidate ultrasound transducer assemblies that can be associated to 
the ultrasound wave generating apparatus, wherein the ultrasound wave generating 
apparatus is operative so that the drive signal output by the driver circuit is responsive 
to each of (a) a switching of a candidate transducer assembly, and (b) a control input 
that is input by an operator utilizing the user interface. 
 
10. The ultrasound wave generating apparatus of claim 9, wherein each of the plurality 
of candidate transducer assemblies includes a timing device disposed therein for 
controlling a timing of the driver circuit. 
 
11. The ultrasound wave generating apparatus of claim 1, wherein the ultrasound wave 
generating apparatus is operative in a first mode of operation and in a second mode of 
operation, wherein the ultrasound wave generating apparatus in the first mode of 
operation outputs an imbalanced bipolar output drive signal, wherein the apparatus in 
the second mode of operation outputs an output drive signal that is selected from the 
group consisting of a unipolar output drive signal and a balanced output drive signal. 
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12. The ultrasound wave generating apparatus of claim 11, wherein the ultrasound 
wave generating apparatus includes a replaceable transducer assembly incorporating 
the transducer, the transducer assembly being one of a plurality of candidate 
transducer assemblies, wherein the ultrasound wave generating apparatus is operative 
so that the ultrasound wave generating apparatus switches operation from the first 
mode of operation to the second mode of operation responsively to the transducer 
assembly being replaced with another of the plurality of candidate transducer 
assemblies. 
 
13. The ultrasound wave generating apparatus of claim 1, wherein the apparatus 
further includes a housing for housing the ultrasound transducer, the housing having a 
distal end at which the ultrasound transducer is disposed, wherein there is further 
disposed at the distal end a standoff component defining a cavity for carrying 
ultrasound coupling medium, the standoff component having a light transmissive wall 
adapted to permit visual viewing of an interior of the cavity through the light 
transmissive wall. 
 
14. The ultrasound wave generating apparatus of claim 1, wherein the apparatus 
includes a transmission line coupling the driver circuit and the transducer, the 
transmission line including a plurality of coaxial cables arranged in parallel, and 
further being arranged in a braid configuration. 
 
15. The ultrasound wave generating apparatus of claim 1, wherein the apparatus 
includes a transmission line coupling the driver circuit and the transducer, the 
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transmission line including a plurality of coaxial cables arranged in parallel, and 
further being arranged in a twisted configuration. 
 
16. The ultrasound wave generating apparatus of claim 1, wherein the transducer 
comprises a single transducer element having a first associated nominal frequency of 
resonance. 
 
17. The ultrasound wave generating apparatus of claim 1, wherein the transducer 
comprises a plurality of transducer elements. 
 
18. The ultrasound wave generating apparatus of claim 1, wherein the transducer 
comprises first and second transducer elements, the first transducer element having a 
first resonant frequency, the second transducer element having a second resonant 
frequency. 
 
19. The ultrasound wave generating apparatus of claim 1, wherein the ultrasound 
transducer comprises first and second transducer elements, the first transducer element 
having a first resonant frequency, the second transducer element having a second 
resonant frequency, and wherein the apparatus is conFigured so that the driver circuit 
is operative to output a frequency sweeping drive signal, the frequency sweeping drive 
signal having a frequency corresponding to the first resonant frequency during a first 
period, the frequency sweeping drive signal having a frequency corresponding to the 
second resonant frequency during a second period. 
 
20. The ultrasound wave generating apparatus of claim 1, wherein the power supply 
has a plurality of power supply stages, each power supply stage having an associated 
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driver circuit and power source, wherein the plurality of the power supply stages 
include first and second power supply stages, the second power supply stage being 
successive in relation to the first power supply stage, and wherein an output of the first 
of the power supply stages is input into a stage ground of the second power supply 
stage. 
 
21. The ultrasound wave generating apparatus of claim 1, wherein the power supply 
includes a user interface conFigured to permit an operator to independently adjust the 
first terminal clamping voltage and the second terminal clamping voltage via input of 
control inputs utilizing the user interface.  
 
22. The ultrasound wave generating apparatus of claim 1, wherein the power source 
includes a battery power source.  
 
23. The ultrasound wave generating apparatus of claim 1, wherein the power source 
includes an AC/DC converter.  
 
24. The ultrasound wave generating apparatus of claim 1, wherein the driver circuit 
includes a MOSFET integrated circuit, and wherein the apparatus includes a housing 
and printed circuit board for carrying the MOSFET integrated circuit, the printed 
circuit having a peripheral edge that is proximate the housing when the printed circuit 
board is disposed in the housing, wherein the MOSFET integrated circuit is disposed 
on the printed circuit at a location that is more proximate the peripheral edge of the 
circuit board that a longitudinal centerline of the printed circuit board. 
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25. The ultrasound wave generating apparatus of claim 1, wherein the driver circuit 
includes a plurality of transistor pairs and a plurality of pin drivers for providing 
switching of the plurality of transistor pairs, wherein the driver circuit is conFigured 
so that each of the plurality of pin drivers for providing switching drives a common 
number of transistor pairs.  
 
26. The ultrasound wave generating apparatus of claim 1, wherein the apparatus 
includes a printed circuit board carrying the first and second transistors of the driver 
circuit and wherein an output of the driver circuit includes common node that 
combines outputs of the first and second transistors, wherein the common output node 
is constituted by an output voltage plane having a planar surface area partially defining 
a surface of the printed circuit board. 
 
27. An ultrasound wave generating apparatus comprising: 
a power supply having a power source, a timing circuit, and a transistor based 
driver circuit for output of a drive signal, wherein the driver circuit includes a 
transistor pair including first and second transistors, and first and second clamping 
voltage terminals, the first and second transistors having respective first and second 
gates, wherein the timing circuit is operative to output a timing signal for controlling 
timing of the drive signal output by the driver circuit; 
a hand held housing for housing the power supply; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein a frequency at which the 
ultrasound transducer emits maximum power when driven by the output drive signal 
defines a resonant frequency of the ultrasound transducer; 
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wherein the driver circuit is operative to output a drive signal having a 
frequency corresponding to the resonant frequency; and 
wherein the apparatus is conFigured so that the transducer has an associated 
load voltage when the driver circuit outputs the drive signal to drive the transducer at a 
frequency corresponding to the resonant frequency, wherein the apparatus is further 
conFigured so that driver circuit has an associated source voltage when the driver 
circuit outputs the drive signal at a frequency corresponding to the resonant frequency, 
and wherein the apparatus is conFigured so that the amplitude of the load voltage is at 
least 90 percent of the amplitude of the source voltage when the driver circuit outputs 
a drive signal at a frequency corresponding to the resonant frequency; 
wherein the ultrasound transducer is operative so that compression force is 
imparted to the ultrasound transducer when the drive signal is of a first voltage 
polarity, and further so that an expansion force is imparted to the ultrasound 
transducer when the drive signal is of a second voltage polarity, and further so that the 
drive signal is an imbalanced continuous bipolar drive signal so that both of 
compression forces and expansion forces are imparted to the ultrasound transducer, 
and further so that the compression forces are of greater magnitude than the expansion 
forces; 
wherein the driver circuit is operative so that the drive signal has an output 
current capacity of greater than 50 amperes. 
wherein the power supply includes a capacitive coupling circuit coupling the 
timing signal to the first and second gates of the transistor pair, wherein the timing 
signal is a unipolar timing signal, and wherein the capacitive coupling circuit converts 
the unipolar timing signal into a bipolar input signal for input into the driver circuit; 
wherein the transistor based driver circuit includes a plurality of transistor pairs 
connected in parallel, each of the transistor pairs having first and second transistors, 
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wherein each of the transistor pairs is coupled to the first and second clamping voltage 
terminals; 
wherein the ultrasound wave generating apparatus includes a user interface and 
is adapted so that the ultrasound transducer is incorporated in a replaceable ultrasound 
transducer assembly that is one of a plurality of candidate ultrasound transducer 
assemblies that can be associated to the ultrasound wave generating apparatus, 
wherein the ultrasound wave generating apparatus is operative so that the drive signal 
output by the driver circuit is responsive to each of (a) a switching of a candidate 
transducer assembly, and (b) a control input that is input by an operator utilizing the 
user interface; 
wherein the apparatus further includes a housing for housing the ultrasound 
transducer, the housing having a distal end at which the ultrasound transducer is 
disposed, wherein there is further disposed at the distal end a standoff component 
defining a cavity for carrying ultrasound coupling medium, the standoff component 
having a light transmissive wall adapted to permit visual viewing of an interior of the 
cavity through the light transmissive wall; 
wherein the apparatus includes a transmission line coupling the driver circuit 
and the transducer, the transmission line including a plurality of coaxial cables 
arranged in parallel, and further being arranged in one of a braid or twisted 
configuration; 
wherein the power supply has a plurality of power supply stages, each power 
supply stage having an associated driver circuit and power source, wherein the 
plurality of the power supply stages include first and second power supply stages, the 
second power supply stage being successive in relation to the first power supply stage, 
and wherein an output of the first of the power supply stages is input into a stage 
ground of the second power supply stage. 
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wherein the user interface is conFigured to permit an operator to independently 
adjust the first terminal clamping voltage and the second terminal clamping voltage 
via input of control inputs utilizing the user interface; 
wherein the power source includes a battery power source; 
wherein the driver circuit includes a MOSFET integrated circuit, and wherein 
the apparatus includes a housing and printed circuit board for carrying the MOSFET 
integrated circuit, the printed circuit having a peripheral edge that is proximate the 
housing when the printed circuit board is disposed in the housing, wherein the 
MOSFET integrated circuit is disposed on the printed circuit at a location that is more 
proximate the peripheral edge of the circuit board that a longitudinal centerline of the 
printed circuit board; 
wherein the driver circuit includes a plurality of transistor pairs and a plurality 
of pin drivers for providing switching of the plurality of transistor pairs, wherein the 
driver circuit is conFigured so that each of the plurality of pin drivers for providing 
switching drives a common number of transistor pairs; and 
wherein the apparatus includes a printed circuit board carrying the first and 
second transistors of the driver circuit and wherein an output of the driver circuit 
includes common node that combines outputs of the first and second transistors, 
wherein the common output node is constituted by an output voltage plane having a 
planar surface area partially defining a surface of the printed circuit board. 
 
28. An ultrasound wave generating apparatus comprising: 
a power supply having a timing circuit for outputting a timing signal, and a 
transistor based driver circuit for output of a drive signal, wherein the driver circuit 
includes a transistor pair including first and second transistors, and first and second 
clamping voltage terminals, the first and second transistors having respective first and 
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second gates, wherein the timing circuit is operative to output a timing signal for 
controlling timing of the drive signal output by the driver circuit; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein the ultrasound transducer 
includes an impedance rating and a frequency rating and wherein the driver circuit is 
operative to output the drive signal at a frequency of about the frequency rating of the 
ultrasound transducer; and 
wherein the driver circuit includes an output impedance and wherein the 
apparatus is conFigured so a value of the output impedance of the driver circuit is less 
than 10 percent of a value of the impedance rating of the ultrasound transducer. 
 
29. The ultrasound wave generating apparatus of claim 28, wherein the ultrasound 
wave generating apparatus is operative to output more than 50 Watts of ultrasound 
energy. 
 
30. The ultrasound wave generating apparatus of claim 28, wherein the power supply 
includes a capacitive coupling circuit coupling the timing signal to the first and second 
gates of the transistor pair, wherein the timing signal is a unipolar timing signal, and 
wherein the capacitive coupling circuit converts the unipolar timing signal into a 
bipolar input signal for input into the driver circuit. 
 
31. The ultrasound wave generating apparatus of claim 28, wherein the transistor 
based driver circuit includes a plurality of transistor pairs connected in parallel, each 
of the transistor pairs having first and second transistors, wherein each of the transistor 
pairs is coupled to the first and second clamping voltage terminals.  
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32. The ultrasound wave generating apparatus of claim 28, wherein the apparatus 
includes a battery power source. 
 
33. The ultrasound wave generating apparatus of claim 28, wherein the power supply 
includes a user interface conFigured to permit an operator to independently adjust the 
first terminal clamping voltage and the second terminal clamping voltage via input of 
control inputs utilizing the user interface. 
 
34. An ultrasound wave generating apparatus comprising: 
a power supply having a timing circuit for outputting a timing signal, and a 
transistor based driver circuit for output of a drive signal, wherein the driver circuit 
includes a transistor pair including first and second transistors, and first and second 
clamping voltage terminals, the first and second transistors having respective first and 
second gates, wherein the timing circuit is operative to output a timing signal for 
controlling timing of the drive signal output by the driver circuit; 
an ultrasound transducer conFigured to emit ultrasound energy, the ultrasound 
transducer being coupled to the driver circuit so that the drive signal output by the 
driver circuit drives the ultrasound transducer, wherein the ultrasound transducer 
includes an impedance rating and a frequency rating and wherein the driver circuit is 
operative to output the drive signal at a frequency of about the frequency rating of the 
ultrasound transducer; 
wherein the driver circuit includes an output impedance and wherein the 
apparatus is conFigured so a value of the output impedance of the driver circuit is less 
than 10 percent of a value of the impedance rating of the ultrasound transducer; 
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wherein the ultrasound wave generating apparatus is operative to output more 
than 50 Watts of ultrasound energy; 
wherein the power supply includes a capacitive coupling circuit coupling the 
timing signal to the first and second gates of the transistor pair, wherein the timing 
signal is a unipolar timing signal, and wherein the capacitive coupling circuit converts 
the unipolar timing signal into a bipolar input signal for input into the driver circuit; 
wherein the transistor based driver circuit includes a plurality of transistor pairs 
connected in parallel, each of the transistor pairs having first and second transistors, 
wherein each of the transistor pairs is coupled to the first and second clamping voltage 
terminals; 
wherein the apparatus includes a battery power source; and 
wherein the power supply includes a user interface configured to permit an operator to 
independently adjust the first terminal clamping voltage and the second terminal 
clamping voltage via input of control inputs utilizing the user interface.
 
